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Oestrogens have long been implicated in prostatic pathology including benign
prostatic hyperplasia. Their actions and metabolic pathways within the organ are yet
unclear. The aim of this project was to investigate the factors that affect the actions
of oestrogens in the prostate. A role for 5a-reductase type 1 isozyme (5aRl) in
oestrogen metabolism was also examined.
Little is known about the functions of 5aRl in the human prostate.
Substrates for 5a-reductase are also substrates for aromatase. The hypothesis that
5aRl plays a role in the regulation of aromatase activity by limiting substrate
availability to the latter in the human prostate was tested in a co-transfection model
and in primary cultures of prostatic cells. In COS-1 cells transiently co-transfected
with plasmids encoding 5aRl and aromatase, inhibition of 5aRl led to an increase
in aromatase activity but not vice versa. This pattern of interaction between the two
enzymes was also shown to occur with endogenous enzymes expressed in primary
cultures of prostatic fibroblasts. No aromatase activity was detectable in epithelial
cells. By regulating aromatase activity, 5aRl may therefore contribute to the local
control of oestrogen concentration within the prostate gland.
In this study, prostatic cells were revealed to be oestrogen target cells, not
only expressing mRNAs of both subtypes of oestrogen receptor (ERa and ERP) but
also responding to oestradiol with increased proliferation rates. This oestrogen
stimulation of proliferation was antagonised by the antioestrogen ICI 182,780.
Moreover, prostatic fibroblasts aromatised androgen substrates to oestrogens
(oestrogen formation). Both fibroblast and epithelial cell cultures also converted
oestradiol to oestrone (oestrogen catabolism) but not vice versa. Primary cultures of
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prostatic cells therefore responded to oestrogen stimulation and expressed major
components for oestrogen action including oestrogen receptors and oestrogen-
metabolising enzymes; they would serve as a useful model to further study oestrogen
action, regulation and signalling pathways in the prostate.
In addition to the above enzyme inhibitors, the effects of Permixon® (a
phytotherapeutic agent for the management of prostatic hyperplasia) were
investigated. The mechanism of action of Permixon® is not entirely clear; however,
in previous studies it inhibited both 5a-reductase isozymes in prostatic cells.
Permixon® was herein shown to have pro-oestrogenic properties. It not only
indirectly increased the conversion of androstenedione to oestrone in fibroblasts by
inhibiting 5aRl, but also inhibited the conversion of oestradiol to the weaker
oestrogen oestrone. It is therefore conceivable that Permixon® exerts its therapeutic
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1.1 Anatomy, Embryology and Functions of the Prostate
1.1.1 Gross anatomy
Situated inferior to the urinary bladder and posterior to the symphysis pubis,
the human prostate gland is approximately the size of a walnut. It is shaped like an
inverted pyramid surrounding the uppermost (prostatic) part of the urethra. The
gland has a fibromuscular capsule and is pierced by two ejaculatory ducts, through
which the seminal vesicles expel their contents during ejaculation into the prostatic
urethra (fig. 1.1).
1.1.2 Histology
McNeal (1968) identified three distinct histological zones within the human
prostate: peripheral zone, central zone, and transition zone (fig. 1.2). The peripheral
zone in the normal gland comprises approximately 65% of the total prostatic volume
and its histological appearance is characterised by small acini lined by columnar
epithelial cells. The second largest component is the central zone, accounting for
about 25% of normal prostatic volume. It surrounds the ejaculatory ducts and is
characterised by large irregular acini lined by cuboidal epithelium. The smallest
zone, transition zone, comprises only 5-10% of normal prostatic volume and is
composed of two lobules found on either side of the prostatic urethra. Benign
prostatic hyperplasia (BPH) is believed to arise from the transition zone whereas
malignancy may affect any or all of the three zones with the majority of cases
originating from the peripheral zone.
The prostate is an aggregate of 30 to 50 tubuloalveolar glands embedded in a
fibromuscular stroma (fig. 1.3); these glands drain into the prostatic part of the
urethra. Morphometric analysis showed that the normal adult prostate consists of 45-
60% stromal tissue, 30-35% acinar lumen and 10-20% epithelial tissue (Uson et al.
1991).
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Fig. 1.2 Schematic diagrams of (a) coronal and (b) oblique-coronal sections of
the human prostate gland. The verumontanum (V) is shown with its relationship to
the ductular network draining the central zone (C), peripheral zone (P) and transition
zone (T). E, ejaculatory duct; S, preprostatic sphincter. U, urethra; UD, distal





Fig. 1.3 Histology of normal human prostate. The glandular lumen is lined by
epithelial cells, which are embedded in a stroma consisting mainly of fibroblasts and
smooth muscle cells. Haematoxylin and eosin staining.
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The prostatic epithelium consists of two cell types. The luminal cells are
columnar or cuboidal secretory cells lining the lumen whereas the basal cells are
either trigonal or flattened cells situated below or between luminal cells. It has been
suggested that basal cells represent precursors of luminal cells (Robinson et al.
1998). The cells of the underlying stroma vary from almost exclusively fibroblasts
to almost exclusively smooth muscle cells with a mixture of both cell types in most
areas.
1.1.3 Embryology and development
The human prostate begins its morphogenesis at about the twelfth week of
development. All tissues within the prostatic capsule are traditionally thought to
arise from the urogenital sinus. The only exception to this is the intraprostatic vasa
deferentia and ejaculatory ducts, which are of Wolffian duct origin. However, it has
been proposed that the central zone of the prostate may also be of Wolffian duct
derivation (McNeal 1968). Embryonic development of the prostate is under the
influence of testicular androgens (McNeal 1989).
Before puberty, the immature prostate is small in size and growth is minimal;
distinct histological zones are not well differentiated in the pre-pubertal prostate.
During puberty, the large amount of androgens secreted from the testes stimulates
prostatic cells to undergo morpho-functional maturation, giving rise to the various
histological zones and functional tubuloalveolar glands. The prostate reaches its full
size and mature morphology at the age of 18 to 20 (Uson et al. 1991).
1.1.4 Functions
More and more is known about the pathology of common diseases of the
prostate. However, two simple questions remain unanswered - why do we have a
prostate, and what does the gland do? The gland is not essential for life but is
functionally associated with reproduction. It produces a thin alkaline fluid, which
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contributes to the volume of seminal fluid. At the time of ejaculation, smooth
muscle cells in the prostatic capsule and stroma contract, and the secretion from the
many tubuloalveolar glands is expelled into the prostatic urethra. Prostatic secretion
contains many substances including citric acid, prostaglandins, zinc and various
enzymes including amylase, fibrinogenase, acid and alkaline phosphatases and is
believed to neutralise the acidic environment of the vagina (Blandy & Lytton 1986).
However, the precise functions of these substances are not fully understood.
1.2 Endocrinology of the Prostate
Although little is known about the physiological functions of the prostate, the
maintenance of normal growth and development of this gland is widely accepted to
be under the influence of testicular androgens. The essential role of androgens is
illustrated by patients with the complete androgen insensitivity syndrome, also
known as testicular feminisation. The main phenotypic characteristics of human
males with testicular feminisation are female external genitalia, a short and blind-
ending vagina, absence ofWolffian duct-derived structures and absence of a prostate
(Brinkmann 2001). Moreover, in patients suffering from benign prostatic
hyperplasia (BPH), prostate volume was decreased by the administration of the
antiandrogen flutamide (Stone & Clejan 1991). Because androgens are crucial to the
growth and development of the prostate, an account of their production and
metabolism is outlined below.
1.2.1 Regulation of androgen secretion
In the normal male, the major source of circulating androgens is the testes,
with a very small contribution from the adrenal glands (Griffin & Wilson 1992).
Testicular function is regulated by the two pituitary gonadotrophins, follicle-
stimulating hormone (FSH) and luteinizing hormone (LH) (fig. 1.4). LH stimulates
Leydig cells to convert cholesterol to testosterone (section 1.2.2), which is then
secreted into the bloodstream. Within the testis, testosterone acts synergistically with
FSH on Sertoli cells to maintain spermatogenesis.
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Fig. 1.4 The human hypothalamic-pituitary-testicular axis. The schematic
diagram indicates the site of action of follicle-stimulating hormone (FSH) and
luteinizing hormone (LH). Testosterone (T) is synthesised from cholesterol (C) in
Leydig cells of the testis. Both testosterone and inhibin influence the pituitary gland
and the hypothalamus by a negative feedback mechanism. LHRH, luteinizing
hormone-releasing hormone. Adapted from Griffin & Wilson (1992).
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Secretion of the two gonadotrophins is regulated by luteinizing hormone-
releasing hormone (LHRH) secreted by the hypothalamus (fig. 1.4). The testis exerts
an influence on the hypothalamic-pituitary unit by a negative feedback mechanism
via both testosterone and inhibin, the latter being secreted by Sertoli cells of the
testis. Other steroids, including dihydrotestosterone and oestradiol, can also affect
this feedback control.
Another source of circulating androgens is the adrenal glands. The major
adrenal androgens are dehydroepiandrosterone (DHEA), DHEA-sulphate and
androstenedione. Although they are weak androgens compared with testosterone or
dihydrotestosterone (Orth et al. 1992), these steroids are potential precursors ofmore
active metabolites (fig. 1.5). Oesterling et al. (1986) demonstrated that the adrenal
glands did not have a significant stimulatory effect on the human prostate and were
not capable ofmaintaining prostatic growth without testicular androgens.
1.2.2 Androgen and oestrogen biosynthesis
The principal testicular androgen is testosterone. Besides testosterone, the
testis also secretes smaller amount of other steroids including androstenedione,
dihydrotestosterone, oestradiol and oestrone. In Leydig cells of the testis,
testosterone is synthesised from cholesterol (fig. 1.5), which can either be locally
produced from acetate or derived from the plasma pool of cholesterol. The first
reaction in converting cholesterol to C-18, C-19 and C-21 steroids involves the
cleavage of a 6-carbon group by cholesterol side-chain cleavage enzyme to form
pregnenolone. Figure 1.5 shows that there are two possible pathways for the
conversion of pregnenolone to androstenedione, one via the formation of
dehydroepiandrosterone (DHEA) (A5 pathway) and the other via the formation of
progesterone (A4 pathway). The predominant pathway in human testis is believed to
be the A5 pathway (Griffin & Wilson 1992). Androstenedione can then be reduced
to the potent androgen testosterone by 17P-hydroxysteroid dehydrogenase.
Aromatase in the testis converts a small proportion of testosterone and





Fig. 1.5 Pathways of androgen and oestrogen biosynthesis. Numbered arrows
represent enzymes involved in steroid conversion: (1) cholesterol side-chain cleavage
enzyme; (2) 3p-hydroxysteroid dehydrogenase-A4'5-isomerase; (3) 17a-hydroxylase;
(4) 17,20-desmolase; (5) 17[3-hydroxysteroid dehydrogenase; (6) aromatase.
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Of the circulating oestrogens in men, 75-90% arises from peripheral
conversion of testosterone to oestradiol and androstenedione to oestrone in adipose,
brain, bone and other tissues (Farnsworth 1999). The testes synthesise the remaining
10-25% of oestrogens by aromatisation of androgen precursors. The two natural
oestrogens in man, oestradiol and oestrone, are interconverted by 17(3-hydroxysteroid
dehydrogenase (fig. 1.5).
The majority of circulating steroid hormones are bound to plasma proteins.
The major binding proteins are cortisol-binding globulin (CBG), sex hormone-
binding globulin (SHBG) and albumin (Orth et al. 1992, table 1.1). The formerly
held notion that the active fraction of testosterone is identical to the unbound fraction
in plasma has been refuted by the findings that dissociation of protein-bound
hormone can occur within the capillary bed (Pardridge 1981). Moreover, SHBG,
which binds to steroid hormones (testosterone, dihydrotestosterone and oestradiol in
particular), has been suggested a vehicle for incorporating steroid hormones into the
cytoplasm of prostatic cells (Farnsworth 1999), implying that the actual active






Dehydroepiandrosterone 4.1 <0.1 92.4 3.4
Androstenedione 7.9 1.4 88.0 2.8
Testosterone 2.2 3.6 49.9 44.3
Dihydrotestosterone 0.9 0.2 39.2 59.7
Oestradiol 2.3 <0.1 78.0 19.6
Oestrone 4.0 <0.1 88.6 7.4
Table 1.1 Transport of steroid hormones in plasma ofmen. Adapted from Orth et al.
(1992). CBG, cortisol-binding globulin; SHBG, sex hormone-binding globulin.
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1.2.3 Androgen and oestrogen metabolism in prostate
Steroid hormones, because of their hydrophobic nature, enter cells by
diffusion. Before binding to specific intracellular receptors in the prostate, they may
be subject to the action of steroid-metabolising enzymes. Indeed, these enzymes
play important roles in steroid activation/inactivation or converting one class of
steroids to another. A large number of androgen/oestrogen-metabolising enzymes
have been reported in the prostate (Krieg et al. 1995, Stone et al. 1987); some
potential pathways of steroid conversion are summarised in figure 1.6. Three of the
enzymes which are of immediate relevance to the present thesis are discussed in the
following sections.
1.3 5a-reductase
Steroid 5a-reductase, also known as 3-oxo-5a-steroid-A4-oxidoreductase, is
the major androgen metabolising enzyme in the human prostate (Krieg et al. 1995).
It was reported to have higher steroid-metabolising activity than any of 17(3-
hydroxysteroid dehydrogenase (17J3HSD), 3a-hydroxysteroid dehydrogenase
(3aHSD), 3(3-hydroxysteroid dehydrogenase (3(3HSD), 6a-hydroxylase and 7a-
hydroxylase in prostate tissue.
1.3.1 Two isozymes of 5a-reductase
Two distinct isozymes of 5a-reductase, namely type 1 (5aRl) and type 2
(5aR2), have been identified in man (Andersson & Russell 1990, Andersson et al.
1991, Jenkins et al. 1992). Andersson & Russell (1990) first cloned the cDNA
encoding 5aRl (gene symbol SRD5A1). It is located on chromosome 5 and consists
of 5 exons and 4 introns. The gene encodes a protein of 259 amino acids; over 40%
of the amino acids are hydrophobic and only 60% are identical to those of the rat
5aRl (Andersson & Russell 1990). A non-functional pseudogene for 5aRl has been
described and mapped to the X chromosome (Jenkins et al. 1991).
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The same group subsequently cloned the cDNA encoding 5aR2 (gene
symbol SRD5A2) from the prostate (Andersson et al. 1991). The human 5aR2 gene
also has 5 exons and 4 introns and encodes a hydrophobic protein of 254 amino
acids, ofwhich 50% are identical to those of human 5aRl and 77% identical to those
of the rat type 2 isozyme (Andersson et al. 1991). Hydropathy plots of the two
enzymes indicate no obvious transmembrane regions, suggesting that with
hydrophobic amino acids distributed throughout their structures, these isozymes are
intrinsic membrane proteins embedded in the lipid bilayer (reviewed in Russell &
Wilson 1994).
Both isozymes convert testosterone to dihydrotestosterone (DHT) and
androstenedione to 5a-androstanedione (5aA); a variety of other steroids with a 3-
oxo-A4'5 structure including progestagens and glucocorticoids are also substrates of
the two isozymes (Thigpen et al. 1993a, Levy et al. 1995). Levy et al. (1995)
demonstrated that the substrate affinity order for human 5aRl (20a-
hydroxyprogesterone > progesterone > androstenedione > testosterone >
corticosterone) was similar to that for human 5aR2 (20a-hydroxyprogesterone >
progesterone > testosterone > androstenedione > corticosterone).
Different pH optima was one of the first characteristics that distinguished the
two isozymes (Andersson et al. 1991). 5aRl exhibits a broader pH optimum (pH 7.0
- 8.5) than 5aR2 (pH 5.0 - 5.5). The unusual acidic pH optimum of 5aR2 in vitro is
probably an experimental artefact due to disruption of membranes intimately
associated with the isozyme (reviewed in Russell & Wilson 1994). Chinese hamster
ovary (CHO) cells which had been transfected with a 5aR2-encoding plasmid and
gently permeabilised with digitonin showed similar 5a-reductase activity at pH 5.0
and 7.0; in contrast, completely perforated cells had a typical acidic pH optimum at
5.0 (Thigpen et al. 1993a). The type 2 isozyme thus appears to function at a neutral
pH within the cell and to shift to a form active at pH 5.0 upon cell lysis; this shift in
pH requirement may reflect a conformational change in the isozyme. Nevertheless,
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the neutral to basic and the acidic pH optima in vitro are in general diagnostic for the
type 1 and type 2 isozymes respectively (Russell & Wilson 1994).
Between the two androgen substrates androstenedione and testosterone, 5aR2
has similar Km values for androstenedione and testosterone, whereas the type 1
isozyme has lower Km value (and therefore higher affinity) for androstenedione than
testosterone (table 1.2; Thigpen et al. 1993a, Levy et al. 1995). Also, 5aR2 exhibits
nearly identical catalytic efficiency ratios (Vmax/Km) with the two androgen
substrates, whereas Vmax/Km ratio for 5aRl is 6 to 11 times higher with
androstenedione than testosterone (table 1.2). It is therefore likely that 5aRl also
exhibits some selectivity towards androstenedione in vivo. Both isozymes utilize
NADPH as a cofactor, with Km values of 3 - 5 pM for 5aRl and 7-10 pM for 5aR2
(Thigpen et al. 1993a).
study substrate
5ocRl





















A 0.3 5.7 19 0.2 2.4 12
T 1.7 2.8 1.6 0.2 2.4 12
Levy et al.
(1995)
A 1.0 0.40 0.40 0.8 0.09 0.11
T 3.5-5.2 0.22 0.04-0.06 0.7 0.09 0.12
Table 1.2 Kinetic parameters of the two human 5a-reductase isozymes. Kinetic
constants were determined using cell homogenates prepared from CHO cells
transfected with plasmids encoding either of the two 5a-reductase isozymes. A,
androstenedione; T, testosterone; Km, Michaelis constant; Vmax, maximal rate of
reaction; Vmax/Km, catalytic efficiency.
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1.3.2 5a-reductase and prostate development
Normal prenatal development of the prostate and Wolffian ducts requires
androgen stimulation. While Wolffian duct differentiation is testosterone-dependent,
dihydrotestosterone (DHT) is essential for the development of the prostate and male
external genitalia. DHT is produced by 5a-reduction of testosterone and 5aR2 is the
predominant isozyme detectable in fetal genital skin and male accessory sex glands
including the prostate (Thigpen et al. 1993b). The importance of 5aR2 in normal
prostate development is illustrated by mutations of the 5aR2 gene, which result in
male pseudohermaphroditism. Affected individuals were shown to have male
internal Wolffian-derived structures but female or ambiguous external genitalia and
rudimentary prostates (Walsh et al. 1974, Andersson et al. 1991, Zhu et al. 1998).
Transrectal ultrasonography and magnetic resonance imaging demonstrated that
adult pseudohermaphrodites with 5aR2 deficiency had significantly smaller prostates
than age-matched control males (reviewed in Zhu et al. 1998). Their prostates
appeared as plate-like soft tissue structures on both imaging methods and transrectal
prostate biopsies revealed fibrous connective tissue, smooth muscle and no epithelial
tissue (Imperato-McGinley et al. 1992). No 5aRl deficiency in human has yet been
identified.
In contrast, male mice lacking 5aR2 or both 5a-reductase isozymes only had
mild virilisation defects (Mahendroo et al. 2001). On the other hand, male mice
homozygous for a targeted disruption of the 5aRl gene were shown to have normal
development of their reproductive organs including the prostate and normal
endocrine profiles (Mahendroo et al. 1996). It was suggested that testosterone is the
only androgen required for differentiation of the male urogenital tract in mice and
that synthesis of DHT serves mainly as a signal amplification in this species
(Mahendroo et al. 2001).
In comparison, data from female mice homozygous for a targeted disruption
of the 5aRl gene highlight the functions of the type 1 isozyme; in pregnant mice,
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impairment of androgen 5a-reduction to non-aromatisable forms due to 5aRl
deficiency led to increased androgen aromatisation, elevation in plasma oestrogen
levels and mid-gestational fetal loss (Mahendroo et al. 1997). This observation of
increased plasma oestrogen concentrations in 5aRl-deficient mice indicates that a
normal role for 5aRl in the female mouse is to prevent the metabolism of placental
androgens to oestrogens by converting aromatisable androgens to non-aromatisable
forms. However, no specific role has yet been proposed for 5aRl in the male or in
humans.
1.3.3 Intraprostatic distribution of 5a-reductase isozymes
Some studies have been carried out to examine if any differential spatial
distribution of the two isozymes, which may suggest differential functions of the two
isozymes, exists in the prostate. In situ mRNA hybridisation studies to localize
mRNA distribution of both isozymes showed labelling predominantly in epithelial
cells but also in the stromal compartment (Habib et al. 1998, Pelletier et al. 1998).
Iehle et al. (1999) demonstrated both 5aRl and 5aR2 mRNA in all of the peripheral,
transition and central zones of normal prostate by RT-PCR. Most
immunohistochemical studies have similarly localised both isozymes mainly in the
epithelial layer; less immunoreactivity was detected in the stroma (Eicheler et al.
1994, Silver et al. 1994, Bonkhoff et al. 1996).
Using RT-PCR, Delos et al. (1998) detected mRNA of both 5aRl and 5aR2
in primary cultures of epithelial cells grown from benign prostatic hyperplasia
tissues; only 5aRl, but not 5aR2, mRNA was detectable with Northern blot analysis
in the same study. Previous studies from the Prostate Research Group (University of
Edinburgh) have shown that BPH-derived fibroblasts and epithelial cells in primary
culture expressed mRNA detectable by RT-PCR and activity of the type 1 isozyme
only (Bayne et al. 1998).
In summary, all three zones and both epithelial and stromal compartments of
the human prostate have been reported to express both isozymes of 5a-reductase.
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However, in interpreting these results, the limitations of each of the above techniques
should be noted. For example, the presence of mRNA (detectable by either in situ
hybridisation or Northern analysis) is not equivalent to the expression of protein.
RT-PCR is a sensitive technique and can detect very small amount ofmRNA present
in tissue samples, whereas the usefulness of immunohistochemical studies is limited
by specificity of the antibody used and antigen retrieval methods employed.
1.4 Aromatase
1.4.1 Aromatase enzyme
Aromatase, also known as oestrogen synthetase, catalyses the formation of
aromatic C-18 oestrogens from C-19 androgen precursors. It is a microsomal
member of the superfamily of enzymes collectively known as cytochrome P450
(Simpson et al. 1997). Associated with aromatase cytochrome P450 is the NADPH-
cytochrome P450 reductase (reviewed in Simpson et al. 1994, Sasano & Harada
1998). The essentially ubiquitous NADPH-cytochrome P450 reductase transfers
reducing equivalents from NADPH to any microsomal cytochrome P450 with which
it comes into contact (Simpson et al. 1994). The aromatase reaction utilises 3 moles
of oxygen molecules and 3 moles of NADPH for every mole of C-19 steroid
metabolised, resulting in the aromatisation of A ring to give the phenolic structure
characteristic of oestrogens (Simpson et al. 1997).
Both androstenedione and testosterone are substrates for aromatase.
However, 5a-reduced steroids such as 5a-androstanedione and 5a-
dihydrotestosterone cannot serve as precursors because 5a-reduction of the A ring
precludes the completion of aromatisation. Kinetic studies have demonstrated that
the enzyme has higher affinity for androstenedione than testosterone; Km of
aromatase in a variety of human tissues for androstenedione (25 - 100 nM) was
slightly lower than Km for testosterone (166 - 201 nM) (Schweikert 1979, Ackerman
et al. 1981, Stone et al 1986, Krekels et al. 1991, Block et al. 1996). Km for NADPH
in human placental microsomes was reported to be 1 pM (Reed & Ohno 1976).
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Aromatase is expressed in a wide variety of human tissues including adipose
tissue, various regions of the brain, placenta, ovary and testis. In men, oestrogens are
thought to be formed primarily by aromatisation in adipose tissue (section 1.2.2).
1.4.2 Aromatase (CYP19) gene
Within the cytochrome P450 superfamily of enzymes, aromatase is presently
the sole member of the gene family 19, designated CYP19. This designation is based
on the fact that the C-19 methyl group of androgens is the site of attack by oxygen.
Corbin et al. (1988) cloned the full-length cDNA for CYP19 from human placenta;
the cDNA encodes a predicted protein of 503 amino acids. CYP19 has been
localised to human chromosome 15; it spans more than 120 kb of genomic DNA and
comprises 10 exons (Sebastian & Bulun 2001). The coding region spans nine exons
beginning with exon 2. Tissue-specific expression of aromatase is determined in part
by alternative use of tissue-specific promoters, which give rise to mRNA with unique
5' noncoding ends (fig. 1.7; Simpson et al. 1997, Harada 1999). Numerous
untranslated exons 1 have been identified. Two different systems of nomenclature of
major splicing variants are currently in use (table 1.3); Harada's nomenclature is
used in the following discussion. The predominant forms of various alternative
exons 1 in tissues have recently been summarised by (Harada 1999) and Sebastian &
Bulun (2001).
nomenclature human tissues where splice variant is
predominantly detectedHarada Simpson
la 1.1 placenta
lb 1.4 fetal liver, adipose stroma,
skin fibroblasts, bone
lc 1.3 ovary
Id PII ovary, testis, prostate
le 1.2 placenta
If - brain
Table 1.3 Two different nomenclatures ofmajor aromatase splice variants. Adapted




Placenta Placenta Adipose Tissue Placenta Ovary Ovary
Fig. 1.7 Structure of the human aromatase gene (CYP19) upstream of exon 3
showing alternative splicing patterns. Ex, exon. Seven untranslated exons (Ex la
- Ex If and Ex 2a) and the first two coding exons (Ex 2 and Ex 3) are shown. The
most common sites of tissue-specific utilisation of alternative exon 1 are indicated.
Adapted from Harada (1999). Exon Ifwas later localised between exons lb and le,
approximately 30 kb upstream of exon le (Sebastian & Bulun 2001).
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1.4.3 Aromatase expression in the prostate
Aromatase expression in the human prostate is controversial. Some have
reported aromatase mRNA (Harada et al. 1993, Tsugaya et al. 1996, Hiramatsu et al.
1997) and activity (Schweikert 1979, Stone et al. 1986) in the prostate but others
could not detect any enzyme activity in prostate tissues (Bartsch et al. 1987, Brodie
et al. 1989).
The expression of aromatase mRNA has been reported in normal prostate,
BPH and prostate cancer specimens (Harada et al. 1993, Tsugaya et al. 1996,
Hiramatsu et al. 1997). A tissue-specific utilisation of exon Id in the normal prostate
was described by Harada et al. (1993). However, in another study, exons lb, lc and
Id (in decreasing order of prevalence) were reported in mRNA prepared from both
BPH and cancer tissue samples (Hiramatsu et al. 1997). To date, it is not entirely
clear which splice variant is the predominant one in human prostate.
To study the intraprostatic distribution of aromatase, two
immunohistochemical studies using polyclonal antibodies have localised the enzyme
mainly to the prostatic stroma (Matkin & Soloway 1992, Hiramatsu et al. 1997).
Both normal and BPH tissues showed pronounced immunopositivity in the stroma
but the epithelium was also stained when a higher antibody concentration was used
(Matkin & Soloway 1992). Immunoreactivity was likewise observed by Hiramatsu
et al. (1997) in stromal cells with marked heterogeneity among various regions of
individual specimens; no immunoreactivity was detected in epithelial cells.
Although three studies (Smith et al. 1982, Bartsch et al. 1987, Brodie et al.
1989) have failed to detect any aromatase activity in BPH or prostate cancer tissues,
aromatisation in normal, BPH and cancerous specimens have been shown by other
investigators (Schweikert 1979, Kaburagi et al. 1987, Stone et al. 1986 & 1987,
Hiramatsu et al. 1997). Stone et al. (1987) revealed higher aromatase activity in
BPH than in cancer tissues, whereas Hiramatsu et al. (1997) reported no difference in
aromatase activity between the two types of pathological tissues. Aromatase activity
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was also detected in primary cultures of prostatic fibroblasts grown from BPH and
prostate cancer tissues (Schweikert 1979).
1.4.4 Abnormal aromatase expression
One way to understand the functional role of an enzyme is to look at
individuals deficient in that particular enzyme. There are two well-documented
cases of aromatase deficiency in adult males in the literature to date (Morishima et al.
1995, Carani et al. 1997). Both of the patients had decreased plasma levels of
oestrogens, and either normal or increased levels of androgens including
androstenedione, testosterone and dihydrotestosterone (table 1.4); the plasma levels
of FSH, LH and androgens decreased after oestrogen supplement treatment (Carani
et al. 1997).
hormone














Table 1.4 Pre-treatment plasma concentrations of hormones in two men with
aromatase deficiency compared with normal males. E2, oestradiol; Ei, oestrone; A,
androstenedione; T, testosterone; DHT, dihydrotestosterone; FSH, follicle-
stimulating hormone; LH, luteinizing hormone; DHEA-S, dehydroepiandrosterone-
sulphate. T, increased; -l, decreased; <-», normal; ?, not reported.
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These two reports show that aromatase deficiency can lead to increased
plasma concentrations of androgens, secondary to elevated levels of gonadotrophins;
the role of oestrogens in the normal feedback control of plasma androgen levels in
the male was also confirmed. The prostate phenotype was, however, not mentioned
in either of the two case reports.
To further understand the role of aromatase, animal models of abnormal
aromatase expression have been studied. Hormonal profiles in aromatase knockout
(ArKO) mice were similar to those found in aromatase-deficient human males
(Fisher et al. 1998, McPherson et al. 2001). The size of the prostate in ArKO mice
was increased, when compared with the wild-type prostate, with histological
evidence of epithelial hyperplasia (McPherson et al. 2001). In contrast, transgenic
mice over-expressing aromatase were reported to have elevated E2 levels, with
reduced testosterone and FSH levels; their prostates were small in size and poorly
developed when compared with the wild-type prostate (Li et al. 2001). These mouse
models confirmed the importance of aromatase and oestrogens in the normal
development of the prostate in mice. Taken together, the above animal studies and
natural human models of abnormal aromatase expression emphasise that in
considering a role for aromatase in prostate development, the effects of oestrogens on
plasma levels of androgens (crucial for prostate embryogenesis and growth, section
1.2) must be taken into account.
1.5 17p-Hydroxysteroid Dehydrogenase
Both androgens and oestrogens have the highest affinity for their receptors in
the 17P-hydroxyl steroid form. 17p-hydroxysteroid dehydrogenase/17-ketosteroid
reductase, hereafter called 17p-hydroxysteroid dehydrogenase (17PHSD), is
therefore considered important in regulating the biological activity of androgens and
oestrogens.
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At present, no less than 10 different mammalian 17pHSDs have been identified;
at least six types of 17PHSD have been cloned in human (Peltoketo et al. 1999,
Labrie et al. 2000, Nordling 2001). 17pHSDs belong to at least two distinct enzyme
families: the short-chain alcohol dehydrogenase family and the aldo-keto reductase
family (Penning 1997). The primary structures of the various 17PHSD enzymes are
not very similar to one another, with amino acid identity among types 1 to 5 17PHSD
ranging from 15% to 26% (Labrie et al. 1997). Because of the large number of
17PHSD enzymes present in human, only a synopsis will be given for types 1 to 5,
which have been more characterised than the other types, in the following discussion.
In intact cells, the activity catalysed by each type of 17pHSD is thought to be almost
exclusively unidirectional (reviewed in Peltoketo et al. 1999, Labrie et al. 2000).
Whereas types 1,3, and 5 catalyse the reductive reaction, types 2 and 4 catalyse the
oxidative reaction.
1.5.1 17PHSD type 1
17PHSD type 1, abundantly expressed in ovarian granulosa cells, is
essentially an enzyme of oestradiol synthesis. It catalyses the conversion of oestrone
(Ei) to oestradiol (E2) with 100-fold higher affinity for C-18 than for C-19 steroids
(reviewed in Penning 1997, Labrie et al. 2000). Immunostaining of 17pHSD type 1
was detectable in very few epithelial cells and no stromal cells of normal prostate
tissue (Pylkkanen et al. 1994, Elo et al. 1996).
1.5.2 17PHSD type 2
17PHSD type 2 has less substrate specificity than type 1 17PHSD and
catalyses the conversion of E2 to Ei, testosterone to androstenedione, DHT to 5a-
androstanedione (5aA) and androst-5-ene-3P,17P-diol (A5diol) to DHEA (Peltoketo
et al. 1999, Labrie et al. 2000). It also possesses 20aHSD (Wu et al. 1993) and
3PHSD (Suzuki et al. 2000) activities. It is widely distributed in many tissues
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(Peltoketo 1999). Using Northern analysis, Elo et al. (1996) reported highly variable
17PHSD type 2 mRNA expression in prostatic tissue specimens.
1.5.3 17PHSD type 3
Predominantly expressed in the testis, 17[1HSD type 3 converts
androstenedione to testosterone; it is also capable of reducing 5aA to DHT and Ei to
E2 (Peltoketo et al. 1999). Its importance in testosterone biosynthesis is exemplified
by male pseudohermaphroditism due to deficiency in 17PHSD type 3 (Zhu et al.
1998). Affected 46,XY individuals have testes and Wolffian duct-derived structures
but ambiguous external genitalia. Their plasma androstenedione, FSH and LH levels
are elevated, with low plasma testosterone levels. Plasma levels of E2 and Ei are
normal to increased (reviewed in Zhu et al. 1998). Using Northern analysis, Elo et
al. (1996) failed to detect 17PHSD type 3 mRNA in BPH or prostatic cancer tissue.
1.5.4 17pHSD type 4
17PHSD type 4 is expressed in many human tissues including the prostate
(Delos et al. 1998) and oxidises both androgens and oestrogens. It is a
multifunctional enzyme, with 17PHSD and 2-enoyl-acyl-CoA hydratase activity and
capable of facilitating the transfer of 7-dehydrocholesterol and phosphatidylcholine
between membranes (Peltoketo et al. 1999).
1.5.5 17PHSD type 5
Unlike the above 4 types of 17PHSD, which belong to the short-chain alcohol
dehydrogenase superfamily of enzymes, 17PHSD type 5 is a member of the aldo-
keto reductase family (Peltoketo et al. 1999, Labrie et al. 2000). In fact, it is highly
homologous to other members of the aldo-keto reductase family, including 3aHSD
types 1 and 3 as well as 20a-HSD. It converts androstenedione to testosterone and
possesses 3a-HSD activity to some extent (Peltoketo et al. 1999). Using both in situ
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mRNA hybridisation and immunohistochemistry, El-Alfy et al. (1999) detected
strong 17(3HSD type 5 labelling in the stromal fibroblasts and basal epithelial cells of
normal and hyperplastic prostate; luminal epithelial cells were more variably
labelled.
In summary, 17PHSD types 2, 4 and 5 have been reported in the human
prostate. Whereas type 1 17|3HSD converts Ei to E2, 17PHSD type 3 and type 5 can
metabolise androstenedione to testosterone. Types 2 and 4 17PHSD, on the other
hand, oxidise androgens and oestrogens with a 17p-hydroxyl group, including E2,
testosterone and DETT (table 1.5; Labrie et al. 1997). Other types of 17PHSD are less
well reported in the literature. Human 17PHSD type 7 cDNA has also been cloned
and mRNA of 17PHSD type 7 was detectable using RT-PCR in human prostate









present in a few epithelial cells onlyw
(Pylkkanen et al. 1994, Elo et al. 1996)
2 dehydrogenase inactivation of
androgens and
oestrogens
present but mRNA levels highly
variable between specimens^
(Elo et al. 1996)
3 reductase testosterone
production
not detectable^ (Elo et al. 1996)
4 dehydrogenase inactivation of
androgens and
oestrogens
present^ (Delos et al. 1998)
5 reductase testosterone
production
strongly immunopositive in basal
epithelial cells and stromal fibroblasts;
staining more variable in luminal
epithelial cells(a) (El-Alfy et al. 1999)
Table 1.5 Characteristics of 17PHSD types 1 to 5 and their expression in human
prostate. Method of detection in prostate: (a)immunohistochemistry, (b)Northern
analysis.
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Two studies have investigated the expression of various types of 17PHSD in
BPH-derived epithelial cells in primary culture (Delos et al. 1995, Delos et al. 1998).
Types 2 and 4 17pHSD mRNA were present in epithelial cells in culture; neither
type 1 nor type 3 was detectable by Northern analysis. Other types of 17pHSD were
not examined in either of the two studies.
1.6 Steroid Receptors
Steroid hormones, including androgens and oestrogens, exert their actions
directly on target gene expression by binding to specific intracellular receptors which
function as hormone-inducible transcription factors. Steroid receptors belong to the
steroid/nuclear receptor (NR) superfamily, which includes the class I NR, the steroid
receptors, e.g. androgen, oestrogen, glucocorticoid, mineralocorticoid and
progesterone receptors, and the class II NR, e.g. retinoic acid receptor, retinoid X
receptor, vitamin D receptor, thyroid receptor, and peroxisome proliferator activated
receptor (PPAR). The NR superfamily also includes numerous 'orphan receptors',
denoted as such because their endogenous ligands are unknown (Evans 1988,
reviewed in Klinge 2000). In the following discussion, oestrogen receptor (ER) and
its mechanism of action will be used as an example for steroid receptors in general.
1.6.1 General structural characteristics
Steroid receptors have evolutionarily conserved similarities in a series of
structural domains. For example, oestrogen receptors (ERa and ERp) have six
domains named A to F from the N- to the C-terminus (fig. 1.8 and section 1.6.3,
Krust et al. 1986, Green & Chambon 1986). The three major functional domains of
the ER are: 1) an N-terminus (domains A and B) that modulates transcription by its
activation function-1 (AF-1); 2) a central DNA-binding domain (DBD, consisting of
the C domain), whose zinc fingers interact directly with target DNA; and 3) the
ligand-binding domain (LBD, domain E) that contains activation function-2 (AF-2)
(reviewed in Klinge 2000, Katzenellenbogen et al. 2000).
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Fig. 1.8 Schematic representation of the structural and functional domains of
human oestrogen receptors (ERa and ERP). Numbers of amino acids from N-
terminus corresponding to the boundaries of various domains are indicated. The
percentages of amino acid homology between structural domains A to F in the two
ER subtypes are indicated by numbers in parentheses. AF, activation function.
Adapted from Katzenellenbogen et al. (2000).
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1.6.2 Mechanism of action
The unbound steroids are generally believed to diffuse through the cell
membrane. It is currently not clear whether a transport protein is required for the
movement of hydrophobic steroid molecules through the aqueous cytoplasm into the
nucleus. ER resides in the nucleus in an unliganded state and is thought to be
complexed with other proteins, e.g. hsp90 (reviewed in Katzenellenbogen et al.
2000). Binding of oestrogen to ER activates the receptor to undergo conformational
changes to form an 'activated' ER, presumably by dissociation of hsp90 and other
proteins (Williams & Franklyn 1994). Liganded ERa and ERp can then form
homodimers or heterodimers and bind to specific DNA sequences called oestrogen
response elements (EREs) (fig. 1.9); the minimal consensus ERE sequence is a
palindromic inverted repeat of 5'-GGTCAnnnTGACC-3', where n is any nucleotide
(Katzenellenbogen et al. 2000). Examples of human genes whose promoters contain
functional EREs include progesterone receptor, pS2 and oxytocin (Katzenellenbogen
et al. 2000, Klinge 2000).
Initiation of transcription is a complex event occurring through the co¬
operative interaction ofmultiple factors at the target gene promoter (fig. 1.9). When
bound to an ERE, ER interacts with transcription factors and other proteins,
including co-activators, that may promote the assembly of the transcription initiation
complex. Once the transcription initiation complex is complete, RNA polymerase II
can initiate transcription (Klinge 2000). It has been suggested that oestrogen target
cells express different levels of ERs, co-activators and co-repressors in order to




















Fig. 1.9 Schematic model for oestrogen receptor (ER) action. Oestrogens bind to
ER, inducing the latter to undergo conformational changes and to dissociate from
other proteins of the ER complex including heat-shock protein (hsp). Two liganded
ER molecules then dimerise and bind to specific DNA sequences known as
oestrogen response element (ERE). RNA polymerase and coregulatory proteins are
then recruited to regulate gene transcription.
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1.6.3 Two oestrogen receptor subtypes
In 1996, the cloning of a new member of the nuclear receptor superfamily
from the rat prostate (Kuiper et al. 1996) and human testis (Mosselman et al. 1996)
was reported. It has been named oestrogen receptor beta (ERP) to distinguish it from
the oestrogen receptor (ERa) cloned from the breast cancer cell line MCF-7 (Green
et al. 1986). The identification of ERp has prompted re-evaluation of the molecular
basis for oestrogen action in health and diseases.
The ERa gene (ESR1), located on chromosome 6, encodes a protein of 595
amino acids, whereas the ERp gene (ESR2), on chromosome 14, encodes a slightly
shorter protein of 530 amino acids; both ESR1 and ESR2 consist of 8 exons (Enmark
1997, reviewed in Saunders 1998). The two ER subtypes contain the same
arrangement of functional domains with the most conserved region being the DNA-
binding domain (97% identity; fig. 1.8), consistent with the receptors binding to
similar DNA response elements (Klinge 2000). Their ligand-binding domains are
relatively well conserved (59% identity), which explains their similar affinities for
various oestrogens and oestrogenic compounds (table 1.6). However, their A/B
domains and activation function-1 (AF-1) share 18% homology only, suggesting that
their transcriptional activation of different oestrogen-responsive genes may show
distinctly different patterns (Katzenellenbogen & Korach 1997).
Both ER subtypes have similar relative binding affinities for a number of
oestrogenic compounds (E2 > E] > E3 > A5diol > 3pAdiol; table 1.6). However,
ERP has a lower affinity for E2 than ERa does; 1% values of the rat ERP (0.4 - 0.6
nM) are higher than the rat ERa (0.1 nM) (Kuiper et al. 1996, Kuiper et al. 1997).
Similarly, 1% for the mouse ERp (0.5 nM) is also slightly higher than the mouse ERa








oestradiol (E2) 100 100 100
diethylstilboestrol 236-468 221 295
oestrone (Ei) 60 NA 37
oestriol (E3) 14 NA 21
tamoxifen 4-7 3 6
androst-5-ene-3P, 17p-diol (A5diol) 1-6 7 17
5a-androstane-3 p, 17p-diol (3PAdiol) 3 NA 7
5a-androstane-3a,17P-diol (3aAdiol) 0.07 NA 0.3
5a-dihydrotestosterone (DHT) 0.05 NA 0.17
dehydroepiandrosterone (DHEA) 0.04 NA 0.07
5a-androstanedione (5aA) <0.01 NA <0.01
testosterone <0.01 <0.01 <0.01
androstenedione <0.01 NA <0.01
Table 1.6 Relative binding affinity of various compounds for the two ER subtypes.
Relative binding affinity value for oestradiol was arbitrarily set at 100. Adapted
from Kuiper et al. (1997) and Kuiper et al. (1998). The ligand binding domains of
human and rat ERp share 93.4% homology (Enmark et al. 1997). NA, data not
available.
1.6.4 ER expression in prostate
Using in situ hybridisation, Ehara et al. (1995) localised ERa mRNA to the
stroma of BPH; epithelial cells were not labelled. Three immunohistochemical
studies have also localised the ERa mainly to the stroma of normal prostate and BPH
but immunostaining in the epithelial compartment was less intense and more variable
(Ehara et al. 1995, Bonkhoff et al. 1999, Royuela et al. 2001).
Whereas expression of ERP in the rat is highest in prostate and ovary (Kuiper
et al. 1997), ERp expression was relatively low in human prostate as detected by
Northern analysis (Enmark et al. 1997). Using in situ hybridisation, Enmark et al.
(1997) reported low ERp mRNA expression in the epithelium of normal prostate
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while the stroma was not labelled. Immunostaining of ERP was positive in 13%,
30% and 80% of epithelial cells in normal prostate, BPH and cancer tissues
respectively (Royuela et al. 2001); the same study reported no ERP staining of
stromal cells in normal or BPH tissues but 12% of cancer stromal cells were
immunopositive. Another study also localised ERp to the epithelium and a few
stromal cells in normal prostate tissue by immunohistochemistry (Pasquali et al.
2001a).
To summarise, it is unclear whether ERa and ERp are localised exclusively
to either of the stromal or epithelial compartments. It appears that both in situ
mRNA hybridisation and immunohistochemical studies have localised ERa mainly,
but not exclusively, to the stroma and ERp predominantly to the epithelium, at least
in normal and BPH tissues.
1.7 Benign Prostatic Hyperplasia
Three disease categories are common in the prostate; they are benign
prostatic hyperplasia (BPH), prostatitis and carcinoma. BPH is the primary concern
of this thesis.
1.7.1 Epidemiology
BPH patients, on average, first present with urinary symptoms in their 60s
with symptoms of lower urinary tract obstruction. The percentage of men with
pathologically identifiable BPH at autopsy increases every year in men between 41
and 90 years of age; in general, about 40-50% of the male population have
histological evidence ofBPH at the age of 50 (Uson et al. 1991). Autopsy studies of
BPH in different parts of the world showed that the age-specific prevalence of BPH
was similar in many countries including Austria, Denmark, England, India, Japan
and the United States (Isaacs & Coffey 1989). This is in contrast to the wide
variation seen in the prevalence of clinically diagnosed BPH; one reason for the
variation is the lack of a widely accepted case definition ofBPH (Guess 1995).
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1.7.2 Pathology
The majority of hyperplasia arises from the transition zone and periurethral
region. Most clinically significant cases consist of enlargement of the transition
zone; whereas periurethral hyperplasia seldom reaches clinically significant size,
except as an occasional midline mass at the bladder neck protruding into the bladder
lumen (McNeal 1990). The hyperplastic tissue usually comprises a mixture of
fibroleiomyomatous nodules and glandular areas. It has been suggested that
abnormal proliferation begins most likely in the stroma, while the proliferation of the
glandular epithelium is secondarily induced (Helpap 1992).
1.7.3 Pathogenesis
Only two factors are generally considered essential for the development of
BPH, ageing and the presence of a testis. At least two approaches to BPH aetiology
that emphasise different possible mechanisms have evolved over the years.
1.7.3a Theories based on hormonal mechanisms
The observation that the prostate does not develop in patients with testicular
feminisation syndrome or 5aR2 deficiency highlights the importance of androgens,
DHT in particular, in the normal growth and development of this gland. Since the
early report (Siiteri & Wilson 1970) that intraprostatic DHT concentrations were
higher in BPH tissue than in normal tissue, DHT has been considered a factor in
promoting the development of BPH. However, Walsh et al. (1983) demonstrated
that DHT levels were not higher in BPH than in normal prostate tissue and argued
that previously reported differences in prostatic DHT levels were artefacts due to
differences in sample collection methods. Nevertheless, in patients with BPH,
inhibition of 5aR2 activity decreased both intraprostatic DHT concentrations and the
prostate size (Rittmaster 1994). It is therefore possible that DHT plays a permissive
rather than causative role in BPH pathogenesis.
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It is noteworthy that BPH manifests clinically at a stage in life when both
testosterone and DHT levels are declining. While plasma androgen levels decrease
gradually, plasma oestrogen levels remain more or less constant, resulting in
gradually increasing ratios of oestrogens to androgens with advancing age (table 1.7;












Androstenedione -l 1.3%/yr 5.5b 30.0b*
Testosterone 0.4%/yr 18.4a; 20b 1.3a; 14.lb*
Dihydrotestosterone 2.6a,b 25.6a; 45.5b*
DHEA i 3.1%/yr 15c 69c
DHEA-sulphate ± 2.2%/yr NA NA
3aAdiol f 0.8%/yr 0.84a 1.43a
3pAdiol NA 1.4s 7.1c
A5diol NA 2.2C 9.9C
Oestradiol <-» 0.147a; 0.064c 0.229a; 0.095c
Oestrone 0.098c 0.198c
Table 1.7 Mean androgen and oestrogen levels in plasma and prostate of men.
(a)Ghanadian & Puah (1981); (b)Habib et al. (1976); (c)Voigt & Bartsch (1986); ^Gray
et al. (1991). -I, decreasing trend with age; <r+, no change with age; NA, data not
available; *, prostate hormone levels expressed as nmol/kg dry tissue weight.
DHEA, dehydroepiandrosterone; 3aAdiol, 5a-androstane-3a,17(3-diol; 3pAdiol, 5a-
androstane-3p,17P-diol; A5diol, androst-5-ene-3p,17P-diol.
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With advancing years, therefore, the ageing prostate is influenced by a
gradually changing oestrogen/androgen balance. In the 1970s and 1980s, a lot of
attention was focused on the role for oestrogens in BPH pathogenesis and
management. Oestradiol was shown to exert a synergistic effect with androgens in
inducing glandular prostatic hyperplasia in castrated dogs (Walsh & Wilson 1976,
DeKlerk et al. 1979), whereas castrated dogs treated with oestradiol alone developed
squamous epithelial metaplasia in their prostates (DeKlerk et al. 1979). It was thus
hypothesised that oestrogens might also exert a synergistic effect with androgens in
inducing prostatic hyperplasia in man (Walsh & Wilson 1976, DeKlerk et al. 1979).
In another study, diethylstilboestrol (a synthetic oestrogen) also induced squamous
metaplasia of the epithelium in prostatic tissue isolated from aborted human fetuses
and then grown in athymic male mice (Sugimura et al. 1988). However, the role of
oestrogens in the pathogenesis of BPH, a predominantly stromal disease, is not yet
clear. With the discovery of a second oestrogen receptor (ERP) in 1996 (Kuiper et
al. 1996, Mosselman et al. 1996), interests have once again focused on the role of
oestrogens and the two ER subtypes in prostatic pathophysiology.
Recently, Weihua et al. (2001) demonstrated that in normal mice, but not in
ERp knockout mice, treatment with the C-19 steroid 5a-androstane-3p,17P-diol
(3pAdiol) led to decreased androgen receptor protein expression in the prostate; they
suggested that 3pAdiol could be an important ligand for ERp in the prostate. Indeed,
plasma levels of 3pAdiol are about 10-fold higher than plasma E2 and Ei levels,
whereas in BPH tissue, concentrations of 3pAdiol are >30-fold higher than those of
E2 and Ei (table 1.7). Another C-19 steroid is androst-5-ene-3p,17P-diol (A5diol).
Plasma and prostatic levels of A5diol were shown to be even higher than those of
3pAdiol (table 1.7); it also has relatively high binding affinity for ERP (table 1.6,
p.33). However, the function of this putative weak oestrogen in the prostate is
unknown.
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1,7.3b Stromal-epithelial interaction theory
During embryonic development, epithelial cells are directed by stromal
signalling towards functional differentiation (Cunha et al. 1987). McNeal (1978)
proposed the embryonic reawakening hypothesis and suggested that some stroma-
derived humoral factor might induce glandular budding and branching, giving rise to
new alveoli in the transition zone and eventually hyperplastic nodules. It has also
been proposed that hyperplasia can be induced by abnormal levels of growth factors
secreted from the epithelial or stromal compartment; these growth factors include the
epidermal growth factor (EGF), basic fibroblast growth factor (bFGF) and
transforming growth factor-(3 (TGF-P) (Habib 1994). Supporting this hypothesis are
experiments on the transgenic mouse model, in which introduction of the int-2 proto-
oncogene (a member of the FGF gene family) into the mouse genome resulted in
enlargement of the animal's prostate gland (reviewed in Habib 1994).
Although the above theories of BPH pathogenesis appear to differ from one
another in mechanism, it is possible that hormonal changes and epithelial-stromal
interactions may synergistically influence the growth and function of various
prostatic cell types, leading to hyperplasia of both epithelial and stromal components
of the prostate. For example, locally produced steroid metabolites might act as cross¬
talk signals between the epithelium and stroma, and thus contribute to the
development of BPH. Recently, Labrie et al. (2000) proposed that in basal cells of
the prostatic epithelium, the inactive precursor DHEA is converted to
androstenedione (by 3PHSD) and then testosterone (by 17PHSD); this locally
produced testosterone is then transported into luminal cells and is further converted
to the potent androgen DHT by 5a-reductase. Whether this type of local steroid
metabolism can lead to development of hyperplasia awaits further investigation. To
date, the pathogenesis ofBPH remains largely unresolved.
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1.8 Management of BPH
Until about 20 years ago, the only options for patients with lower urinary
tract symptoms (LUTS) due to BPH, which include both irritative symptoms
(urgency, frequency, nocturia and urge incontinence) and obstructive symptoms
(hesitancy, weak stream, straining, prolonged micturition and urinary retention),
were either 'watchful waiting' or surgical treatment. However, with the advent of
effective and safe medical therapies, the first-line treatment for BPH patients today is
in most cases medical rather than surgical. Many different classes of drugs are
currently available for the treatment of BPH. Because of limited space, only the
three most commonly used are discussed below, followed by a brief outline of
surgical options.
1.8.1 a-adrenoceptor blockers
The principal motor control of the prostate is via action on ai-adrenoceptors,
which are localised predominantly within the stromal compartment of the prostate
(Chappie 2000). a-blockers relax the smooth muscle found in the prostatic capsule,
stroma, urethra as well as bladder neck and can therefore relieve some BPH
symptoms. The most widely prescribed ai-antagonists include prazosin, alfuzosin,
doxazosin and terazosin. They can be used in prostates of any size and have a rapid
onset of action (Djavan & Marberger 1999). Important side-effects in up to 10% of
patients include tiredness, dizziness and headache due to a-blockade in the brain and
cardiovascular system (Djavan & Marberger 1999).
1.8.2 5a-reductase type 2 (5aR2) inhibitors
Finasteride is the only 5aR2 inhibitor widely available for the treatment of
BPH. It inhibits the conversion of testosterone to DHT, which plays an important
role in maintaining prostatic growth (reviewed in section 1.3.2). Finasteride has been
shown to effectively decrease the volume of the prostate, reduce BPH symptoms and
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improve urinary flow rate measurements (Rittmaster 1994). Its main side-effects are
reduced libido and impotence.
1.8.3 Phytotherapy
Phytotherapy, or the medicinal use of plant extracts, for treating LUTS and
BPH is common in continental Europe and is increasing in the Western Hemisphere.
There are currently more than 30 phytotherapeutic agents commercially available. In
Italy, phytotherapeutic agents represent nearly half of all the medications dispensed
for the treatment of LUTS, compared with 5% each for a-adrenoceptor blockers and
5aR2 inhibitors. In Germany and Austria, phytotherapy is the first-line treatment for
mild-to-moderate LUTS. In the USA, phytotherapeutic agents for the treatment of
LUTS are readily available as non-prescription dietary supplements (Wilt 2000).
Plants from which common phytotherapeutic compounds were extracted for LUTS
management include dwarf American palm (Serenoa repens), South African star
grass (Hypoxis rooperi), rye-grass pollen (Secale cereale), African plum (Pygeum
africanum) and stinging nettle (Urtica dioica).
1.8.3.1 Permixon®
Of all the phytotherapeutic agents available for the management of LUTS and
BPH, the most widely researched one is Permixon®. Permixon® is the lipido-sterolic
extract of the fruit of Serenoa repens. The predominant constituents are free fatty
acids (approximately 90%) including oleic acid, lauric acid, myristic acid and
palmitic acid; there are also small quantities of aliphatic alcohols (C26, C28 and C30)
and phytosterols including (3-sitosterol, campesterol and stigmasterol (Neuzil &
Cousse 1993).
Clinical studies have shown that compared with finasteride (a 5aR2
inhibitor), Permixon® produced similar improvements in both urological symptoms
and urinary flow measures in patients with BPH and was associated with fewer
adverse side effects (Carraro et al. 1996, Wilt et al. 1998).
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Very limited data are available on the pharmacokinetic properties of
Permixon®, probably because it is a complex mixture of various compounds. In
healthy young male volunteers, after oral administration of a single dose of 320 mg
Permixon® (usual recommended dose for BPH patients), mean peak plasma
concentrations of the drug and elimination half-life were estimated to be 2.6 mg/1 and
1.9 h respectively (Plosker & Brogden 1996).
The mechanism of action of Permixon® is not entirely clear. It has been
shown to inhibit both isozymes of 5a-reductase in a baculovirus-directed insect cell
system expressing either of the two isozymes (Iehle et al. 1995) and in human BPH-
derived cells in primary culture (Bayne et al. 1999). The conversion of testosterone
to androstenedione in human prostatic cells in primary culture was also inhibited by
Permixon® (Delos et al. 1995). In a clinical study, Permixon®-treated patients were
shown to have decreased levels of nuclear oestrogen receptors but no difference in
concentrations of cytosolic oestrogen receptors in their prostate tissue compared with
the placebo-treated group (Di Silverio et al. 1992). Other reported effects of
Permixon® include inhibition of DHT binding to androgen receptor (Carilla et al.
1984) and reduction of prostatic concentrations of epidermal growth factor (Di
Silverio et al. 1998).
1.8.4 Surgical management
Transurethral resection of the prostate (TURP) has been a gold-standard
treatment for BPH for many years. It started to develop in the early 20th century and
remains the procedure of choice for patients with severe LUTS and those whose
symptoms do not improve with non-surgical treatment. It involves the removal of
prostatic tissue in a slice-by-slice manner through a transurethral resectoscope.
Other options of surgical treatment include bladder neck incision and open
prostatectomy.
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1.9 Experimental Models of BPH
1.9.1 Animal models
Spontaneous prostatic hyperplasia occurs commonly in only two species, man
and dog (Walsh & Wilson 1976). While the human disease often has a multinodular
pattern with predominantly stromal tissue, prostatic hyperplasia in the ageing dog is a
diffuse epithelial process with little stromal involvement. Prostatic hyperplasia can
also be induced in younger dogs by a combination of androgens and oestrogens,
resulting in cystic glandular hyperplasia (Walsh & Wilson 1976, DeKlerk et al.
1979).
A transgenic mouse model which over-expressed the fibroblast growth factor
family member, int-2, was reported to develop prostatic hyperplasia (Tutrone et al.
1993). The histology of the enlarged murine prostate resembled that of the dog; it
was characterised by epithelial hyperplasia and cystic enlargement of the glandular
lumen with no fibromuscular involvement (Tutrone et al. 1993), which is quite
different from the usual histological features found in human BPH. The prostate of
aromatase knockout mice also showed epithelial hyperplasia (McPherson et al.
2001). Because of the complications associated with animal experimentation and the
differences in pathology between animal models and human BPH, other models to
study BPH pathogenesis have been developed over the years.
1.9.2 Immortalised cell lines
Most immortalised cell lines are populations of aneuploid cells. The most
commonly used human prostate cell lines are PC3, DU145 and LNCaP, all of which
are derived from prostate cancer metastases and are epithelial in origin (Kaighn et al.
1979, Stone et al. 1978, Horoszewicz et al. 1983). The PC3 cell line was isolated
from a bone metastasis and its characteristics are consistent with a poorly
differentiated adenocarcinoma (Kaighn et al. 1979). The DU145 cell line derived
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from a metastatic brain lesion in a patient who had undergone oestrogen therapy for
advanced prostate cancer (Stone et al. 1978). The LNCaP cell line was established
from needle biopsies taken from a supraclavicular lymph node containing prostate
cancer metastatic cells (Horoszewicz et al. 1983); it expresses a mutated androgen
receptor that binds to androgens, oestrogens and progestagens (Veldscholte et al.
1992). Because all of these three cell lines derived from prostate cancer metastases,
they are not considered ideal models ofbenign hyperplastic cells.
Other prostate cell lines have also been developed, one example of which is
the BPH-1 cell line. BPH-1 is an immortalised cell line derived from primary human
epithelial cell cultures obtained by transurethral resection (Hayward et al. 1995).
Although cell lines, in general, are relatively easy to maintain, long-term culturing of
cells alters their phenotypes with increasing passage numbers, and brings into
question the reliability of cell lines as representative models of the in vivo situation.
1.9.3 Primary cultures of BPH-derived cells
Short-term primary cell cultures derived from fresh BPH tissues should, in
theory, not be too different from their tissue of origin in phenotypes. They represent
the various cell populations normally present in the tissue of origin and yet provide
the advantages normally associated with monolayer cell cultures. Methods to
separate epithelial cells from fibroblasts using enzymatic digestion of prostate tissue
chips obtained from BPH patients are well established in the Prostate Research
Group Laboratory, University of Edinburgh. The cell cultures have been
characterised by microscopy and immunohistochemistry employing a number of
antibodies to identify epithelial cells, fibroblasts and smooth muscle cells (Tsugaya
et al. 1996a). These immunohistochemical characteristics were also confirmed at the
beginning of this project and corresponded well with the various cell types found in
histological sections. These cells in primary culture provide in vitro models to study
prostatic cells which are BPH in origin. However, primary prostatic cell cultures are
by no means ideal experimental models of BPH. Their phenotypes are not entirely
identical to cells in vivo; for example, 5a-reductase type 2 isozyme is not expressed
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in either epithelial cells or fibroblasts in primary culture (Bayne et al. 1998) but has
been demonstrated in both compartments of hyperplastic prostate tissue (reviewed in
section 1.3.3). Compared with immortalised cell lines, it is also relatively difficult to
maintain viable and proliferating epithelial cells after sub-culturing. Although
surgical resection of the prostate is a common treatment for BPH, the supply of
prostate chips fluctuates and depends on many logistic factors. Bacterial and fungal
contamination due to infected tissues is another problem associated with primary
cultures.
1.10 Objectives of Thesis
There are two main questions which this thesis set out to answer and they are:
1. What is the function of 5a-reductase type 1 isozyme in the human prostate?
2. What is the role of oestrogens in BPH pathogenesis?
To date, two distinct isozymes of 5a-reductase, 5aRl and 5aR2, have been
identified in man; both are expressed in the prostate. The role of 5aR2 is well
established. It is the predominant isozyme in the human prostate, where it converts
testosterone to the more potent androgen dihydrotestosterone, crucial for maintaining
growth and function (section 1.3.2). In contrast to 5aR2, the function of 5aRl in the
prostate is still unknown. Recent data from female 5aRl knockout mice indicated
that a normal role for 5aRl in the female mouse is to prevent the metabolism of
placental androgens to oestrogens by converting aromatisable androgens to non-
aromatisable forms (Mahendroo et al. 1997). Here the hypothesis that 5aRl also
plays a role in regulating aromatase activity in human prostatic cells was tested, first
in a co-transfection model and then in primary cultures of prostatic cells. To this
end, because aromatase expression in the human prostate is controversial, aromatase
mRNA expression and activity in prostatic cells were also examined.
The aim of the second part of this study was to determine the effects of
oestrogens on prostatic cells and whether these effects can contribute to the
development of BPH. Classically, oestrogen action is mediated by oestrogen
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receptor (ER); the expression of both ER subtypes in prostatic cells was thus
investigated. This was followed by experiments to explore any effects of oestrogens
on prostatic cell proliferation. As BPH is a result of increased cell proliferation or
decreased cell death or both, results from such experiments would shed light on any
possible role of oestrogens in BPH pathogenesis. Recently, 5a-androstane-3(3,17(3-
diol (3pAdiol) was suggested as an important ligand for ERp in the prostate (Weihua
2001), its effects on prostatic cell proliferation were therefore examined and
compared to those of oestradiol.
Many drugs are currently available for the treatment of BPH, one of which is
the phytotherapeutic agent Permixon®. Although it has been shown to be clinically
efficient in reducing the size of hyperplastic prostate (section 1.8.4), the mechanism
ofPermixon® is not yet clear. Part of this project was to look at yet unknown effects
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Unless otherwise stated, all chemicals and reagents were purchased from
Sigma (Poole, Dorset, UK)
2.1.1 Cell culture
2.1.1a Cell lines
The PC3 cell line was isolated from a poorly differentiated bone metastasis of
human prostatic carcinoma (Kaighn et al. 1979). The COS-1 cell line was derived
from the simian kidney CV-1 cell line (Gluzman 1981). The CHO cell line was
derived from a biopsy of an adult Chinese hamster ovary (Puck 1958). The C6 cell
line was cloned from a rat glial cell tumor (Benda et al. 1968). All cell lines were
obtained from the European Collection of Cell Cultures (ECACC), Centre for
Applied Microbiology and Research, Salisbury, Wiltshire, UK and were regularly
screened for mycoplasma contamination using a mycoplasma detection kit
(Boehringer Mannheim UK, Lewes, UK).
2.1.1b General consumables
All plasticware including tissue culture flasks, Universal containers,
Erlenmeyer flasks and disposable pipettes was obtained from Bibby Sterilin
(Staffordshire, UK). All media and solutions were sterile-filtered before use with
either 0.2 pm bottle-top filter or 0.2 pm Acrodiscs supplied by Sigma and Gelman
Sciences (Northampton, UK) respectively. Dulbecco 'A' phosphate buffered saline
(PBS) was purchased from Unipath (Basingstoke, Hampshire, UK). lOx Trypsin-
EDTA (0.5% w/v trypsin, 0.2% w/v EDTA and 0.85% w/v NaCl) was from Life
Technologies (Paisley, Scotland, UK).
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2.1.1c Cell culture media and supplements
RPMI 1640 medium, DMEM medium and WAJC 404 medium were obtained
from Life Technologies. All media, unless specified otherwise, were supplemented
with foetal calf serum (FCS), L-glutamine (200 mM), penicillin (10,000 units/ml)
and streptomycin (10,000 pg/ml), which were acquired from Life Technologies.
Collagenase was obtained from Worthington Biochemical Corporation (Freehold,
New Jersey, USA). MTS reagent (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxy-phenyl)-2-(4-sulfophenyl)-2H-tetrazolium) was purchased from
Promega (Southampton, UK).
2.1.2 Molecular biology
All materials utilised in reverse transcription (RT) and polymerase chain
reaction (PCR) were from Promega (Southampton, UK). Restriction enzymes were
also from Promega. PfuTurbo DNA polymerase was purchased from Stratagene
(Amsterdam, the Netherlands). Agarose NA was obtained from Amersham
Pharmacia Biotech (Little Chalfont, Bucks, UK). Sterile screw cap Eppendorf tubes
were purchased from Sarstedt (Beaumont Leys, Leicester, UK). All primers were
synthesised by Oswel DNA Service (University of Southampton, Southampton, UK).
2.1.3 Steroids
All non-radiolabelled steroids were from Sigma. Radiolabelled steroids
including [4-14C]-androstenedione, [4-14C]-dihydrotestosterone, [4-14C]-testosterone
(all of S.A. 53.6 mCi/mmol) and [4-14C]-oestrone (S.A. 50.3 mCi/mmol) were
obtained from NEN Life Science Products (Hounslow, UK). [4-14C]-5a-
androstanedione was synthesised from [4-14C]-androstenedione as described in
section 2.3.3. Tritium-labelled steroids, including [l,2,6,7-3H]-androstenedione (S.A.
100 Ci/mmol), [l,2,6,7-3H]-testosterone (S.A. 95 Ci/mmol), [2,4,6,7-3H]-oestrone
(S.A. 101 Ci/mmol) and [2,4,6,7-3H]-oestradiol (S.A. 99 Ci/mmol) were from
48
Amersham (Little Chalfont, Bucks, UK). Radiolabeled steroids were purified by
thin layer chromatography before use as described in section 2.3.3.
2.1.4 Chromatography
2.1.4a Thin layer chromatography (TLC)
ITLC™ SA polysilica acid gel impregnated glass fibre TLC plates were
purchased from Gelman Sciences (Ann Arbor, Michigan, USA). Ultima Gold Liquid
Scintillation Cocktail was supplied by Packard Bioscience (Pangbourne, Berks, UK).
Diethyl ether, dichloromethane, ethanol and benzene were obtained from Fisher
Scientific (Leicestershire, UK).
2.1,4b High performance liquid chromatography (HPLC)
All HPLC grade solvents were supplied by Rathburn Chemicals (Walkerburn,
Peebleshire, UK). Quicksafe Flow-2® scintillant was purchased from Zinsser
Analytic (Maidenhead, Berks, UK)
2.2 Cell Culture
2.2.1 Cell lines
2.2.1a Culture of cell lines
The COS-1, CHO, C6 and PC3 cell lines were cultured in Dulbecco's
Modified Eagles Medium (DMEM) supplemented with 10% foetal calf serum (FCS),
L-glutamine (2 mM), penicillin (100 units/ml) and streptomycin (100 pg/ml). The
cell lines were grown in monolayer culture in 75 cm2 tissue culture flasks in a
humidified incubator (T305GF Assab; Kebo Assab AB, Solna, Sweden) maintaining
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an atmosphere of 95% air and 5% C02 at 37°C. All tissue culture procedures were
carried out in a laminar flow cabinet (Howarth Air Engineering Ltd., Farnworth,
Bolton, UK) using aseptic techniques and sterile, disposable plastic pipettes and
pipette tips. To ensure that a sterile environment was maintained, the laminar flow
cabinet was thoroughly cleaned before, during and after operations with a solution of
70% ethanol. In addition, all handling of cell lines was performed using disposable
latex gloves.
Continuous cell growth was maintained through regular sub-culture 2-3 times
per week. Upon achieving approximately 80% confluence, cells were harvested
through trypsinisation, diluted 1:3 in medium and delivered into 3 fresh flasks. The
sub-culture process involved the aspiration of spent medium from cells followed by 2
washes with phosphate buffered saline (PBS) and a 3 min incubation at 37°C in 2 ml
lx trypsin-EDTA (0.2 ml lOx trypsin-EDTA and 1.8 ml PBS). The cells were then
detached through gentle agitation and 10 ml of the appropriate medium was added to
the cell suspension. Following centrifugation at 2000 rpm for 5 min, resuspension of
the pellet in 12 ml medium with repeated pipetting ensured cell suspension. 4 ml of
this suspension was delivered to each flask, to which an additional 11 ml medium
was added. The medium was changed every 48-72 h.
2.2. lb Long term storage of cells
Cell lines could be stored for long periods by freezing in a gas phase liquid
nitrogen storage container. Cells were prepared for freezing by trypsinisation as
described above. The cells were pelleted by centrifugation at 2000 rpm for 10 min
and the pellet was then resuspended in 1 ml freezing medium, which consisted of
10% dimethyl sulphoxide (DMSO) in FCS. The cells were mixed with the freezing
medium by tituration before being transferred to cryogenic ampoules (Corning) and
stored at -70°C overnight. The cells were then transferred to the gas phase of liquid
nitrogen.
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2.2. lc Thawing of frozen cells
Frozen cells were thawed in a 37°C water bath. DMSO in the freezing
medium was washed out of the thawed cell suspension by transferring it to a
Universal containing 20 ml culture medium. The cell suspension was thoroughly
mixed by vortexing prior to centrifugation at 2000 rpm for 10 min. The cell pellet
was then resuspended in 10 ml culture medium and transferred to a 75 cm2 cell
culture flask.
2.2.2 Culture of epithelial cells and fibroblasts from human prostatic tissue
The primary culture of epithelial cells from prostatic acini in serum-free
medium was first described by Chaproniere & McKeehan (1986). The protocol
described here is based on the technique developed by Chaproniere & McKeehan
(1986) and described by Habib et al. (1992). Verification of the purity of epithelial
cells and fibroblasts was established by immunohistochemistry using a variety of
mouse monoclonal anti-human antibodies as described by Tsugaya et al. (1996).
Prostate tissue was obtained with informed consent from patients undergoing
transurethral resection of the prostate (TURP) for the treatment and relief of the
symptoms of BPH. The prostate chips were immediately placed in 15 ml Transport
Medium (RPMI 1640 medium supplemented with 5% FCS) and were stored for up to
7 days at 4°C before use. Pathology of prostate tissue was determined by routine
examination of representative samples of excised tissue by histopathologists at the
Department ofPathology, Western General Hospital, Edinburgh.
2.2.2a Enzymatic dissociation of fibroblasts and epithelial cells
The prostate chips were washed twice in 25 ml PBS, weighed and cut into
approximately 2 mm3 cubes using sterilised scissors and forceps. The tissue was
subsequently transferred to a sterile Erlenmeyer flask, washed with 20 ml Transport
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Medium and finally suspended in 5 ml Transport Medium per gram of tissue. 2.5 ml
filter-sterilised collagenase solution (600 units/ml) in Transport Medium was mixed
with each gram of tissue and the flask placed in a 37°C shaking incubator (Luckham
R300; Luckham Ltd., Burgress Hill, UK). The tissue was incubated for 20 h with
gentle agitation to maintain the integrity of the acini. The digest was then triturated
by repeated pipetting, decanted into sterile Universal containers and centrifuged at
2000 rpm for 10 min. The supernatant was decanted and the cell pellet resuspended
in 20 ml PBS to wash out the collagenase. The cells were again centrifuged at 2000
rpm for 10 min and washed in PBS. These steps of centrifugation and washing were
repeated prior to suspension of the pellet in 10 ml Transport Medium. The acini,
containing epithelial cells, were sedimented by ccntrifugation at 800 rpm for 20 s.
The supernatant contained aggregates of fibroblasts. The acini were carefully
aspirated using a sterile Pasteur pipette and transferred to a fresh Universal container.
The acini were spun down twice more and collected in the same manner.
2.2.2b Epithelial cell culture
Epithelial cells were maintained in epithelial cell growth medium (EGM),
each litre ofwhich consisted of the following in distilled water:
11.04 g WAJC 404 medium powder
6.7 g HEPES
1.2 g sodium hydrogen carbonate
0.5 mg zinc stabilised insulin
20 pg cholera toxin
392 pg dexamethasone




pH of the growth medium was adjusted to 7.6 using 1M NaOH.
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After enzyme dissociation, acinar deposits were resuspended in 5 ml EGM
per gram of original tissue and plated out in 75 cm2 tissue culture flasks. One flask
was used for every 2-4 g tissue. The cultures were incubated at 37°C for 72 h before
being supplemented with 10 ml EGM. After a further 48 h incubation, the spent
medium could be replaced with fresh medium. Upon reaching 80% confluence,
epithelial cells were harvested by trypsinisation using lx trypsin-EDTA solution.
Following the detachment of epithelial cells from the flask, the trypsin solution was
inactivated using RPMI 1640 medium supplemented with 10% FCS. The cells were
then centrifuged at 1500 rpm for 5 min and resuspended in 20 ml EGM. The cell
suspension was divided equally between two 75 cm2 tissue culture flasks. In general,
it was possible to passage the cells once. Beyond passage number one, epithelial
cells displayed a reduced growth rate and had difficulty adhering to the flasks.
2.2.2c Fibroblast cell culture
The supernatant from 2.2.2a was centrifuged at 2000 rpm for 10 min and the
resulting cell pellet was resuspended in 10 ml fibroblast growth medium (FGM;
RPMI 1640 medium supplemented with 10% FCS, 2 mM L-glutamine, 100 units/ml
penicillin and 100 pg/ml streptomycin). The fibroblast cell suspension was seeded
into one 75 cm2 flask and grown in monolayer culture at 37°C for 72 h. Following a
change of fresh medium, the cells were maintained until 80% confluent. Sub-culture
was performed as described in section 2.2.1a.
2.2.3 Determination of cell numbers
2.2.3a Manual determination of cell numbers by haemocytometer
Cells to be counted were washed in PBS, incubated with lx trypsin-EDTA
for 2 min at 37°C, centrifuged and resuspended in culture medium. Cell numbers
were determined using both chambers of a haemocytometer with four of the 0.1 mm3
squares in each chamber counted and an average of the counts taken.
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2.2.3b Colorimetric determination of viable cell numbers
The proliferative rates of prostatic cells in primary culture were determined
using the MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-phenyl)-2-(4-
sulfophenyl)-2H-tetrazolium) assay according to the manufacturer's protocol
(Promega). The MTS assay provides a colorimetric method for determining the
number of viable cells in proliferation or cytotoxicity studies (Maghni et al. 1999).
MTS tetrazolium compound is bioreduced by viable cells into a coloured formazan
product that is soluble in tissue culture medium. Dead cells do not cause this change.
The quantity of formazan product is measured spectrophotometrically at 490 nm and
is directly proportional to the number of living cells in culture.
Cells were plated in 96 well plates, supplemented with 150-200 pi per well of
the appropriate medium. At the end of an incubation period of 2-4 d of treatment
with steroids or drugs, the culture medium was removed and 100 pi ofMTS working
solution (MTS stock solution diluted 1:5 in the appropriate culture medium) added.
Cells were then incubated with MTS at 37°C for 1-3 h. Subsequent to this
incubation, the absorbance of the resulting solution was measured at 490 nm with a
microplate reader (model 450; Bio-Rad Laboratories, Hemel Hempstead,
Hertfordshire, UK). At least 2 wells per plate containing no cells were incubated
with the MTS working solution as blanks.
2.2.4 Measurement of the growth response of cultured cells
The growth response of epithelial cells and fibroblasts to oestrogenic
compounds and the anti-oestrogen ICI 182780 (Tochris, Bristol, UK) was determined
using the MTS assay as outlined in 2.2.3b. Whenever possible, media employed
were phenol red-free and the FCS was rendered steroid hormone-free through
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treatment with dextran-coated charcoal (DCC). All cells were grown in 96 well
tissue culture plates.
2.2.4a Preparation of DCC-stripped FCS (DCC-FCS)
1 g DCC was mixed in an Erlenmeyer flask with 100 ml FCS and the mixture
shaken at 4°C for 24 h. The charcoal was then removed by centrifugation and the
serum filter-sterilised through a 0.2 pm filter. To test the efficiency of steroid
stripping, 10 nM of each of the radiolabelled steroids [l,2,6,7-3H]-androstenedione,
[l,2,6,7-3H]-testosterone, [4-14C]-dihydrotestosterone and [2,4,6,7-3H]-oestradiol was
added to 1 of 4 flasks containing FCS. Aliquots of serum before and after DCC-
stripping were added to 6 ml liquid gold scintillation cocktail (Canberra Packard,
Pangbourne, UK). Radioactivity in each sample was then quantified using a Tri-
Carb liquid scintillation counter (Canberra Packard). After DCC treatment, less than
5% of radioactivity remained in each sample of FCS compared with FCS before
stripping.
2.2.4b Preliminary MTS assays
Preliminary experiments were carried out to confirm that the MTS assay is
suitable for determining numbers of prostatic fibroblasts and epithelial cells in 96-
well plates. Epithelial cells (passage number 1; fig. 2.1) and fibroblasts (passage
number 2; fig. 2.2) were harvested as described above and plated in triplicate at a
density of 1-10 x 103 cells per well in 150 pi serum-free EGM and phenol red-free
RPMI medium (PRF-RPMI) supplemented with 5% DCC-FCS respectively. 4 h
after seeding, when cells have attached to the bottom of wells, the medium in each
well was carefully removed and 100 pi MTS working solution was added. MTS
assay was performed as outlined above in section 2.2.3b.
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Figures 2.1 and 2.2 show that absorbance at 490 nm of the MTS solution in
96-well plates was proportional to the number of epithelial cells or fibroblasts seeded
into each well up to approximately 8000 cells/well.
2 4 6 8 10
number of Ep (x1000)
Fig. 2.1 Measurement of epithelial cell number by the MTS assay. Epithelial
cells (Ep) were plated in triplicate in serum-free EGM at 2-10 x 1000 cells/well in a
96-well plate. 4 h after seeding, the medium in each well was removed and 100 pi
MTS working solution (MTS stock solution diluted 1:5 in serum-free EGM) was
added to each well. 2 wells containing no cells were included as blanks. Cells were
then incubated with MTS for 1 h (open bars) or 2 h (solid bars). Absorbance at 490
nm was measured using a microplate reader. Results are corrected by absorbance in
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Fig. 2.2 Measurement of fibroblast cell number by the MTS assay. Fibroblasts
(Fb) were plated in triplicate in PRF-RPMI supplemented with 5% DCC-FCS at 1-10
x 1000 cells/well in a 96-well plate. 4 h after seeding, the medium in each well was
removed and 100 pi MTS working solution (MTS stock solution diluted 1:5 in the
same medium) was added to each well. 2 wells containing no cells were included as
blanks. Cells were then incubated with MTS for 1.5 h (open bars) or 2.5 h (solid
bars). Absorbance at 490 nm was measured using a microplate reader. Results are
corrected by absorbance in control wells and expressed as mean of triplicates ± s.e.m.
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2.2.4c Growth response experiments for epithelial cells and fibroblasts in
primary culture
The growth of prostatic cells in primary culture over a period of 2-4 d was
assessed by the MTS assay. Epithelial cells grown in monolayer culture in 75 cm2
tissue culture flasks were harvested through trypsinisation as described before and
the cell number was determined using a haemocytometer as described in section
2.2.3a. Cells were then resuspended in serum-free EGM to the desired final
concentration and plated at a density of 3000 cells/well in 96-well plates. Fibroblasts
were treated in the same manner except that the medium used was PRF-RPMI
supplemented with 0-10% DCCFCS and the plating density was 1800 cells/well.
The final concentrations of oestrogens and anti-oestrogen in culture medium
ranged from 1 nM to 10 pM. 1 mM stock solutions of the compounds in ethanol
were prepared and serially diluted down to 100 nM. For example, the addition of 20
pi oestradiol (1 pM) to 1.98 ml medium gave a final concentration of 10 nM. The
final concentration of ethanol in medium did not exceed 1% (v/v). The medium in
control wells was supplemented with 1% ethanol.
To investigate the effects of oestrogen/anti-oestrogen, epithelial cells in 96-
well plates were grown in serum-free EGM and fibroblasts in PRF-RPMI
supplemented with 2% or 10% DCC-FCS. 48 h before oestrogen/anti-oestrogen
treatment, cells were plated in 0.15 ml/well of the appropriate medium (6 wells per
treatment/control group) and transferred to a 37°C incubator. The remaining wells in
the plates contained 0.18 ml PBS. 48 h later, the medium was carefully aspirated
from the test wells and replaced with 0.18 ml of medium containing various
concentrations of oestrogen/anti-oestrogen. The culture medium containing
oestrogen/anti-oestrogen was changed every 24 h. Cell numbers were determined
after 2 d of oestrogen/anti-oestrogen treatment using the MTS assay as described in
section 2.2.3b.
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2.3 Analysis of 5a-reductase Activity in Tissue Homogenates
2.3.1 Preparation ofBPH tissue homogenates
Although both isozymes of 5a-reductase convert testosterone to
dihydrotestosterone and androstenedione to 5a-androstanedione, their differential pH
optima was one of the first characteristics leading to the discovery of the two
isozymes (Russell & Wilson 1994). The specific pH sodium phosphate buffers for
5a-reductase isozyme assay were prepared as follows.
5aR2 buffer:
sodium phosphate (0.1M, pH 5.0) 1.5 ml x 1M NadTPC^
98.5 mix 1MNaH2P04
diluted to 1000ml with distilled HzO
5aRl buffer:
sodium phosphate (0.1M, pH 7.5) 81.5 mix lMNajHPC^
18.5ml x lMNaH2P04
diluted to 1000ml with distilled H20
Stock solutions of 0.1 M sodium phosphate buffer were diluted to 40 mM with
distilled H20 and supplemented with 0.32 M sucrose.
Prostate tissue, obtained from men undergoing TURP operations for BPH, was
snap frozen in liquid nitrogen and stored at -70°C. Approximately 300 mg frozen
tissue was added to 6 ml sodium phosphate buffer (40 mM, pH 5.0 or 7.5) containing
0.32 M sucrose and 1 mM dithiothreitol (DTT). The tissue samples were then
homogenised using a Ystral blender (3 x 15 s at 15,000 rpm). The homogenised
tissue was then filtered through sterile gauze and transferred into Eppendorf tubes in
1 ml aliquots. The protein concentration of each aliquot was determined
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colourimetrically using a Bio-Rad protein assay kit as described in section 2.3.4.
Tissue homogenates were then prepared for 5a-reductase assay or stored at -70°C.
2.3.2 5a-reductase isozyme assay
The protocol was an adaptation of that described by Smith et al. (1996). Co-
factor reagents were prepared as described below. All co-factors were aliquoted and
stored at -20°C.
lOmMNADP
255 mg dissolved in 30 ml sodium phosphate buffer (40 mM, pH 5.0 or 7.5)
100 mM glucose-6-phosphate
1.144 g dissolved in 29 ml sodium phosphate buffer (40 mM, pH 5.0 or 7.5)
5 units/ml glucose-6-phosphate dehydrogenase
100 pi of 1 unit/pl glucose-6-phosphate dehydrogenase in 16 ml sodium
phosphate buffer (40 mM, pH 5.0 or 7.5) and 4 ml glycerol
An NADPH-regenerating system (0.75 ml) consisting of 40 mM sodium
phosphate buffer (pH 5.0 or 7.5), 0.32 M sucrose, 1 mM DTT, 0.5 mM NADP, 5 mM
glucose-6-phosphate and 0.25 unit/ml glucose-6-phosphate dehydrogenase was
incubated with 0.2 ml tissue homogenate and 10 nM 3H-substrate (total volume of 1
ml) at 37°C for 0-60 min. Control reactions contained no tissue homogenate.
Reactions were stopped by the addition of 2 vol diethyl ether containing 1000
cpm each of 14C-steroids and 25 pg each of unlabelled androstenedione, testosterone,
5a-androstanedione, dihydrotestosterone, 5a-androstane-3a, 17p-diol and 5a-
androstane-3p,17p-diol. The resultant mixture was vortexed for 60 s. The assay
tubes were then transferred to a -70°C freezer for 10-15 min to freeze the aqueous
phase. The supernatant consisting of diethyl ether and extracted steroids was
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decanted into clean glass test tubes and evaporated to dryness in a vacuum oven at
40°C. This extraction process was repeated once. After diethyl ether was
evaporated, the residue was re-constituted in 50 pi ethanol and subjected to thin layer
chromatography (TLC) as described in section 2.7.1a.
Loss of metabolite due to the extraction procedure was calculated by
analysing the recovery of !4C-steroids from the samples. 5oc-reductase activity was
calculated by taking into consideration blank values, specific activities of
radiolabelled steroids and loss due to the extraction process as follows.
HsxCo HbxCo
No. ofmoles of steroid metabolite formation = Cs Cb
2.22 x 1012 x S.A.
In the above formula, Hs and Hb are the 3H counts (dpm) of the sample and the blank
respectively after TLC separation and scintillation counting. Cs and Cb are the 14C
counts (dpm) of the sample and the blank respectively after TLC separation and
scintillation counting. Co is the original 14C count (dpm) of the 14C-labelled steroid
added to the assay for calculation of recovery. S.A. is specific activity of the 3H-
labelled steroid (Ci/mol).
2.3.3 Preparation of [4-14C]-5a-androstanedione
[4-14C]-5a-androstanedione is not commercially available and was therefore
synthesised in-house. Preparative reactions to synthesise [4-14C]-5a-androstanedione
were carried out under conditions identical to the 5a-reductase assay except that 1
pM [4-'4C]-androstenedione was incubated with BPH tissue homogenate for 24 h and
no other steroid was added at the end of the incubation. The resultant radiolabelled
5a-androstanedione was purified by TLC as follows. The dried steroid was re¬
constituted in 50 pi ethanol and run in parallel to non-radiolabelled 5a-
androstanedione on TLC plate as described in section 2.7.1a except that only the non-
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radiolabeled standards were sprayed with a tracer and baked. The area of TLC plate
containing [4-14C]-5a-androstanedione was scraped off and eluted in diethyl ether,
which was then evaporated to dryness in a vacuum oven at 40°C. The purity of the
synthesised [4-14C]-5a-androstanedione was confirmed by high performance liquid
chromatography.
2.3.4 Determination ofprotein concentration
Protein concentrations of tissue homogenates and cell lysates were determined
colorimetrically using a protein assay kit (Bio-Rad DC Protein Assay Kit; Bio-Rad,
Herriel Hempstead, UK) according to the manufacturer's protocol, which is based on
the method of Lowry (Lowry et al. 1951). A range of protein standards (0.1-5.0
mg/ml) was prepared using bovine serum albumin (BSA) in the appropriate buffer. 5
pi protein sample or standard was transferred to a 96 well plate. To this sample, 25
pi reagent A (an alkaline copper tartrate solution) and 200 pi reagent B (containing
Folin reagent) were added. The plate was then gently shaken on an orbital shaker for
15 min at room temperature. Subsequent to this incubation, the absorbance of the
samples was read at 595 nm using a microplate reader (model 450; Bio-Rad
laboratories, Hemel Hempstead, Hertfordshire, UK).
2.4 Preparation of Expression Plasmids
2.4.1 Plasmids for transfection studies
pSV2L: This is an expression plasmid containing a luciferase reporter gene
driven by the simian virus 40 early promoter (De Wet et al. 1987). It was used as an
internal standard for transfection efficiency.
pCMV2 (GenBank accession no. AF239247): This 4.7 kb expression plasmid
is a kind gift from Prof. Ian Mason (Clinical Biochemistry, University of Edinburgh)
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and contains a simian virus 40 origin of replication, a cytomegalovirus promoter, and
the human growth hormone termination and polyadenylation signals (Corbin et al.
1988).
pCMV2.arom (Corbin et al. 1988): This 6.6 kb plasmid encoding the human
aromatase enzyme (also a gift of Prof. Ian Mason) was constructed by ligating a 1.9
kb cDNA fragment (encoding the full-length aromatase) between the EcoKl and
Smal restriction sites of the pCMV2 plasmid (Corbin et al. 1988).
pCMV2.5aRl: This is a 5.5 kb expression plasmid constructed by ligating a
0.8 kb fragment of cDNA encoding human 5a-reductase type 1 isozyme between the
Bglll and Hindlll restriction sites of pCMV2 as described below in section 2.4.2.
2.4.2 Subcloning of 5aRl cDNA
To construct a plasmid expressing human 5a-reductase type 1 (5aRl), a
strategy similar to that used by Andersson & Russell (1990) was employed. The
plasmid ph5a45 encoding full-length 5aRl (Andersson & Russell, 1990; a gift from
Dr. David Russell, University of Texas) was used as a template to synthesise 5aRl
cDNA. Two oligonucleotide primers derived from the 5' end of the cDNA
Bglll
(5' -ATAGATCTACCATGGCAACGGCGACGGGGGTGGCGG-3')
and corresponding to the 3' untranslated region
(5' -AAAGTCCATAGAGAAGCGCCATTGG-3')
were used in a polymerase chain reaction (PCR) with PfuTurbo DNA polymerase
(Stratagene) to remove an upstream ATG and introduce a unique Bglll restriction
enzyme site in the 5' untranslated region.
The polymerase chain reaction consisted of denaturing at 94°C for 5 min,
followed by 30 cycles of denaturing at 94°C for 1 min, annealing at 55°C for 1 min
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and extension at 74°C for 1 min, with a final extension step at 74°C for 10 min.
After amplification, the PCR product of 854 bp was isolated from a 1% low-melting-
point agarose gel (Life Technologies, Paisley, UK) and purified with a DNA
purification kit (Hybaid, Ashford, UK) according to the manufacturer's protocol.
Identity of the purified PCR product was confirmed by the restriction enzyme Pvull
as described in section 2.9.4 (fig. 2.3).
Fig. 2.3 Restriction enzyme digestion of 5aRl PCR product. The 854-bp 5aRl
PCR product was digested with restriction enzyme Pvull to confirm its identity.
Pvull produced two fragments of 649 and 205 bp. L, 100-bp DNA ladder; lane 1,
854 bp undigested PCR product; lane 2, Pvull digestion ofPCR product.
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The purified PCR product and the expression plasmid pCMV2 were cut with
both BgHl and Hindlll restriction enzymes. These two restriction sites are located in
the 5' and 3' untranslated regions of the 5aRl cDNA respectively. The 5aRl cDNA
restriction fragment was then inserted between the BglII and Hindlll restriction sites
of pCMV2 in a 10 pi ligation reaction according to the supplier's protocol
(Promega). The ligation mixture containing 1 pi of lOx ligation buffer (300 mM
Tris-HCl pH 7.8, 100 mM MgCl2, 100 mM DTT, 10 mM ATP), 1 unit T4 DNA
ligase (Promega) and 1:3 molar ratio of linearised pCMV2:cDNA fragment was
incubated overnight at 4°C. The resultant pCMV2.5aRl was then used for bacterial
transformation and plasmid DNA preparation ('miniprep') as described in section
2.4.3c.
2.4.3 Plasmid DNA preparation
2.4.3a Bacterial media
Luria-Bertoni (LB) broth was prepared by dissolving 10 g tryptone (Difco), 5
g yeast extract (Difco) and 5 g sodium chloride in 1000 ml distilled water. For LB
agar, 3.75 g agar was added to 250 ml LB broth. Ampicillin (Sigma) was added to
LB broth at a concentration of 100 pg/ml to select for plasmids with ampicillin
resistance.
All media were sterilised by autoclaving. Bacteria were grown at 37°C in a
shaking incubator to provide aeration.
2.4.3b Bacterial transformation
Escherichia coli strain FIB 101 was made competent for DNA uptake by the
calcium chloride method (Sambrook et al. 1989). Cells were grown in 50 ml LB to
mid-log phase (A600 = 0.3-0.6) and then harvested by centrifugation at 7000 rpm in a
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Beckman J2-20 rotor for 5 min at 4°C. The pellet was resuspended in 20 ml ice-cold
0.1 M CaCl2 and stored on ice for 10 min. Cells were then repelleted and
resuspended in 2 ml ice-cold 0.1 M CaCl2. Competent cells could be stored at 4°C
for up to 24 h before transformation.
200 pi competent cells were mixed with up to 50 ng plasmid DNA in TE
buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8.0) and stored on ice for 20-30 min.
The cells were then heat-shocked at 42°C for 50 s and transferred back on ice for 2-3
min. The transformation mixture was spread onto an LB agar plate supplemented
with 100 pg/ml ampicillin and was incubated at 37°C overnight. Control plates for
bacterial transformation contained HB101 alone (which does not have the ampicillin
resistance gene and thus acted as a negative control) or cells transformed by 10 ng of
positive control plasmid, e.g. pGEM3. Cells that grew on the selective LB agar were
successfully transformed by the recombinant DNA bearing the ampicillin resistance
gene.
2.4.3c Plasmid DNA minipreparation ('miniprep')
To screen the transformed cells for the presence of insert, 8 transformed
bacterial colonies on the agar plates were transferred to 8 separate tubes containing 2
ml LB broth supplemented with 100 pg/ml ampicillin. The tubes were incubated
overnight at 37°C in a shaking incubator. 1.5 ml of the overnight culture was
recovered by centrifugation at 14,000 rpm in a bench top Eppendorf centrifuge for 1
min (the rest of the culture was stored at 4°C). The pellet was then resuspended in
100 pi ice-cold GTE (50 mM glucose, 25 mM Tris-HCl pH 8.0 and 10 mM EDTA),
mixed gently with 200 pi freshly prepared alkaline-SDS solution (0.2 M NaOH, 1%
w/v SDS) and stored on ice for 15 min. This cell lysate was then mixed with ice-cold
150 pi potassium acetate (3 M with respect to potassium and 5 M with respect to
acetate respectively, pH 4.8) and stored on ice for 15 min. Chromosomal DNA and
cellular proteins were removed by centrifugation at 14,000 rpm for 5 min. 400 pi of
the supernatant was transferred to a fresh Eppendorf tube and mixed with 400 pi
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phenol:chloroform (1:1, v/v). After vortexing and centrifugation for 2 min, the
supernatant was transferred to a fresh Eppendorf tube. DNA was then precipitated
with 2 vol ethanol at room temperature for 5 min. After centrifuging for 5 min, the
supernatant was removed. The DNA pellet was washed with 70% ethanol and dried
at room temperature before resuspension in 50 pi TE buffer containing DNase-free
RNase A.
8 samples of plasmid DNA obtained from the above 'miniprep' were then
subjected to restriction enzyme digestion by Hin&lll and BglU to confirm the
presence of 5aRl cDNA insert before large scale plasmid preparation (fig. 2.4).
2.4.3d Large scale plasmid DNA preparation ('Maxiprep')
2 ml LB broth supplemented with 100 pg/ml ampicillin was inoculated with a
single bacterial colony which contained the required plasmid and incubated overnight
at 37°C. The overnight culture was diluted in 500 ml LB broth supplemented with
100 pg/ml ampicillin, grown in a 2 litre flask at 37°C overnight and centrifuged at
6000 rpm for 5 min at 4°C in a Beckman J2-20 rotor. The bacterial pellet was then
resuspended in 12 ml ice-cold GTE solution (50 mM glucose, 25 mM Tris-HCl pH
8.0 and 10 mM EDTA), mixed immediately with 24 ml freshly prepared alkaline-
SDS solution (0.2 M NaOH, 1% w/v SDS) and stored on ice for 5 min. 16 ml ice-
cold potassium acetate (3 M with respect to potassium and 5M with respect to acetate
respectively, pH 4.8) was added, mixed and stored on ice for 10 min before
centrifuging at 6000 rpm for 10 min at 4°C. The supernatant was filtered through 4
layers of sterile gauze into 250 ml centrifuge pots, and precipitated at room
temperature for 30 min by the addition of 32 ml isopropanol. Plasmid DNA was
recovered by centrifuging at 10,000 rpm for 3 min. The supernatant was removed
and the pellet dried at room temperature before resuspension in 2.2 ml TE buffer.
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Fig. 2.4 Restriction enzyme digestion of the plasmid pCMV2.5aRl. 8 samples
(numbered 1-8) of the plasmid pCMV2.5aRl obtained from minipreparation (section
2.4.3c) were digested with Hindlll and Bglll to confirm their identity. L, DNA
ladder; (a), uncut pCMV2.5aRl; (b) plasmid digested with Hindlll to produce
linearised DNA (5.5 kb); (c) plasmid digested with both Hindlll and Bglll to produce
2 fragments of 4.7 kb and 0.8 kb.
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1 g caesium chloride (CsCl) was added to each ml of DNA solution. 50 pi
ethidium bromide (10 mg/ml) was then added. The resulting DNA/CsCl solution
was transferred to a 3 ml Beckman Quick Seal ultracentrifuge tube with enough CsCl
solution (prepared by adding 100 g CsCl to 100 ml TE buffer) to fill the tube and
centrifuged at 70,000 rpm for 16 h or 100,000 rpm for 4 h at 20°C in a Beckman
Optima LTX Ultracentrifuge. The plasmid DNA band was collected through the seal
tube wall using a gauge 21 needle coupled to a syringe. The plasmid was then
transferred to a fresh seal tube with enough CsCl solution to fill the tube, and
centrifuged again at 70,000 rpm for 16 h or 100,000 rpm for 4 h at 20°C. The
plasmid DNA band was again collected through the wall of the seal tube.
The ethidium bromide was removed from the CsCl solution by repeated
extraction with isopropanol until the pink colour disappeared from the CsCl-DNA
solution. Plasmid DNA was purified from CsCl by dialysis in Visking dialysis
tubing (molecular weight cut-off 12-14 kDa; Medicell, London, UK) against 3
changes of 2 1 TE buffer at 4°C for 4 h or overnight. DNA concentration of the
resultant plasmid was determined spectrophotometrically at 260 nm (section 2.8.1)
and stored at -20°C.
After large scale plasmid DNA preparation, pCMV2.5aRl was fully
sequenced by Mr. Stewart McKay (Human Genetics Unit, Medical Research
Council, Edinburgh) using the ABI PRISM® sequencing kit (Applied Biosystems,
Warrington, UK) to verify its authenticity.
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2.5 Transfection Studies
2.5.1 Screening of cell lines for endogenous enzyme activities
CHO, COS-1 and C6 cells were screened for their endogenous 5a-reductase
and aromatase activities. On day 1 of experiment, cells were harvested by
trypsinisation. 3 x 105 cells were plated in 4 ml DMEM with 10% DCCFCS in 60
mm culture dishes and allowed to adhere overnight in a 37°C incubator. The
medium was replaced by 4 ml of the same medium the next day. On day 3, the
medium was replaced with 4 ml of the same medium containing 10 nM 3H-
androstenedione or 3H-testosterone. After 4, 6 or 24 h of incubation, the medium
was collected into a 20 ml glass vial (Packard Biosciences, Pangbourne, UK) and
stored at -20°C. Steroids in the medium were extracted with 5 volumes of HPLC
grade ethyl acetate and dried under a nitrogen gas stream at 45°C. The residue was
then resuspended in 1 ml HPLC mobile phase (50% water, 35% acetonitrile and 15%
methanol) and analysed by an HPLC system (section 2.7.2), which had been
optimised to separate testosterone, androstenedione, oestradiol, oestrone, 5a-
dihydrotestosterone, 5a-androstanedione and androsterone.
2.5.2 Solutions and buffers for transfection
The compositions of solutions and buffers employed in transfection
experiments are as follows.
2x HBS (HEPES-buffered saline) 50 mM HEPES
280 mM NaCl
1.5 mM Na2HP04, pH 7.05
filter-sterilised through 0.2 pm filter
Calcium chloride (CaCl2) 2 M filter-sterilised through 0.2 pm filter
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Luciferase assay buffer 40 mM tricine
67 mM DTT
0.2 mM EDTA
magnesium carbonate (48.6 mg/ml)
magnesium sulphate (0.64 mg/ml)
co-enzyme A (0.2 mg/ml)
2.5.3 Transient transfection by the calcium phosphate method
Cells were transiently transfected using the calcium phosphate co-
precipitation method as described (Sambrook et al. 1989) with minor modifications.
Exponentially growing cells were harvested by trypsinisation. 2-3 x 105 cells were
plated in 4 ml DMEM supplemented with 10% DCC-FCS in 60 mm culture dishes
and the cultures were incubated for 20-24 h at 37°C in a humidified incubator. The
next day, 4 ml of the same medium was replaced at least 1 h before transfection. 300
pi solution containing 37 pi CaCl2 (2 M) and a total of 15 pg plasmid DNA was
added dropwise to an equal volume of 2x HBS with gentle vortexing. The calcium
phosphate-DNA coprecipitate was allowed to form at room temperature for 15 min.
The calcium phosphate-DNA suspension was then transferred drop by drop into the
medium above the cell monolayer and the cells were incubated at 37°C for 20-24 h.
On day 3 of experiment, the medium and precipitate were removed by aspiration and
washed once with serum-free DMEM. Each culture dish was then covered with 3 ml
DMEM containing 10% DCC-FCS and returned to the incubator at least 1 h before
steroid/drug treatment. Steroids/drugs in 1 ml medium were then added to the
monolayer cell culture and incubated for 2-6 h. The medium was subsequently
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collected into a 20 ml glass vial and stored at -20°C until steroid extraction. Steroids
were extracted from the culture medium with 5 vol ethyl acetate, dried at 45 °C under
a nitrogen gas stream and stored at -20°C until high performance liquid
chromatography (HPLC) analysis. After removal of culture medium, the cell
monolayer was washed twice with 3 ml PBS and lysed with 300 pi lysis buffer X for
10-15 min at room temperature. Cells from each dish were then scraped, transferred
to an Eppendorf tube and centrifuged at 14,000 for 2 min in a bench top
microcentrifuge. An aliquot of the supernatant was used immediately for luciferase
assay.
2.5.4 Luciferase assay
The firefly luciferase catalyses the ATP-dependent conversion of luciferin to
oxyluciferin with light emission. 100 pi luciferase assay buffer was mixed with 5 pi
ATP (0.1 M, pH 7) and 40 pi cell lysate containing luciferase. Cell lysate prepared
from COS-1 cells transfected with pCMV2 alone was included in every assay to give
a background reading of luciferase activity. The reaction mixture was placed in the
counting chamber of a single-tube luminometer coupled with injector (Lumat
LB9501, Berthold) and 105 pi beetle luciferin (1 mM, Promega) was injected to the
reaction mixture. An instantaneous measurement of light emission was then
recorded.
2.6 Steroid Metabolism in Prostatic Cells in Primary Culture
2.6.1 Androstenedione metabolism in epithelial cells and fibroblasts
After the establishment of a relationship between 5a-reductase type 1
isozyme and aromatase in the co-transfection model, interaction between the two
enzymes was further investigated in prostatic fibroblasts and epithelial cells in
primary culture. On day 1 of each experiment, fibroblasts (passage number 2 or 3) in
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2 ml phenol red-free RPMI medium supplemented with 10% DCCFCS were seeded
in 6-well plates at a density of 3 x 105 cells/well. The medium in each well was
replaced by the same medium the following day. 24 h later, cells were incubated
with 2 ml of the same medium containing 20 nM [3H]-androstenedione for 2-52 h. 2
wells with no cells were included in each experiment as controls to detect any non-
enzymatic degradation of steroids. Epithelial cells (passage number 1) were treated
in the same manner except that 2 x 105 cells were incubated in 2 ml serum-free EGM
per well for up to 24 h because of their high rates of substrate metabolism. The
culture medium was then transferred to a 20 ml glass vial and 14C-steroids (500-1000
cpm each) added for determination of recovery after extraction. Steroids were
extracted with 5 vol ethyl acetate and dried under a nitrogen gas stream at 45°C.
After collection of medium, the remaining cells were washed twice with 3 ml PBS
and lysed with 300 pi lysis buffer X (25 mM Tris phosphate pH 7.8, 2 mM DTT, 1%
Triton X-100 and 10% glycerol). Determination of cell lysate protein concentration
was as described in section 2.3.4. Steroids were initially dissolved in 1 ml mobile
phase (50% water, 35% acetonitrile and 15% methanol) to identify all metabolites by
HPLC. Because of the small amount of oestrone formed, a two-step thin layer
chromatography system was employed later to isolate oestrone from 5a-
androstanedione and other steroids (section 2.7.1b).
2.6.2 Oestrogen metabolism in epithelial cells and fibroblasts
The metabolism of oestradiol and oestrone was examined in prostatic
fibroblasts and epithelial cells. Fibroblasts (passage number 2 or 3) were seeded in
6-well plates at 50-200 x 103 cells/well in 2 ml PRF-RPMI medium with 10% DCC¬
FCS. Epithelial cells (passage number 1) were seeded in 6-well plates at 50-75 x 103
cells/well in 2 ml serum-free EGM. 2 control wells in each experiment contained no
cells but were treated otherwise in the same manner as test wells. After 48 h, cells
were incubated with 2 ml fresh medium containing 10 nM of either [3H]-oestrone or
[3H]-oestradiol for 2-24 h. Preliminary experiments were carried out to establish the
number of cells and incubation time required to achieve linear rates of oestrogen
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metabolism (section 4.4). In subsequent experiments, culture medium was collected
after 4 h of incubation with substrate and transferred to 20 ml glass vials to be stored
at -20°C until steroid extraction. At the end of the incubation period, the monolayer
cell culture was washed twice with 3 ml PBS and lysed with 300 pi lysis buffer X
(section 2.5.2) for determination of protein concentration as described in section
2.3.4. Steroids were extracted from culture medium with 5 vol ethyl acetate and
dried under a nitrogen gas stream. The residue was reconstituted in mobile phase
(water 50%, acetonitrile 35%, methanol 15%) and analysed by reversed-phase high
performance liquid chromatography.
2.7 Analysis of Steroid Metabolites
2.7.1 Thin layer chromatography (TLC)
2.7.1a Separation of 5a-reductase metabolites by TLC
Following evaporation to dryness, products of 5a-reductase isozyme assay
were resuspended in 50 pi ethanol. The resuspended extract was spotted onto
ITLC™ SA polysilica acid gel impregnated glass fibre TLC plates (Gelman Sciences)
and separated by TLC with a mobile phase of dichloromethane:diethyl ether (9:1,
v/v) in a glass chromatography tank for approximately 40 min, or until the solvent
front reached the boundary of the TLC plate. Separated steroids were then visualised
by spraying the TLC plates with 10% phosphomolybdic acid and baking at 90°C for
colour development. Relative positions of steroids on TLC plate were as previously
described by Houston et al. (1985). Areas of TLC plates corresponding to various
steroids run alongside the steroid standards were removed by scraping the
appropriate area into scintillation vials with a clean scalpel. 6 ml liquid gold
scintillation cocktail (Canberra Packard, Pangbourne, UK) was added to each
scintillation vial and radioactivity was quantified using a Tri-Carb liquid scintillation
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counter (Canberra Packard). 5a-reductase activity was calculated, taking into
consideration recovery, blank values and specific activities of radiolabeled steroids.
2.7.1b Two-step TLC for the separation of steroid metabolites from
primary prostatic cell cultures
A two-step TLC system was employed to isolate oestrone (E,) from 5a-
androstanedione (5aA) and other steroids. For the first TLC run, the residue was
reconstituted in 60 pi ethanokethyl acetate (50:50, v/v) and developed in
dichloromethane:diethyl ether (9:1, v/v) on ITLC™ SA polysilica acid gel
impregnated glass fibre TLC plates (Gelman Sciences) alongside steroid standards.
Under these conditions, 5aA was clearly separated from androstenedione and all
other metabolites, except E,. In order to separate E, from 5aA, areas of TLC plate
corresponding to E, and 5aA were scraped off, eluted with ethyl acetate, dried and
reconstituted as above. The second TLC run consisted of a mobile phase of
benzene:ethanol (40:1, v/v). Areas of 5aA and E, were visualised by spraying the
TLC plates with 10% phosphomolybdic acid and baking at 90°C for colour
development, scraped off and quantified using a Tri-Carb liquid scintillation counter.
Rf values of 5aA and E, in the second TLC run were 0.70 and 0.55 respectively.
Identities of steroid eluant from TLC scrapings were further confirmed by reversed-
phase HPLC.
2.7.2 High performance liquid chromatography (HPLC)
Dried steroids were resuspended in 1 ml mobile phase (50% water, 35%
acetonitrile and 15% methanol) and 200 pi was injected into the high performance
liquid chromatography (HPLC) system. The HPLC system consists of a Waters
(Watford, UK) auto-injector, mobile phase pump, reversed-phase Symmetry® C8
column (4.6 x 150 mm, particle size 5 pm; Waters), a column heater and a Berthold
radioactivity monitor linked to a scintillation fluid pump. The system is controlled
by computer software Winflow (JMBS Developments, Fontanil, France). The flow
75
rates of the mobile phase and Quicksafe Flow-2® scintillant (Zinsser Analytic,
Maidenhead, UK) were set at 0.7-1.0 ml/min and 2.1-3.0 ml/min respectively to
achieve optimal counting. The column heater was set at 35°C to maintain stability of
retention times. Radioactive standards were injected at the start of every batch of
samples to confirm the identities of the peaks. The area under each peak was
integrated using the Winflow software and compared with the total area under all
peaks. Routinely, blank incubations with no cells or tissues were performed for each
experiment to detect any degradation of radiolabeled steroids.
The temperature of column, composition of HPLC mobile phase and pump
rate were systematically optimised. At 35°C and mobile phase (50% water, 35%
acetonitrile and 15% methanol) at a flow rate of 0.7 ml/min, retention times (min) of
the following steroids were: oestradiol (10.18), testosterone (12.95), oestrone (15.01),
androstenedione (16.34), 5a-dihydrotestosterone (19.95), 5a-androstanedione
(22.14) and androsterone (29.70).
2.8 Isolation of Ribonucleic Acids from Cell Cultures
Total RNA was extracted from cultured cells using either a modification of
the method of Chomczynski & Sacchi (1987) or the TRI reagent (Sigma) according
to the manufacturer's protocol. In order to minimise RNase contamination of the
RNA preparation, all solutions were prepared using RNase-free glassware,
plasticware, water and chemicals. Wherever possible, the solutions were treated with
0.1% DEPC (diethyl pyrocarbonate) for 24 h at room temperature and subsequently
autoc laved.
2.8.1 Guanidium thiocyanate (GTC) method
The GTC method is based on the one described by Chomczynski & Sacchi
(1987). GTC denaturing solution (20 ml) was prepared by dissolving 9.46 g
guanidine isothiocyanate in a mixture of 11.08 ml DEPC-treated H20 and 636 pi
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sodium citrate (0.75 M, pH 7.0), followed by the addition of 144 pi 2-
mercaptoethanol.
Cells were grown in monolayer culture to 80% confluence in 75 cm2 tissue
culture flasks, washed twice in DEPC-treated PBS and lysed in 1.9 ml GTC
denaturing solution per flask. 100 pi n-lauryl sarcosine (10%) was then added to
each flask and mixed by gentle agitation. The tissue culture flask was shaken at 4°C
for 10 min to ensure complete lysis of the cells. 500 pi aliquots of the cell lysate
were pipetted into Eppendorf tubes and 50 pi sodium acetate (2 M, pH 4.0) was
added to each tube. The tubes were vortexed for 10 s prior to the addition of 500 pi
water-saturated phenol and 100 pi chloroform-isoamyl alcohol (49:1, v/v). The
resulting suspension was vortexed for 10 s and then cooled on ice for 15 min. The
samples were centrifuged at 13,000 rpm for 20 min at 4°C in a microcentrifuge.
Subsequently, the upper aqueous phase was transferred to a fresh Eppendorf tube
where it was mixed with an equal volume of isopropanol. The RNA was precipitated
overnight at -20°C. The RNA precipitate was sedimented by further centrifugation at
13,000 rpm for 20 min at 4°C. The RNA pellet was subsequently resuspended in 60
pi GTC denaturing solution. The samples were pooled and precipitated with an
equal volume of isopropanol at -20°C for 2 h. The RNA was centrifuged at 13,000
rpm for 20 min at 4°C and the resulting pellet was washed in 200 pi ethanol (75%)
prior to a further 10 min centrifugation. The supernatant was carefully aspirated and
the RNA allowed to air dry at room temperature before resuspension in 50 pi
nuclease-free water.
A 5 pi aliquot of the RNA solution was diluted in 1.495 ml of DEPC-treated
water and the concentration and purity of the preparation determined
spectrophotometrically. In order to quantify the amount of RNA in the sample,
readings were taken at 260 nm and 280 nm. An OD260 of 1 corresponds to an RNA
concentration of approximately 40 pg/ml (Sambrook et al. 1984). The ratio between
readings taken at 260 nm and 280 nm (OD260/OD280) provides an estimate of the
purity of the sample. A ratio of 2 corresponds to a pure sample. If the OD260/OD280
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ratio was less than 1.7, the sample was re-extracted with phenol-chloroform as
follows. 45 pi phenol:chloroform (1:1) was added to the RNA solution and the
suspension vortexed and centrifuged at 13,000 rpm for 5 min at 4°C. The aqueous
phase was transferred to a fresh Eppendorf tube and mixed with 45 pi
chloroforrmisoamyl alcohol (49:1) prior to further centrifugation at 13,000 rpm for 5
min at 4°C. The aqueous phase was removed and the RNA precipitated by the
addition of 3 vol ethanol and 3 M sodium acetate to 0.3 M final concentration. The
precipitated RNA was pelleted and resuspended in 50 pi nuclease-ffee water. The
concentration and purity of the RNA solution was then re-assessed
spectrophotometrically as before.
2.8.2 TRI reagent method
TRI reagent (Sigma) was used later in the project because it involved less
steps and time than the traditional GTC method. The reagent is a mixture of
guanidine thiocyanate and phenol in a mono-phase solution. The procedure is an
improvement of the method of Chomczynski & Sacchi (1987).
Cells were grown in monolayer culture to 80% confluence in 75 cm2 tissue
culture flasks, washed twice in DEPC-treated PBS and lysed with 2 ml TRI reagent
at room temperature for 5 min. The cell lysate was passed several times through a
pipette to form a homogenous lysate, 1 ml aliquot of which was then transferred to
each of two Eppendorf tubes. 0.2 ml chloroform was added to each Eppendorf tube.
The mixture was shaken vigorously for 15 s and allowed to stand at room
temperature for 10 min before centrifugation at 13,000 rpm for 15 min at 4°C.
Centrifugation separated the mixture into 3 phases: a red organic phase (containing
protein), an interphase (containing DNA) and an uppermost colourless aqueous phase
(containing RNA).
The aqueous phase was carefully transferred to a fresh Eppendorf tube and
the RNA was precipitated by 0.5 ml isopropanol per ml of TRI reagent used in
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sample preparation at room temperature for 10 min. The RNA precipitate was
subsequently pelleted by centrifugation at 13,000 rpm at 4°C for 10 min. The
supernatant was removed and the pellet washed with 1 ml of 75% ethanol. The
sample was then vortexed and centrifuged at 6,500 rpm at 4°C for 5 min. The
supernatant was carefully aspirated and the RNA allowed to air dry at room
temperature before resuspension in 50 pi nuclease-free water. Concentration ofRNA
and purity of samples were determined spectrophotometrically as described before.
2.9 Analysis ofNucleic Acids
2.9.1 Reverse transcription of total RNA
The protocol for first strand synthesis of cDNA from total RNA is a
modification of that described in the Promega Protocols and Applications Guide (3rd
Edition, 1996). A volume of total RNA solution corresponding to 1 pg total RNA
was aliquoted into a 500 pi microcentrifuge tube. The following solutions (all from
Promega) were added to the RNA solution:
0.5 pi of rRNasin ribonuclease inhibitor (40 units/pl)
2 pi of 10 mM dNTP mixture
2 pi of lOx reverse transcription buffer containing
100 mM Tris-HCl (pH 9.0), 500 mM KC1 and 1% Triton X-100
4 pi of 25 mM MgCl2
1 pi of oligo(dT)15 (0.5 pg/pl)
0.75 pi ofAMV reverse transcriptase (20 units/pl)
Made up to a final volume of 20 pi with nuclease-free H,0
The tube was vortexed, pulsed in a microcentrifuge and then incubated at
42°C for 60 min. Following the incubation, the reverse transcription mixture was
heated to 99°C for 5 min, followed by incubation on ice for 5 min.
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Aromatase Arom-2b CCTCTGAGGTCAAGGAACAC 294 Harada et al.
(1993)
Arom-3 CAGAGATCCAGACTCGCATG Dr. Forbes
Howie*
ERa ERa-1 TACTGCATCAGATCCAAGGG 650 Lau et al.
(1999)ERa-2 ATCAATGGTGCACTGGTTGG
ERp ERpF GTTGCGCCAGCCCTGTTAC 317 Dr. Colin
Bayne+ERPR CTCGTCGGCACTTCTCTGTCTC
GAPDH GAPDHF CCACCCATGGCAAATTCCATGGCA 598 Lau ct al.
(1999)GAPDHR TCTAGACGGCAGGTCAGGTCCACC
Table 2.1 Sequences of primers for polymerase chain reaction (PCR). All primer
sequences are written 5' to 3'. PCRP, polymerase chain reaction product. *Dr.
Forbes Howie, Clinical Biochemistry, Royal Infirmary, University of Edinburgh.
+Dr. Colin Bayne, Breast Unit Research Group, Western General Hospital,
University of Edinburgh.
The procedure for the amplification of cDNA sequences was based on that
described in the Promega Protocols and Applications Guide (3rd Edition, 1996). The
reaction mixture consisted of the following.
10 pi of reverse transcription reaction
5 pi of upstream primer (4 pM)
5 pi of downstream primer (4 pM)
4 pi of lOx reaction buffer containing
100 mM Tris-HCl (pH 9.0), 500 mM KC1 and 1% Triton X-100
4 pi ofMgCl2 (25 mM)
1 pi of dNTP mix (10 mM)
1.25 units of Taq DNA polymerase
Made up to a final volume of 50 pi with nuclease-free water
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10 % (v/v) dimethyl sulphoxide (DMSO) was also included in the PCR of
ERa and ERP to improve the yield of PCR product. The components of the reaction
mixture were thoroughly mixed by brief vortexing. The mixture was overlaid with
50 Jill mineral oil and pulsed in a microcentrifuge. PCR cycles consisted of 35-40
cycles (denaturation at 94°C for 1 min, annealing at 55-58°C for 1 min and extension
at 72°C for 1 min) followed by a final extension step at 72°C for 10 min.
2.9.3 Agarose gel electrophoresis ofDNA
PCR products were separated by electrophoresis on 1.5% agarose gels
containing 0.5x Tris-borate-EDTA (TBE) buffer. 5x TBE buffer was prepared as
follows.
5x TBE buffer 54 g Tris-base
27.5 g boric acid
10 ml EDTA (5 M, pH8.0)
distilled H20 to a final volume of 1 litre
2.9.3a Preparation of agarose gels
1.5% agarose gel was prepared by melting 1.5 g agarose NA in 100 ml 0.5x
TBE in a microwave oven. The molten agarose was cooled to approximately 40°C
before the addition of 1 pi ethidium bromide (10 mg/ml). The agarose was then
poured into a level tray containing a 16-well comb of well dimensions 5.5x1.5 mm
and allowed to set at room temperature.
2.9.3b Electrophoresis of samples in agarose gels
The gel was run in 800 ml 0.5x TBE in midi-gel apparatus (Northumbria
Biologicals). 18 pi of each PCR reaction with 3 pi of DNA loading buffer (0.25%
bromophenol blue and 30% glycerol, v/v) could be loaded per well alongside 20 pi
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of 100 bp ladder (approx. 0.1 mg/ml). Electrophoresis was performed for 2 h at 75 V
(or as long as required to see sufficient separation ofDNA fragments) after which the
gel was examined and photographed under ultraviolet illumination.
2.9.4 Restriction enzyme digest
PCR products were cut by restriction enzymes to confirm their identities.
The protocol is based on that described in the Promega Protocols and Applications
Guide (3rd Edition, 1996). The restriction digest reaction consisted of the following.
Nuclease-free water
Restriction enzyme lOx buffer 2 pi
PCR product 5-10 pi
Restriction enzyme (2-10 units) 1 pi
Final volume 20 pi
The mixture was incubated at 37°C for 2 h. 15 pi of the digested PCR product was
then mixed with 3 pi DNA loading buffer and analysed by gel electrophoresis as
described in section 2.9.3b. Sizes of the DNA fragments produced by various









5aRl 854 PvwII 205,649
aromatase 294 Avail 102,192
ERa 650 Pvull 308, 342
Pstl 325(x2)
ERp 317 Dral 125, 192
Hinfl 91,226
Table 2.2 Restriction enzymes for identification of PCR products and predicted sizes
ofDNA fragments.
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2.10 Preparation of Permixon®
Permixon® was supplied as an n-hexane extract by Pierre-Fabre Medicament
(Castres, France). The hexane was dried under a nitrogen gas stream at room
temperature and the remaining residue dissolved in 10 ml ethanol to give a stock
concentration of 10 mg/ml. Serial dilution of this stock solution was made in
ethanol. Two different batches (batch numbers 735 and 762) were tested in all
experiments involving Permixon®. Final concentration of ethanol in culture medium
never exceeded 1%.
2.11 Statistical Analysis
To determine if the means of two control/test groups were significantly
different, statistics were carried out using the unpaired Student's /-test, unless
otherwise specified, to calculate the P value. P value of <0.05 is considered
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The role of 5aR2 in the maintenance of normal prostatic growth and function
is well established (section 1.3.2). In contrast, the function of 5aRl in the prostate is
still unclear. To determine if 5aRl is a suitable target for therapeutic intervention, its
function in the prostate needs to be clarified. Substrates for 5aRl are also substrates
for aromatase but products of 5aRl activity are non-aromatisable steroids (section
1.4.1). Recent work in female mice suggested a key role for 5aRl during pregnancy
in directing androgen substrates away from oestrogen synthesis by the enzyme
aromatase in the utero-placental unit (Mahendroo et al. 1997). In the present study,
the hypothesis that 5aRl plays a role in the regulation of aromatase activity in man
by limiting substrate availability to the latter was tested first in a co-transfection
model and then in human prostatic cells in primary culture. As the expression of
aromatase in the human prostate is still controversial, this issue was also examined.
3.1 5a-Reductase Isozyme Activity in BPH Tissue Homogenates
Before investigating the role of 5aRl in androgen metabolism, it was
necessary to determine which of the two androgens is a better substrate for 5aRl.
Previous kinetic studies demonstrated that human 5aRl expressed in CHO cells
displayed higher affinity and catalytic efficiency with androstenedione than with
testosterone (table 1.2, p.16; Thigpen et al. 1993, Levy et al. 1995). Moreover,
androstenedione concentrations are higher than those of testosterone within the
human prostate, whereas the reverse is true in plasma (Habib et al. 1976). To
establish if androstenedione is the more metabolically relevant substrate for 5aRl in
the human prostate, 5a-reductase conversion of the two androgens at physiological
concentrations was therefore examined in prostate tissue homogenates.
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3.1.1 Preliminary 5a-reductase assays
Preliminary experiments were carried out for the 5a-reductase assays with
both androstenedione and testosterone using tissue homogenates prepared from two
BPH patients. For both 5a-reductase isozymes, the conversion of androstenedione to
5aA and that of testosterone to DHT was essentially proportional with time within
45 min incubation (fig. 3.1). Subsequent assays were therefore incubated for 30 min,
using the same substrate concentrations and amount of tissue homogenates.
3.1.2 Comparison of androstenedione and testosterone metabolism
Using the same physiological substrate concentration, i.e. 10 nM, more
samples of BPH tissue homogenates were assayed to compare 5a-reduction of
androstenedione and testosterone by the two isozymes (fig. 3.2). Assay of 5aRl (pH
7.5) in prostate tissue homogenates demonstrated approximately 50% more 5a-
reduction of androstenedione than testosterone (mean ± s.d.; 2.70 ± 0.63 and 1.77 ±
0.51 pmol/mg protein/h respectively; fig. 3.2). In contrast, 5a-reduction of
androstenedione by 5aR2 (pH 5.0) was similar to that of testosterone (mean ± s.d.;
4.70 ± 0.95 and 4.86 ± 0.97 pmol/mg protein/h respectively; fig. 3.2).
Less than 10% of substrate was metabolised in each assay. Table 3.1 shows
the profiles of steroid metabolites in 5a-reductase assays. With androstenedione as
substrate for 5aRl assays, the two most abundant metabolites, 5aA and testosterone,
accounted for 93.1% and 3.1% of all metabolites respectively. With testosterone as
substrate, the major metabolite was DHT (94.7%) and androstenedione accounted for
3.4% of all metabolites measured (table 3.1). With both substrates, the profiles of





Fig. 3.1 Time course of 5a-reductase assay. Duplicates of BPH tissue
homogenates (prepared from two patients) containing 0.2 mg protein each were
incubated with 10 pmol (10 nM in a final volume of 1 ml) radiolabelled
androstenedione (A) or testosterone (T) for 0-60 min at (a) pH 7.5 for 5aRl isozyme
or (b) pH 5.0 for 5aR2 isozyme. Steroids were extracted and separated by thin layer
chromatography as described in sections 2.3.2 & 2.7.1. Results are expressed as




Fig 3.2 Comparison of androstenedione and testosterone 5a-reduction at pH
7.5 and pH 5.0 in BPH tissue homogenates. Tissue homogenates in duplicate
containing 0.2 mg protein each were incubated for 30 min with 10 pmol (10 nM in a
final volume of 1 ml) of androstenedione (A) or testosterone (T). Steroids were
extracted and separated by thin layer chromatography as described in sections 2.3.2
& 2.7.1. Results are expressed as mean ± s.d. n = 7 patients (pH 7.5) and n = 5





percentage of metabolite (%)
A 5aA And/EA T DHT Diols
type 1
(pH 7.5)
A NA 93.1±2.7 0.5±0.3 3.1±1.5 2.0±0.8 1.3±0.7
T 3.4±1.1 0.3±0.1 0.2±0.1 NA 94.7±1.2 1.5±0.9
type 2
(pH 5.0)
A NA 94.0±1.2 1.2±0.5 2.7±0.8 1.3±0.3 0.8±0.4
T 1.9±0.5 1.1±0.4 0.5±0.4 NA 95.8±0.7 2.8±0.3
Table 3.1 Profiles of metabolites formed from androstenedione and testosterone by
5a-reductase isozymes. Tissue homogenates in duplicate containing 0.2 mg protein
each were incubated for 30 min with 10 pmol (10 nM in a final volume of 1 ml) of
androstenedione (A) or testosterone (T). Results are expressed as percentage of total
amount of all metabolites (mean ± sd). n = 4 patients. Steroids were extracted and
separated by thin layer chromatography as described in sections 2.3.2 & 2.7.1. 5aA,
5a-androstanedione; And/EA, androsterone and epiandrosterone; DHT, 5a-
dihydrotestosterone; Diols, 5a-androstane-3a,17p-diol and 5a-androstane-3p,17p-
diol; NA, not applicable.
3.2 Establishment of a Co-transfection Model
Results from the above 5a-reductase assays demonstrate a higher conversion
rate of androstenedione than testosterone by 5aRl in prostate tissue homogenates.
Moreover, previous kinetic studies have also shown that aromatase exhibits higher
affinity for androstenedione than testosterone (section 1.4.1). The hypothesis that
5aRl plays a role in the regulation of aromatase activity by limiting substrate
availability to the latter was therefore tested using androstenedione as the androgen
substrate. Because of the mixture of various steroid-metabolising enzymes expressed
in the human prostate, cells co-transfected with plasmids encoding the two enzymes
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5aRl and aromatase were first employed to investigate any possible interrelationship
between the two enzymes.
To set up a co-transfection model, three cell lines were screened for
endogenous androgen-metabolising enzyme activities (table 3.2). No aromatase
activity was detectable in any of the cell lines screened. Although C6 cells have
been reported to express 5aRl activity (Morita et al. 1999), they were used in initial
transfection experiments because they had the lowest levels of endogenous 5a-
reductase activity among the three cell lines. However, after transfection with an
aromatase-encoding plasmid pCMV2.arom, C6 cells not only metabolised
androstenedione to oestrone (aromatase activity) but also actively converted oestrone
to oestradiol (17(3HSD type 1 -like activity; data not shown). They were therefore not
used in subsequent experiments. Similarly, CHO cells were not used in transfection
experiments because of their high 17(3HSD type 3-like activity, converting
androstenedione to testosterone. In comparison, COS-1 cells did not metabolise
androstenedione to testosterone (17|3HSD type 3-like activity) and were therefore
employed to establish a co-transfection model. To reduce background 5a-reductase
activity in COS-1 cells, plating density was decreased to 2xl05 cells per 60 mm dish.
To establish a co-transfection model expressing both human 5aRl and
aromatase, a series of preliminary experiments were carried out to determine the
amount of each plasmid used in the co-transfection model and the duration of
substrate incubation. COS-1 cells transfected with various amount of plasmid were
incubated with 10 nM androstenedione; the medium was then collected after 2, 4 or 6
h (fig. 3.3). Figure 3.3a shows that in COS-1 cells transfected with pCMV2.5aRl
only, 5a-androstanedione (5aA) formation within 4 h of incubation was essentially
proportional to the amount of plasmid used (up to 20 pg). In contrast, within 4 h of
incubation, oestrone (Ei) formation was proportionally increased in cells transfected
with up to about 5 pg ofpCMV2.arom only (fig. 3.3b).
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Fig 3.3 Conversion of androstenedione to (a) 5a-androstanedione and (b)
oestrone in COS-1 cells transfected with 1-20 pg of either (a) pCMV2.5aRl or
(b) pCMV2.arom. 2xl05 COS-1 cells were plated in duplicate in 60 mm dishes on
day 1 of the experiment. The expression plasmids were transfected into cells on day
2. Transfected cells were then incubated with 30 pmol (10 nM in a final volume of 3
ml) of androstenedione for 2, 4 or 6 h on day 3 of the experiment. Steroids were
extracted and analysed by HPLC as described in sections 2.6.1 & 2.7.2. Results are







T A DHT 5aA androsterone unknown
CHO
A 4 h 8% 86% ND 6% ND ND
24 h 49% 14% 6% 26% ND 5%
T 4 h 98% ND 2% ND ND ND
24 h 93% ND 7% ND ND ND
COS-1
A 6 h ND 98% ND 2% ND ND
24 h ND 60% ND 30% 7% 3%
T 6 h 8% 90% ND 2% ND ND
24 h ND 60% ND 30% 6% 4%
C6
A 4 h ND 100% ND ND ND ND
24 h 3% 94% ND 3% ND ND
T 4 h 100% ND ND ND ND ND
24 h 96% ND 4% ND ND ND
Table 3.2 Endogenous androgen-metabolising activities in cell lines. 3xl05 cells per
60 mm dish were plated in DMEM supplemented with 10% DCC-FCS 48 h before
incubation with 30 pmol radiolabelled substrate (10 nM in a final volume of 3 ml).
Medium was collected after 4, 6 or 24 h incubation and steroids were analysed by
HPLC. T, testosterone; A, androstenedione; DHT, dihydrotestosterone; 5aA, 5a-
androstanedione; ND, not detectable. No oestrone or oestradiol was detectable
within 24 h incubation.
In subsequent experiments to set up a co-transfection model, combinations of
various amounts of pCMV2.5aRl and pCMV2.arom as well as 2 pg pSV2L
(luciferase-encoding plasmid as internal control) were tested. Figure 3.4 shows that
in COS-1 cells co-transfected with 10 pg pCMV2.5aRl, 3 pg pCMV2.arom and 2
pg pSV2L, formation of both 5aA and Ei was proportional with time up to 4 h of
incubation. Endogenous metabolism of androstenedione to 5aA in COS-1 cells
mock-transfected with 13 pg pCMV2 and 2 pg pSV2L was approximately 2% in 6 h.
There was no background aromatase activity. No other steroid metabolites were
detectable within 6 h of incubation. In all subsequent experiments using this co-
transfection model, COS-1 cells were therefore incubated for 3 h.
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Fig 3.4 Metabolism of androstenedione in co-transfection model. COS-1 cells
were co-transfected with 10 pg pCMV2.5aRl, 3 pg pCMV2.arom and 2 pg pSV2L.
Apart from 5a-androstanedione (5aA) and oestrone (El), no other steroid
metabolites were detectable within 6 h incubation. Experimental procedure was the
same as that described in fig. 3.3. Results are expressed as mean of duplicates and
corrected by baseline conversion of androstenedione to 5aA in mock-transfected
COS-1 cells.
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3.3 Interaction between 5aRl and Aromatase in a Co-transfection Model
To investigate any interaction between 5aRl and aromatase, 2 x 105 COS-1
cells were plated in triplicate in DMEM supplemented with 10% DCC-FCS on day 1
of the experiment. COS-1 cells were then co-transfected with a total of 15 pg
plasmid DNA (10 pg pCMV2.5aRl, 3 pg pCMV2.arom and 2 pg pSV2L) on day 2.
On day 3 of the experiment, transfected cells were incubated with 30 pmol (10 nM in
a final volume of 3 ml medium) of androstenedione for 3 h to achieve similar levels
of 5aA and Ei formation (approximately 20% each). Ethanol or one of the following
2 drugs was added onto the monolayer cell cultures at the time of substrate
incubation:
a. 1-10 nM aromatase-specific inhibitor, letrozole (Bhatnagar et al. 1990; Novartis,
New Jersey, USA; a gift ofDr. Colin Bayne, University ofEdinburgh);
b. 1-10 nM 5aRl-specific inhibitor, LY306089 (Kaefer et al. 1996; Eli Lilly
Laboratories, Greenfield, Indiana, USA).
At the end of the incubation period, steroids were extracted from the medium and
analysed by HPLC; cells were lysed and luciferase activity was determined as
described in sections 2.5.3 & 2.5.4.
3.3.1 Effects of letrozole
In COS-1 cells transfected with pCMV2.arom alone, addition of the
aromatase inhibitor letrozole inhibited androstenedione aromatisation in a dose-
dependent manner as expected (fig. 3.5a). 5aRl activity encoded by pCMV2.5aRl
was not affected by letrozole (fig. 3.5b). In cells co-transfected with both
pCMV2.arom and pCMV2.5aRl, letrozole inhibited aromatase activity in a dose-
dependant manner and did not affect the conversion of androstenedione to 5aA (fig.
3.5c).
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Fig. 3.5 Effects of letrozole (aromatase inhibitor) on enzyme activities in COS-1
cells transfected with (a) pCMV2.arom (aromatase-encoding plasmid) only, (b)
pCMV2.5aRl (5aRl-encoding plasmid) only, and (c) both pCMV2.arom and
pCMV2.5aRl. Enzyme activities are expressed as mean of triplicates ± s.e.m.
Arbitrary unit of steroid-metabolising enzyme activity is calculated by the following
formula: steroid formation (pmol) x 106 / luciferase activity (relative light unit).
Results are representative of 3 different experiments. *P<0.01 compared with
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3.3.2 Effects of LY306089
In contrast, the 5aRl inhibitor LY306089 (10 nM) had no effect on
aromatase activity in cells transfected with pCMV2.arom alone (fig. 3.6a) but
inhibited 5a-reduction in cells transfected with pCMV2.5aRl (fig. 3.6b). In cells
co-transfected with both pCMV2.arom and pCMV2.5aRl, addition of 10 nM
LY306089 decreased 5aRl activity by 64% and led to a concomitant 45% increase
in aromatase activity (fig. 3.6c).
Collectively, these data indicate that in COS-1 cells co-expressing human
5aRl and aromatase, the former enzyme regulates the activity of the latter but not
vice versa.
3.4 Aromatase mRNA Expression in Prostatic Cells in Primary Culture
Aromatase expression in the prostate is controversial (reviewed in section
1.4.3). Therefore, before investigating whether the interaction between 5aRl and
aromatase demonstrated in the above co-transfection model also occurs in prostatic
cells, the expression of aromatase activity and mRNA in primary cultures of prostatic
cells was examined using aromatase enzyme assays and RT-PCR respectively.
To determine if prostatic cells in primary culture express aromatase mRNA,
total RNA was prepared from epithelial cells and fibroblasts in primary culture
derived from 3 BPH patients and analysed for aromatase mRNA by RT-PCR. All
RT reactions were carried out under identical conditions at the same time. Also, to
determine whether aromatase mRNA levels are affected by the process of cell
passaging, serial dilutions of fibroblast (passage numbers 1-5) RT reactions were
used in the PCR reactions. Although the PCR used was not quantitative, the results
obtained from serial dilutions of RT reactions give an indication as to the relative
levels of aromatase mRNA expression in fibroblasts at different passage numbers.
Only epithelial cells of passage number 1 were used because they did not grow well
after the second passage.
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Fig. 3.6 Effects of LY306089 (5aRl inhibitor) on enzyme activities in COS-1
cells transfected with (a) pCMV2.arom (aromatase-encoding plasmid) only, (b)
pCMV2.5aRl (5aRl-encoding plasmid) only, and (c) both pCMV2.arom and
pCMV2.5aRl. Enzyme activities are expressed as mean of triplicates ± s.e.m.
Arbitrary unit of steroid-metabolising enzyme activity is calculated by the following
formula: steroid formation (pmol) x 106 / luciferase activity (relative light unit).
Results are representative of 3 different experiments. *P<0.01 compared with
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3.4.1 Epithelial cells
None of the three epithelial cell samples expressed aromatase mRNA (fig. 3.7
and table 3.3). Positive control reactions using RNA prepared from PC3 cells
confirmed that the PCR reaction yielded a product of 294 bp (fig. 3.7). Identity of
the 294-bp PCR product was verified by the restriction enzyme Avail (fig. 3.8).
Control PCR reactions using primers for the housekeeping GAPDH gene to detect
GAPDH cDNA in the above epithelial cell RT reactions demonstrated that the RNA
samples were not degraded and reverse transcription had taken place (data not
shown).
3.4.2 Fibroblasts
In contrast to epithelial cells, most samples of fibroblasts (up to passage
number 5) expressed aromatase mRNA (fig. 3.9 & table 3.3). RT-PCR products
were, however, only detectable using undiluted RT reactions, indicating that the
levels of aromatase mRNA expression in fibroblasts were relatively low. In
comparison, using fibroblast RT reactions diluted up to 104-fold, control PCR
reactions detected the PCR product of GAPDH in all samples, confirming that the
RNA/cDNA samples were not degraded (data not shown).
Taken together, these results indicate that aromatase mRNA is expressed in
prostatic fibroblasts in primary culture but not in epithelial cells. With increasing
passage number, no consistent change in aromatase mRNA levels in fibroblasts is
obvious.
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Fig. 3.7 Aromatase mRNA is not expressed in epithelial cells cultured from BPH
tissues. Total RNA was prepared from epithelial cells (passage number 1) of 3
different BPH patients (AM, GR, GW) and from PC3 cells. The same amount of
RNA from each sample underwent RT at the same time under identical conditions.
PCR reactions (40 cycles) were carried out on (a) undiluted, (b) 10-fold diluted or
100-fold diluted (not shown) RT reactions. RT-, negative control in which reverse
transcriptase was omitted; C, positive control using RNA isolated from PC3 cells. L,
100-bp DNA ladder.
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Fig. 3.8 Restriction enzyme digestion of aromatase PCR product. The 294-bp
aromatase PCR product was digested with Avail to confirm its identity. Avail
produced two fragments of 102 and 192 bp. L, 100-bp DNA ladder; lane 1, 294-bp
undigested PCR product; lane 2, Avail digestion of PCR product.
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L P2 P3 —P4 P5— PC3- H20
a b c RT- a b c RT- a b c RT- a b c RT- C RT-
300 bp —> <- 294 bp
Fig. 3.9 Aromatase mRNA is expressed in fibroblasts cultured from BPH tissue.
Total RNA was prepared from fibroblasts (passage numbers 2 to 5) of BPH patient
GR and from PC3 cells. The same amount of RNA from each sample underwent RT
at the same time under identical conditions. PCR reactions (40 cycles) were carried
out on (a) undiluted, (b) 10-fold diluted, and (c) 100-fold diluted RT reactions. L,
100-bp DNA ladder; P2-P5, fibroblasts of passage numbers 2 to 5; RT-, negative
control in which reverse transcriptase was omitted; C, positive control using RNA
isolated from PC3 cells; H20, negative PCR control with water in place of RT
reaction. RT-PCR reactions carried out on total RNA prepared from two other
patients' fibroblasts generated similar results (table 3.3).
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number 1:1 1:10 1:100 1:1 1:10 1:100 1:1 1:10 1:100
Ep PI - - - - ~ ~ ~ ~ ~
Fb
PI - - - nt nt nt + -
P2 + - - + - - + -
P3 + - - + - - + " -
P4 + - - + - - + " -
P5 + - - + - - + " -
Table 3.3 Aromatase mRNA is expressed in fibroblasts but not epithelial cells in
primary culture. Total RNA was prepared from epithelial cells (Ep, passage number
1) and fibroblasts (Fb, passage number up to 5) derived from three BPH tissue
samples (designated AM, GR and GW). PCR reactions (40 cycles) were carried out
using RT reactions diluted up to 100-fold. +, present; absent; nt, not tested. The
PCR was repeated using the undiluted fibroblast RT reaction (passage number 1,
patient AM) and again yielded no PCR product.
3.5 Androstenedione Metabolism in Prostatic Cells in Primary Culture
Previous studies from the Prostate Research Group (University ofEdinburgh)
have shown that BPH-derived fibroblasts and epithelial cells in primary culture
express 5aRl but not 5aR2 activity (Bayne et al. 1998). Results in this chapter have
already confirmed the expression of aromatase mRNA in prostatic fibroblasts. The
next set of experiments aimed at investigating any aromatase enzyme activity in
prostatic cells in primary culture with a view to ascertain whether an interaction
between 5aRl and aromatase also exists in prostatic cells.
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3.5.1 Fibroblasts
Preliminary experiments showed that in fibroblasts, the conversion of
androstenedione to 5aA (by 5aRl) and E] (by aromatase) was essentially
proportional to the duration of incubation up to 52 h (figs. 3.10a & 3.10b). In
comparison, testosterone formation (by 17(3HSD) increased with time only within 26
h (fig. 3.10c). The activity of 5aRl was the highest among the three enzymes. In
subsequent experiments to examine the relationship among these enzymes,
fibroblasts were incubated with androstenedione for 24 h to allow formation of
reasonable amount of all 3 metabolites.
3.5.2 Epithelial cells
In comparison, the conversion of androstenedione in epithelial cells to both
5aA and testosterone was more or less proportional to the duration of incubation up
to 6 h, with the rate of 5aA formation higher than that of testosterone (fig. 3.11).
However, no Ei or E2 was detectable within 24 h. Epithelial cells were incubated
with androstenedione for 4 h in subsequent experiments to study the effects of
enzyme inhibitors.
3.6 Interaction between 5aRl and Aromatase in Prostatic Cells in Primary
Culture
Results from COS-1 cells co-transfected with pCMV2.arom and
pCMV2.5aRl suggest that 5aRl inhibition leads to an increase in aromatase activity
by alleviating 5aRl competition for the common substrate androstenedione. To
ascertain if the regulatory interaction between aromatase and 5aRl observed in co-
transfected cells also occurs in a more physiologically relevant system, the
metabolism of androstenedione in prostatic fibroblasts and epithelial cells under the
influence of LY306089 (5aRl-specific inhibitor) and letrozole (aromatase-specific
inhibitor) was investigated.
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Fig. 3.10 Time course of androstenedione metabolism in fibroblasts in primary
culture. 3xl05 fibroblasts/well in phenol red-free RPMI supplemented with 10%
DCC-FCS were seeded in duplicate into 6-well plates 48 h before incubation with 40
pmol (20 nM in a final volume of 2 ml, approximately 8x106 dpm) androstenedione.
Medium was collected 0, 2, 4, 6, 26 or 52 h later. Steroids were separated by thin-
layer chromatography and the formation of (a) 5aA, (b) Ei and (c) testosterone was
quantitated by scintillation counting. Results are expressed as mean ± s.d. (n=4)






























































Fig. 3.11 Time course of androstenedione metabolism in epithelial cells in
primary culture. 2xl05 cells/well in serum-free EGM were seeded in duplicate into
6-well plates 48 h before incubation with 40 pmol (20 nM in a final volume of 2 ml,
approximately 8x106 dpm) androstenedione. Medium was collected 0, 2, 4, 6 or 24 h
later. Steroids were separated by thin-layer chromatography and the formation of (a)
5aA and (b) testosterone was quantitated by scintillation counting. No oestrone
formation was detectable up to 24 h. Results are expressed as mean + s.d. (n=4)
from 2 separate experiments using epithelial cells derived from 2 BPH patients.
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3.6.1 Fibroblasts
In prostatic fibroblasts, androstenedione was metabolised to 5aA (by 5aRl,
331 ±29 fmol/mg protein/h), testosterone (17PHSD type 5-like activity, 101 ± 18
fmol/mg protein/h) and Ei (by aromatase, 13 ± 1 fmol/mg protein/h) (fig. 3.12).
5aA formation was inhibited by the 5aRl inhibitor LY306089 in a dose-
dependent manner but not affected by the aromatase inhibitor letrozole (fig. 3.12a).
Testosterone formation was unaffected by either of the two drugs (fig. 3.12b).
Figure 3.12c shows that letrozole inhibited Ei formation as expected in a dose-
dependent manner whereas addition of LY306089 (100 nM) led to a significant
increase in aromatase activity in fibroblasts. These data indicate that by inhibiting
5aRl activity, LY306089 can increase aromatase activity not only in the above co-
transfection model but also in fibroblasts in primary culture.
3.6.2 Epithelial cells
In prostatic epithelial cells, androstenedione was metabolised to 5aA (by
5aRl, 1156 ± 103 fmol/mg protein/h) and to testosterone (17PHSD type 5-like
activity, 153 ± 39 fmol/mg protein/h) (fig. 3.13). Unlike fibroblasts, no
aromatisation of androstenedione to Ei was detectable. It was thus impossible to
confirm the regulatory interaction between 5aRl and aromatase, which was
observed in the above co-transfection model and in fibroblasts.
In epithelial cells, LY306089 inhibited 5aA formation as expected in a dose-
dependent manner (fig. 3.13a) but did not affect the reduction of androstenedione to
testosterone (fig. 3.13b) or produce any aromatase activity (data not shown).
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Fig. 3.12 Effects of LY306089 and Ietrozole on androstenedione metabolism in
fibroblasts in primary culture. 3x105 fibroblasts/well in phenol red-free RPMI
supplemented with 10% DCC-FCS were seeded in triplicate into 6-well plates. 48 h
later, 2 ml of the same medium containing 20 nM androstenedione and either
LY306089 or letrozole was added to the cells. Medium was collected after 24 h
incubation. Fibroblasts were lysed and protein concentrations determined as
described in sections 2.6.1 & 2.3.4 respectively. Steroids were then extracted from
culture medium and separated by thin layer chromatography. The formation of (a)
5aA, (b) testosterone and (c) Ei was quantitated by scintillation counting. Values are
mean of triplicates ± s.e.m. *P<0.01, +P<0.05 compared with controls. Results are
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Fig. 3.13 Effects of LY306089 on androstenedione metabolism in epithelial cells
in primary culture. 2xl05 cells/well in serum-free EGM were seeded in triplicate
into 6-well plates. 48 h later, 2 ml of the same medium containing 20 nM
androstenedione and 10-100 nM LY306089 was added to the cells. Medium was
collected after 4 h incubation. Epithelial cells were lysed and protein concentrations
determined as described in sections 2.6.1 & 2.3.4 respectively. Steroids were then
extracted from culture medium and separated by thin layer chromatography. The
formation of (a) 5aA, and (b) testosterone was quantitated by scintillation counting.
No aromatase activity (formation of Ei or E2) was detectable in epithelial cells.
Values are mean of triplicates ± s.e.m. *P<0.01 compared with controls. Results are
representative of 3 different experiments using epithelial cells from 3 BPH patients.
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3.7 Discussion
Despite recent reports of 5aRl mRNA (Habib et al. 1998, Iehle et al. 1999),
protein (Bonkhoff et al. 1996, Negri-Cesi et al. 1998) and enzyme activity (Bayne et
al. 1998) in the human prostate, its functions in this gland are unclear. In tissues
such as the prostate which express both 5aRl and aromatase, one possible role for
5aRl is the regulation of aromatase activity, which shares common substrates with
5aRl. To test this hypothesis, the interaction between the two enzymes was
investigated firstly in a co-transfection model and then in prostatic cells in primary
culture. In COS-1 cells co-transfected with expression plasmids encoding human
5aRl and aromatase, inhibition of 5aRl increased aromatase activity but the
converse was not true; inhibition of aromatase did not affect 5aRl activity. This
pattern of regulatory interaction also occurred with the endogenous enzymes in
prostatic fibroblasts in primary culture.
The above observations are in keeping with data from female mice
homozygous for a targeted disruption of the 5aRl gene (Mahendroo et al. 1997). In
pregnant mice, impairment of androgen 5a-reduction to non-aromatisable forms due
to 5aRl deficiency led to increased androgen aromatisation, elevation in plasma
oestrogen levels and mid-gestational fetal loss. This observation of increased plasma
oestrogen concentrations in 5aRl-deficient mice indicates that a normal role for
5aRl is to prevent the metabolism of placental androgens to oestrogens by
converting aromatisable androgens to non-aromatisable forms (Mahendroo et al.
1997). However, no specific role for 5aRl has yet been proposed in male mice or in
man. Recent findings that male mice lacking 5aR2 or both 5a-reductase isozymes
only had mild virilisation defects (Mahendroo et al. 2001) are in sharp contrast to
human male pseudohermaphrodites characterised by rudimentary prostates and
female or ambiguous external genitalia due to 5aR2 deficiency (Andersson et al.
1991) (reviewed in section 1.3.2). To date, no 5aRl deficiency has been identified
in humans. These data suggest that functions of the 5a-reductase isozymes can vary
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significantly from species to species. 5aRl was shown to regulate aromatisation of
androgens to oestrogens in the uteroplacental unit of the female mouse (Mahendroo
et al. 1997); here for the first time 5aRl was demonstrated to have the potential to
play a similar role in the prostate ofhuman males.
5a-reductase activities in BPH tissue homogenates in the present study (1.77-
2.70 pmol/mg protein/h for 5aRl and 4.70-4.86 pmol/mg protein/h for 5aR2) are
comparable to the 5a-reductase activity of 6.4 pmol/mg protein/h in prostate cell
suspensions (presumably a mixture of activities of both isozymes because of living
cells) reported by Smith et al. (1996). In keeping with the general consensus that
5aR2 is the predominant isozyme in the human prostate, here it is shown that in BPH
tissue homogenates 5aR2 activities were higher than those of 5aRl.
Although both 5a-reductase isozymes can convert androstenedione to 5aA
and testosterone to DHT, in BPH tissue homogenates 5aRl metabolised more
androstenedione than testosterone at physiological substrate concentrations. These
results are also consistent with previous kinetic data from cell lines expressing 5aRl
(table 1.2, p.16). 5aRl expressed in CHO cells was 6-11 times more efficient at
metabolising androstenedione than testosterone, whereas 5aR2 expressed in the
same cell line demonstrated similar Vmax/Km with both substrates (Thigpen et al.
1993, Levy et al. 1995). By selectively metabolising androstenedione, 5aRl in the
prostate may therefore function as a catabolic enzyme in limiting the conversion of
androstenedione to other active steroids including testosterone and oestrogens. A
catabolic role for 5aRl in limiting substrate availability to other enzymes is likely to
be particularly important in the human prostate, in which the
androstenedione/testosterone ratio is high compared to that in plasma (Habib et al.
1976) and androstenedione can be metabolised by aromatase or 17PHSD to active
steroids. Whilst in theory this regulatory function in androstenedione metabolism
could also be served by 5aR2, evidence suggests that the primary role of 5aR2 is to
convert testosterone to DHT (Imperato-McGinley et al. 1981, Andersson et al. 1991,
Katz et al. 1995). Compared to normal males, individuals with homozygous 5aR2
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deficiency have increased plasma testosterone/DHT ratios but normal oestrogen
levels (Imperato-McGinley et al. 1981). Females homozygous for 5aR2 deficiency
are also characterised by elevated plasma testosterone/DHT ratios but have normal
oestradiol levels throughout the menstrual cycle (Katz et al. 1995).
In both epithelial cells and fibroblasts in the present study, inhibition of 5aRl
did not increase testosterone formation from androstenedione. This is most likely
attributed to the strong oxidative 17PHSD type 2-like activity in these cells
converting testosterone to androstenedione (Delos et al. 1995). Similarly, despite
aromatase activity, oestradiol formation was not detectable in fibroblasts where
androstenedione was converted to testosterone, a precursor of oestradiol. This is also
possibly a result of high 17PHSD type 2-like activity present in fibroblasts, rapidly
oxidising any oestradiol formed from testosterone aromatisation to oestrone.
Interconversion between oestradiol and oestrone in prostatic cells in primary culture
is a subject of the next chapter.
Both aromatase mRNA expression and enzyme activity in the present study
were demonstrated in prostatic fibroblasts in primary culture but were undetectable
in epithelial cells. These observations on the differential distribution of aromatase
between the stromal and epithelial compartments are consistent with previous
immunohistochemical studies (Matzkin & Soloway 1992, Hiramatsu et al. 1997), in
which aromatase protein was localised mainly to the stroma of normal, BPH and
carcinomatous prostate tissues.
The aromatase activities in prostatic fibroblasts in primary culture reported
here (13 ± 1 fmol/mg protein/h) are similar to androstenedione aromatisation
demonstrated in fibroblasts derived from BPH and prostatic cancer tissues (8-116
fmol/mg protein/h, Schweikert 1979). In comparison, oestrone formation from
androstenedione ranged from 22 to 284 fmol/mg protein/h in homogenates prepared
from normal and BPH tissues (Stone et al. 1986).
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In summary, this chapter has shown that in human prostate, 5aRl has the
potential to play a role in regulating aromatase activity, which is found in fibroblasts
but not in epithelial cells in primary culture. In the next chapter, the expression of
oestrogen receptors, which are essential for the action of oestrogens, in prostatic cells
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Clinical presentation of BPH manifests at an age when plasma ratios of
oestrogens/androgens are increasing, implicating an imbalance between oestrogens
and androgens as a factor in the pathogenesis of BPH. The previous chapter has also
shown aromatase mRNA expression and activity in prostatic fibroblasts,
demonstrating that prostatic cells have the potential to synthesise oestrogens from
androgen precursors. Locally produced oestrogens may have intracrine/autocrine
effects on fibroblasts themselves or act on neighbouring epithelial cells in a paracrine
manner, provided that the appropriate receptors are expressed in these cells. To date,
it is not entirely clear whether oestrogens, derived from plasma or locally produced,
can cause or potentiate BPH, a process of excessive cellular proliferation of both
epithelial and stromal components within the prostate gland.
At the beginning of this part of the study, it was hypothesised that prostatic
cells are not only oestrogen target cells expressing oestrogen receptors, but are also
capable of modulating the effects of oestrogens by active oestrogen metabolism. To
test this hypothesis, various oestrogen response parameters were explored in prostatic
cells in primary culture. Firstly, mRNA expression of both oestrogen receptor (ER)
subtypes, crucial for receptor-mediated oestrogen action, in prostatic cells in primary
culture was examined using RT-PCR. Secondly, effects of oestrogens on the
proliferation of prostatic cells in primary culture were investigated, and the anti-
oestrogen ICI 182780 was employed to ascertain if such effects are ER-mediated.
Thirdly, metabolism of the natural oestrogens oestradiol and oestrone in prostatic
cells has not been reported in the literature; experiments were therefore carried out to
determine if prostatic cells in primary culture were capable ofmodulating oestrogen
action by active oestrogen metabolism.
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4.1 Oestrogen Receptor mRNA Expression in Prostatic Cells in Primary
Culture
A number of previous studies have reported the expression of both oestrogen
receptor subtypes (ERa and ER(3) in the human prostate; however, results from
different groups do not entirely agree with one another (Ehara et al. 1995, Bonkhoff
et al. 1999, Royuela et al. 2001, Pasquali et al. 2001a). In this study, to determine if
prostatic cells in primary culture have the potential to respond to oestrogen treatment,
total RNA was prepared from epithelial cells and fibroblasts derived from 3 BPE1
patients and analysed for ERa and ER(3 mRNA expression using RT-PCR. Also, to
determine whether ER mRNA expression is affected by the process of cell passaging,
serial dilutions of fibroblast (passage numbers 1-5) RT reactions were used in the
PCR reactions. Although the PCR used was not quantitative, the results obtained
from serial dilutions of RT reactions give an indication as to the relative levels of
mRNA expression among fibroblasts at different passage numbers. All RT reactions
were carried out under identical conditions at the same time. Epithelial cells of
passage number 1 only were used because they did not grow well after the second
passage.
4.1.1 ERa mRNA expression in prostatic cells in primary culture
4.1.1a Epithelial cells
Of the three samples of epithelial cell RNA tested, two (patients AM and GR)
expressed ERa mRNA (fig. 4.1 & table 4.1). However, no RT-PCR product was
detectable when 10-fold diluted RT reactions were used, suggesting relatively low
levels of ERa mRNA expression in these cells. Identity of the 650-bp PCR product
was confirmed with restriction enzymes Pvull and Pstl (fig. 4.2).
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Fig. 4.1 ERa mRNA is expressed in epithelial cells cultured from BPH tissues.
Total RNA was prepared from epithelial cells (passage number 1) of 3 different BPH
patients (AM, GR, GW) and from PC3 cells. The same amount of RNA from each
sample underwent RT at the same time under identical conditions. PCR reactions (40
cycles) were carried out on (a) undiluted, (b) 10-fold diluted or 100-fold diluted (not
shown) RT reactions. RT-, negative control in which reverse transcriptase was
omitted; C, positive control using RNA isolated from PC3 cells. L, 100-bp DNA
ladder.
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Fig. 4.2 Restriction enzyme digestion of ERa PCR product. The 650-bp ERa
PCR product was digested with two restriction enzymes to confirm its identity. Lane
1, undigested PCR product; lane 2, Pvull produced two fragments of 308 and 342 bp;
lane 3, Pstl produced two fragments of the same size, 325 bp. L, 100-bp DNA ladder.
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4.1.1b Fibroblasts
Fibroblasts (passage numbers 1 to 5) derived from all 3 BPH patients
expressed ERa mRNA (fig. 4.3 and table 4.1). Again, PCR product was only
detectable using undiluted RT reactions, suggesting that the levels of mRNA
expression in these cells were also relatively low.
AM GR GW




number 1:1 1:10 1:100 1:1 1:10 1:100 1:1 1:10 1:100
Ep PI + - - + - - - - -
Fb
PI + - - nt nt nt + - -
P2 + - - + - - + - -
P3 + - - + - - + - -
P4 + - - + - - + - -
P5 + - - + - - + -
Table 4.1 ERa mRNA expression in epithelial cells and fibroblasts in primary
culture. Total RNA was prepared from epithelial cells (Ep, passage number 1) and
fibroblasts (Fb, passage number up to 5) derived from three BPH tissue samples
(designated AM, GR and GW). PCR reactions (40 cycles) were carried out using RT
reactions diluted up to 100-fold. +, present; absent; nt, not tested. PCR was
repeated once on the undiluted epithelial cell RT reaction (patient GW) and again
yielded no PCR product.
123
L P2 P3
Fig. 4.3 ERa mRNA is expressed in fibroblasts cultured from BPH tissues. Total
RNA was prepared from fibroblasts (passage numbers 2 to 5) of BPH patient GR and
from PC3 cells. The same amount of RNA from each sample underwent RT at the
same time under identical conditions. PCR reactions (40 cycles) were carried out on
(a) undiluted, (b) 10-fold diluted, and (c) 100-fold diluted RT reactions. L, 100-bp
DNA ladder; P2-P5, fibroblasts of passage numbers 2 to 5; RT-, negative control in
which reverse transcriptase was omitted; C, positive control using RNA isolated from
PC3 cells. RT-PCR reactions carried out on total RNA prepared from two other
patients' fibroblasts generated similar results (table 4.1).
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4.1.2 ERp mRNA expression in prostatic cells in primary culture
4.1.2a Epithelial cells
All 3 samples of epithelial cells expressed ERp mRNA (fig. 4.4 & table 4.2).
PCR product was detectable with all 3 undiluted RT reactions and only 1 of the 3
samples of 10-fold diluted RT reactions. Identity of the 317-bp PCR product was
confirmed with restriction enzymes Dral and Hinfl (fig. 4.5).
4.1.2b Fibroblasts
Similarly, all 3 samples of fibroblasts (passage numbers 1 to 5) expressed
ERp mRNA (fig. 4.6 & table 4.2). PCR product was detectable with all of the
undiluted RT reactions, some of the 10-fold diluted RT reactions and none of the
100-fold diluted RT reactions. With increasing passage numbers from 1 to 5, there is
no clear pattern of up- or down-regulation ofERp mRNA expression in fibroblasts.
AM GR GW




number 1:1 1:10 1:100 1:1 1:10 1:100 1:1 1:10 1:100
Ep PI + + - + - - + - -
Fb
PI + + - nt nt nt + + -
P2 + + - + - - + + -
P3 + + - + + - + + -
P4 + + - + + - + + -
P5 + - - + + - + + -
Table 4.2 ERp mRNA is expressed in epithelial cells and fibroblasts in primary
culture. Total RNA was prepared from epithelial cells (Ep, passage number 1) and
fibroblasts (Fb, passage number up to 5) derived from three BPH tissue samples
(designated AM, GR and GW). PCR reactions (40 cycles) were carried out using RT
reactions diluted up to 100-fold. +, present; -, absent; nt, not tested.
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a b c RT- a b c RT-
L GW —PC3— H20
a b c RT- C RT-
Fig. 4.4 ERp mRNA is expressed in epithelial cells cultured from BPH tissues.
Total RNA was prepared from epithelial cells (passage number 1) of 3 different BPH
patients (AM, GR, GW) and from PC3 cells. The same amount of RNA from each
sample underwent RT at the same time under identical conditions. PCR reactions (40
cycles) were carried out on (a) undiluted, (b) 10-fold diluted or (c) 100-fold diluted
RT reactions. RT-, negative control in which reverse transcriptase was omitted; C,
positive control using RNA isolated from PC3 cells. L, 100-bp DNA ladder; H2O,
negative PCR control with water in place ofRT reaction.
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Fig. 4.5 Restriction enzyme digestion of ERP PCR product. The 317-bp ERp
PCR product was digested with two restriction enzymes to confirm its identity. Lane
1, undigested PCR product; lane 2, Dral produced two fragments of 125 and 192 bp;
lane 3, Hinfl produced two fragments of 91 and 226 bp. L, 100-bp DNA ladder.
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L PI P2— P3
a b c RT- a b c RT- a b c RT-
<— 317 bp
L P4 P5 -PC3- H20
a b c RT- a b c RT- C RT-
<-317 bp
Fig. 4.6 ERp mRNA is expressed in fibroblasts cultured from BPH tissues. Total
RNA was prepared from fibroblasts (passage numbers 1 to 5) ofBPH patient GW and
from PC3 cells. The same amount of RNA from each sample underwent RT at the
same time under identical conditions. PCR reactions (40 cycles) were carried out on
(a) undiluted, (b) 10-fold diluted, and (c) 100-fold diluted RT reactions. L, 100-bp
DNA ladder; P1-P5, fibroblasts of passage numbers 1 to 5; RT-, negative control in
which reverse transcriptase was omitted; C, positive control using RNA isolated from
PC3 cells. H20, negative PCR control with water in place ofRT reaction.
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4.1.3 Expression of the housekeeping gene glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) mRNA confirms the integrity ofRNA samples
The results shown in tables 4.1 and 4.2 reveal that most of the PCR products
became undetectable when RT reactions were diluted by 10- or 100-fold. To
confirm that the variations in the dilution factors at which PCR products became
undetectable were not due to degradation of RNA or cDNA, the RT reactions were
subjected to PCR using primers for the housekeeping gene GAPDH (data
summarised in table 4.3). The GAPDH PCR product was clearly detectable in all
dilutions up to 104-fold, verifying that the lack of ERa or ERp RT-PCR product in
the corresponding dilutions was not due to RNA/cDNA degradation. Moreover,
there is no correlation among results in tables 4.1, 4.2 and 4.3, suggesting that
variations in ER PCR product reported are not due to variations in the amount of
RNA used.
AM GR GW




number 1:104 1:105 1:106 1:104 1:105 1:106 1:104 1:10s 1:106
Ep PI + + - + + - + " "
Fb
PI + + - nt nt nt + + "
P2 + - - + + - + + "
P3 + + - + + - + " "
P4 + + - + + - + - "
P5 + + - + + - + + -
Table 4.3 GAPDH mRNA expression in epithelial cells and fibroblasts prepared
from three BPH tissues. Total RNA was prepared from epithelial cells (Ep, passage
number 1) and fibroblasts (Fb, passage number up to 5) derived from three BPH
tissue samples (designated AM, GR and GW). PCR reactions (40 cycles) were
carried out using RT reactions diluted up to 106-fold. +, present; -, absent; nt, not
tested.
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4.2 Growth Response of Prostatic Cells in Primary Culture to Oestrogens
The results described above show that both epithelial cells and fibroblasts in
primary culture express mRNA of both ER subtypes, which are essential for
oestrogen action. Both cell types are therefore potential oestrogen target cells. BPH
results from excessive cell proliferation, diminished cell death or a combination of
both. To ascertain whether oestrogens play a role in BPH pathogenesis, the next part
of the present study aimed to examine the effects of oestrogens on prostatic cell
proliferation using prostatic cells in primary culture and the MTS assay described in
section 2.2.4.
Recently, Weihua et al. (2001) suggested a role for 5a-androstane-3p,17(3-
diol (3pAdiol) in prostate oestrogenic response in the mouse. Although 3pAdiol has
low binding affinities for both ER subtypes, its concentrations in the human prostate
are high compared with those ofEi and E2 (table 1.7, section 1.7.3). Also, the potent
androgen DHT can be converted to 3pAdiol by 3p-hydroxysteroid dehydrogenase
within the prostate (Krieg et al. 1995). Thus, 3pAdiol may have a potential role in
the androgen/oestrogen balance within the prostate gland. To this end, effects of this
putative oestrogen on human prostatic cell proliferation were also investigated and
compared with those of oestradiol.
4.2.1 Epithelial cells
Figure 4.7 shows that E2 treatment (1 nM - 10 pM) had no effect on the
growth of epithelial cells (passage number 1) compared with control cells with up to
6 d incubation. Similarly, 3pAdiol treatment (1 nM - 10 pM) did not affect

























Fig 4.7 Oestradiol had no effect on epithelial cell growth. 3000 cells/well in
serum-free EGM were seeded into 96-well plates 2 d before the addition of E2 (1 nM
-10 pM, 6 wells per treatment group). 6 control wells received 1% ethanol (v/v) to
control for the ethanol used as a vehicle for E2. Medium was changed daily. MTS
assay was performed after 2, 4 or 6 d of E2 treatment. Values are expressed as mean
± sem. There is no statistical significance between the various treatments groups on
the same day. +P<0.05 compared with the same treatment/control group on day 2.
Results are representative of 3 separate experiments using epithelial cells derived
from 4 different BPH patients.
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4.2.2 Fibroblasts
In contrast to the absence of effect on epithelial cell proliferation, E2 (1 pM
and 10 pM) stimulated the proliferation of fibroblasts grown in phenol red-free
RPMI supplemented with 10% DCC-FCS (fig. 4.8a). Similarly, at high
concentrations (1 pM and 10 pM), 3pAdiol also stimulated the growth of fibroblasts
grown in medium supplemented with 10% DCC-FCS (fig. 4.8b).
The micromolar concentrations of E2 and 3pAdiol required to stimulate
fibroblast proliferation are much higher than their physiological concentrations (<10
nM; table 1.7, p.36). One possible explanation is that growth factors present in
DCC-stripped serum are masking the stimulatory effects of both oestrogenic
compounds. Accordingly, further experiments were carried out using medium
supplemented with reduced amount ofDCC-FCS.
A preliminary experiment was set up to determine the lowest concentration of
DCC-FCS suitable for fibroblast proliferation experiments (fig. 4.9). Fibroblasts
were seeded into 96-well plates in triplicate and supplemented with various
concentrations of DCC-FCS (0-10%, v/v). After 48 or 96 h incubation in medium
containing 0% or 1% DCC-FCS, microscopic examination of fibroblasts revealed
rounded cells, rather than the normal spindle-shaped fibroblasts (data not shown).
With 2% DCC-FCS concentration and above, fibroblasts not only were spindle-
shaped but also demonstrated proliferation between 48 h and 96 h (fig. 4.9). With
increasing concentrations of DCC-FCS from 1% to 10%, the difference in cell
numbers between 48 h and 96 h after initial plating also increased. To minimise the
background stimulation of fibroblast proliferation by DCC-FCS and yet sustain
continuous growth of fibroblasts in primary culture, 2% DCC-FCS supplement was






































control 10(-9) 10(-8) 10(-7) 10(-6) 10(-5)
3beta-Adiol concentration (M)
Fig. 4.8 Effects of oestradiol and 3pAdiol on fibroblast growth in medium
supplemented with 10% DCC-FCS. 1800 cells/well in phenol red-free RPMI
supplemented with 10% DCC-FCS were seeded into 96-well plates 2 d before the
addition of 10"9 - 10~5 M of (a) E2 or (b) 3pAdiol (6 wells per treatment group). 6
wells received 1% ethanol (v/v) to control for the ethanol used as a vehicle for E2 or
3pAdiol. Medium was changed daily. MTS assay was performed 4 d later. Values
are expressed as mean ± sem. +P<0.05, *P<0.01 compared with controls. Results
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Fig 4.9 Effects of the concentration of DCC-FCS on fibroblast proliferation.
1800 fibroblasts/well in phenol red-free RPMI supplemented with 0-10% DCC-FCS
(v/v) were seeded into 96-well plates in triplicate. Medium was changed daily. MTS
assay was performed 48 h or 96 h after initial plating of cells. Results are expressed
as mean of triplicates ± s.d.
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Figure 4.10a shows that E2 at concentrations between 10 nM and 1 pM
stimulated the proliferation of fibroblasts grown in medium containing 2% DCC-
FCS, with maximal effect at 100 nM. This is in contrast to the high E2
concentrations required to stimulate fibroblasts grown in medium supplemented with
10% DCC-FCS (fig. 4.8a). Similarly, 3pAdiol (100 nM - 10 pM) also stimulated the
proliferation of fibroblasts grown in medium containing 2% DCC-FCS with maximal
effect at 100 nM (fig. 4.10b).
In summary, the above results show that both E2 and 3pAdiol stimulated
fibroblast proliferation. Whereas micromolar concentrations of both compounds
were required to stimulate proliferation of fibroblasts grown in medium
supplemented with 10% DCC-FCS, lower (nanomolar) concentrations increased
fibroblast proliferation in medium containing 2% DCC-FCS only.
4.3 Stimulatory Effects of E2 and 3pAdiol on Prostatic Fibroblasts in
Primary Culture are Antagonised by the Anti-oestrogen ICI 182780
To determine if the stimulatory effects of both E2 and 3pAdiol on fibroblast
growth were oestrogen receptor-mediated, the anti-oestrogen ICI 182780 was added
to fibroblasts grown in medium supplemented with 2% DCC-FCS. ICI 182780
(Tochris, Bristol, UK), a pure anti-oestrogen, competitively inhibits E2 binding to
oestrogen receptor; it does not exhibit agonist or partial agonist actions in vivo or in
vitro (reviewed in MacGregor & Jordan 1998). ICI 182780 (Faslodex®) is currently
being tested in clinical trials for the treatment of breast cancer.
Preliminary experiments were carried out on fibroblasts growing in phenol
red-free RPMI medium supplemented with 2% DCC-FCS and various concentrations
of ICI 182780 but no oestrogens. Treatment with up to 100 nM ICI 182780 had no
effect on fibroblast proliferation. However, 1 pM ICI 182780 inhibited fibroblast































control 10 (-9) 10(-8) 10(-7) 10(-6) 10(-5)
oestradiol concentration (M)
(b) 3pAdiol treatment
Fig. 4.10 Effects of oestradiol and 3pAdiol on fibroblast growth in medium
supplemented with 2% DCC-FCS. 1800 fibroblasts/well in phenol red-free RPMI
supplemented with 2% DCC-FCS were seeded into 96-well plates 2 d before the
addition of 10"9 - 10"5 M of (a) E2 or (b) 3pAdiol (6 wells per treatment group). 6
control wells received 1% ethanol (v/v) to control for the ethanol used as a vehicle
for E2 or 3pAdiol. Medium was changed daily. MTS assay was performed 4 d after
initial plating of cells. Values are expressed as mean ± sem. +P<0.05, *P<0.01
compared with controls. Results are representative of 3 experiments using
















control 10(-8) 10(-7) 10(-6)
ICI 182780 concentration (M)
Fig 4.11 The anti-oestrogen ICI 182780 inhibits the proliferation of prostatic
fibroblasts. 1800 fibroblasts/well in phenol red-free RPMI supplemented with 2%
DCC-FCS were seeded into 96-well plates 2 d before the addition of 10"8 - 10~6 M
ICI 182780 (6 wells per treatment group). 6 control wells received 1% ethanol (v/v)
to control for the ethanol used as a vehicle for ICI 182780. Medium was changed
daily. MTS assay was performed 4 d after initial plating of cells. Values are
expressed as mean ± sem. *P<0.01 compared with controls. Results are
representative of 2 experiments using fibroblasts derived from 2 BPH patients.
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In order to establish whether the fibroblast proliferation stimulated by E2 and
3pAdiol was ER-mediated, and to rule out any effect on fibroblast growth by the
anti-oestrogen on its own, ICI 182780 concentrations less than 100 nM were used in
subsequent experiments involving both oestrogens and ICI 182780.
Figure 4.12 clearly shows that 50 nM ICI 182780 had no effect on fibroblast
growth in the absence of E2 or 3pAdiol. In fibroblasts without any anti-oestrogen
treatment, E2 (10 & 100 nM) and 3pAdiol (100 nM) increased cell proliferation;
these stimulatory effects of both E2 and 3pAdiol were antagonised by 50 nM ICI
182780, confirming that such effects were ER-mediated.
4.4 Oestrogen Catabolism in Prostatic Cells in Primary Culture
The above data demonstrated that cell growth of prostatic fibroblasts, but not
epithelial cells, was stimulated by E2 and 3pAdiol. At the beginning of this chapter,
it was hypothesised that prostatic cells are not only oestrogen target cells but also
capable of modulating the effects of oestrogens by active oestrogen metabolism. In
Chapter 3, it was found that fibroblasts in primary culture expressed aromatase
mRNA and enzyme activity; fibroblasts are thus capable of local biosynthesis of
oestrogens from androgen precursors (oestrogen anabolism). More experiments
were carried out to investigate if prostatic cells in primary culture can further
metabolise oestrogens (oestrogen catabolism) and regulate the local concentrations
and effects of oestrogens in the prostate.
No previous study has reported the conversion of oestrogens to their
metabolites in prostatic cells. To establish if these cells can metabolise the natural
oestrogens E2 and Ej, preliminary time-course experiments were carried out by
incubation of epithelial cells and fibroblasts in primary culture with 10 nM
radiolabelled E2 or E] (fig. 4.13).
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Fig. 4.12 Stimulatory effects of oestradiol and 3pAdiol on fibroblast growth are
antagonised by the anti-oestrogen ICI 182780. 1800 fibroblasts/well in phenol
red-free RPMI supplemented with 2% DCC-FCS were seeded into 96-well plates 2 d
before the addition of 10"8 or 10"7 M (a) E2 or (b) 3pAdiol (6 wells per treatment
group) with or without 50 nM ICI 182780. 6 wells received 1% ethanol (v/v) to
control for the ethanol used as a vehicle for E2, 3pAdiol and ICI 182780. Medium
was changed daily. MTS assay was performed 4 d after initial plating of cells.
Values are expressed as mean ± sem. +P<0.05, *P<0.01 compared with controls.




Fig 4.13 Time course of oestradiol (E2) oxidation to oestrone (Ei) by prostatic
epithelial cells in primary culture. Either 50,000 or 75,000 epithelial cells/well in
serum-free EGM were plated in duplicate in 6-well plates. 48 h later, the cells were
incubated with 2 ml of the same medium containing 10 nM of radiolabelled E2 for up
to 24 h. Steroid metabolites were extracted from the medium and analysed by HPLC
as described in sections 2.6.2 & 2.7.2. Results are expressed as mean of duplicates.
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Figure 4.13 shows that with epithelial cells in primary culture, initial plating
density of 7.5 x 104 cells/well resulted in rapid conversion of approximately 50% of
E2 to Ei within 2 h of incubation. At a reduced plating density of 5 x 104 epithelial
cells/well, E2 metabolism to Ei was more or less proportional with time up to 6 h.
No other steroid metabolites were detectable by HPLC within 24 h of incubation. In
similar experiments using Ei as substrate, no E2 or other metabolite was formed
within 24 h of incubation (data not shown).
Similar to epithelial cells, fibroblasts at a plating density of 20 x 104
cells/well rapidly catabolised E2 to Ej. At a reduced plating density of 5 x 104
cells/well, fibroblast metabolism ofE2to Ej was essentially proportional with time in
up to 6 h (fig. 4.14). Again, no other steroid metabolites were detectable by HPLC
within 24 h of incubation. In similar experiments using E] as substrate, no E2 or
other metabolite was formed within 24 h of incubation (data not shown).
In summary, both cell types converted the most potent natural oestrogen, E2,
to the weaker Ei (oxidative 17PHSD activity) but not vice versa. E] was not further
metabolised by either epithelial cells or fibroblasts using the current culture
conditions. After ethyl acetate extraction of steroids from the culture medium,
scintillation counting of radioactivity remaining in the aqueous phase revealed no
difference among cells incubated for 0, 2, 4, 6 and 24 h, indicating that neither cell
type conjugated E2 or Ei to water-soluble metabolites.
In subsequent experiments to compare oxidative 17PHSD activities
(oestrogen catabolism) in epithelial cells and fibroblasts in primary culture, cells
were plated at a density of 5 x 104 cells/well 48 h before incubation with
radiolabeled E2 for 4 h. Conversion rate of E2 to Ei in fibroblasts (6.12 ± 0.68
pmol/mg protein/h) was approximately 50% less than that in epithelial cells (11.89 ±
0.72 pmol/mg protein/h) (fig. 4.15).
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time (h)
Fig 4.14 Time course of oestradiol (E2) oxidation to oestrone (Ei) by prostatic
fibroblasts in primary culture. Either 50,000 or 200,000 fibroblasts/well in phenol
red-free RPMI containing 10% DCC-FCS were plated in duplicate in 6-well plates.
48 h later, the cells were incubated with 2 ml of the same medium containing 10 nM
of radiolabelled E2 for up to 24 h. Steroid metabolites were extracted from the
medium and analysed by HPLC as described in sections 2.6.2 & 2.7.2. Results are


















Fig 4.15 Comparison of oestradiol catabolism by 17(3HSD in epithelial cells and
fibroblasts. 50,000 cclls/wcll were plated in triplicate in 6-well plates. 48 h later,
the cells were incubated with 10 nM radiolabelled E2 in 2 ml of either serum-free
EGM for epithelial cells (Ep) or phenol red-free RPMI supplemented with 10%
DCC-FCS for fibroblasts (Fb). Medium was collected after 4 h incubation with E2;
steroid metabolites were extracted from medium and analysed by HPLC. Cells were
then lysed and protein concentrations determined as described in sections 2.6.2 &
2.3.4 respectively. Results are expressed as mean ± s.e.m. (n=9) from 3 separate
experiments using epithelial cells (passage number 1) and fibroblasts (passage
number 2 or 3) from 3 BPH patients.
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4.5 Discussion
At the beginning of this chapter, it was hypothesised that prostatic cells not
only are oestrogen target cells but can also modulate the effects of oestrogens. A
number of oestrogen response parameters, including mRNA encoding both oestrogen
receptor subtypes and enzymes responsible for biosynthesis (aromatase) and
catabolism (17PHSD) of oestrogens, were shown to be present in prostatic cells in
primary culture. Moreover, E2 and 3pAdiol stimulated the proliferation of prostatic
fibroblasts but not epithelial cells; these effects on fibroblasts in primary culture were
antagonised by the anti-oestrogen ICI 182780.
Although expression and localisation of both ERa and ERp in the human
prostate is still unresolved, previous in situ mRNA hybridisation and
immunohistochemical studies have localised ERa expression mainly, but not
exclusively, to the stroma, whereas ERp was expressed predominantly in the human
prostatic epithelium (section 1.6.4). In the present study, ERa mRNA was present in
2 out of 3 samples of BPH-derived epithelial cells in primary culture, whereas all 3
samples contained ERp mRNA. Using RT-PCR, Lau et al. (2000) detected ERP
mRNA expression in all 5 primary cultures of normal prostate epithelial cells grown
from patients undergoing radical cystectomy because of bladder cancer; however,
none of the 5 samples contained ERa mRNA. In contrast, another study reported
mRNA encoding both ER subtypes in all of 6 primary cultures of normal prostate
epithelial cells from ultrasound-guided peripheral zone prostate biopsies (Pasquali et
al. 2001b). Taken together, it appears that ERP mRNA is consistently expressed in
epithelial cells in primary culture, while the expression of ERa mRNA is more
variable (summarised in table 4.4).
All 3 prostatic fibroblast samples tested in this study contained both ERa and
ERP mRNA. Only one previous study has looked at ER mRNA expression in
fibroblasts in primary culture; all 6 fibroblast samples collected from patients
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undergoing radical cystectomy because of bladder cancer expressed ERa but not
ERp mRNA (Pasquali et al. 2001b). To summarise, all studies to date on both
prostatic tissues and primary cultures found ERa expression in stromal cells whereas






Ep Ep Fb Ep Fb
ERa - + + ± +
ERP + + " + +
Table 4.4 Expression of ER mRNA in prostatic cells in primary culture as detected
by RT-PCR. Ep, epithelial cells; Fb, fibroblasts. +, present; absent; ±, present in 2
of 3 samples.
Although all 3 samples of epithelial cells examined in this study expressed
mRNA encoding either or both oestrogen receptor subtypes, they did not display any
growth response to E2 or 3pAdiol treatment up to 10 p,M. This observation is
analogous to a previous study in which epithelial cells in primary culture expressed
androgen receptor mRNA detectable by RT-PCR but did not show any growth
response to DHT stimulation (Grant et al. 1996). It is possible that the level of ER
gene expression in epithelial cells in the present study was insufficient to provide the
cells with enough receptor protein to effect any growth response to oestrogen
stimulation. An alternative explanation is that E2 and 3(3Adiol had no effect on
epithelial cell proliferation but affect other oestrogen responsive gene expression
such as progesterone receptor. A third possibility is that the growth-stimulating
substances present in the epithelial growth medium, including insulin and epidermal
growth factor, were masking the effects of oestrogens on these cells.
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In contrast, proliferation of prostatic fibroblasts in primary culture was
stimulated by both E2 and 3(3Adiol. Two previous studies have reported the effects
of E2 on BPH-derived fibroblasts in culture. In one study, E2 (10 pM - 100 nM)
failed to stimulate proliferation of prostatic fibroblasts grown in medium
supplemented with 0% or 1% FCS (Levine et al. 1992). In another study, E2
increased fibroblast proliferation grown in medium containing 0.5% FCS in a dose-
dependent manner with maximal stimulation at 1 nM; this stimulatory effect was
antagonised by the anti-oestrogen tamoxifen (Collins et al. 1994). In comparison, in
an animal model of prostate adenocarcinoma in which rats were castrated and
supplemented with testosterone, additional E2 treatment increased the volume of the
stromal compartment but decreased that of the epithelial compartment (Daehlin et al.
1987). Taken together, results presented in this thesis and from previous in vitro and
in vivo studies suggest that E2 can preferentially stimulate the proliferation of
prostate stromal cells.
This is the first report on oestrogen metabolism by 17(3HSD in prostatic
fibroblasts and epithelial cells in primary culture. Both cell types exhibited 17[3HSD
activity converting E2 to Ei but not vice versa. The rates of conversion of E2 to Ej in
epithelial cells (11.89 pmol/mg protein/h) and fibroblasts (6.12 pmol/mg protein/h)
in the present study are comparable to that of testosterone oxidation to
androstenedione in prostatic fibroblasts in primary culture (3.1 pmol/mg protein/h,
Tsugaya et al. 1996). This observation of 17PHSD metabolism of E2 but not Ej in
primary cultures is in keeping with previous reports on the expression of 17PHSD
types 2, 4 and 5 (but not type 1) in the human prostate tissue (reviewed in section
1.5). Whereas 17PHSD types 2 and 4 exhibit mainly dehydrogenase activity and can
oxidise E2 to Ej, type 1 17PHSD catalyses the reduction of Ei to E2 and type 5
17pHSD the conversion of androstenedione to testosterone (Peltoketo et al. 1999,
Labrie et al. 2000). Therefore, it is likely that 17PHSD metabolism of oestrogens
occurs mainly in the oxidative direction converting E2 to the weaker oestrogen, Ei,
not only in prostatic cells in vitro but also in prostate tissue in vivo. However, it
should be borne in mind that any measurement of 17PHSD activity is the sum of
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both reductive and oxidative reactions catalysed by the various types of 17pHSD
expressed at different levels in a system. The lack of conversion of Ei to E2 in
prostatic cells does not necessarily equate to the absence of enzymes capable of
catalysing Ei reduction but can simply be due to relatively high activities of 17PHSD




Effects ofPermixon® on Oestrogen Metabolism in
Prostatic Cells in Primary Culture
5.1 Effects ofPermixon® on interaction between 5aRl and aromatase




Although Permixon® is commercially available as a phytotherapeutic agent
for the management of BPH, its precise mechanism of action is unknown. Besides
inhibiting the activity of both 5a-reductase isozymes in vitro (Iehle et al. 1995,
Bayne et al. 1999), it has also been shown to decrease the nuclear concentrations of
oestrogen receptor in BPH prostate tissue (Di Silverio et al. 1992). Indeed,
oestrogens have long been implicated in the pathogenesis of BPH (reviewed in
section 1.7.3a) and their concentrations in the prostate may be regulated by various
oestrogen-metabolising enzymes. To better understand the mechanism of action of
Permixon®, this chapter aims at investigating the effects of Permixon® on oestrogen
anabolism (aromatase activity) and catabolism (17PHSD activity) in prostatic cells in
primary culture.
5.1 Effects of Permixon® on Interaction between 5aRl and Aromatase
Results from Chapter 3 reveal that in cells expressing both 5aRl and
aromatase, inhibition of 5aRl led to an increase in aromatase activity but not vice
versa. Previous studies have shown that Permixon® inhibited 5aRl activity in a
baculovirus-directed expression system (Iehle et al. 1995) and in human prostatic
cells in primary culture (Bayne et al. 1999). Further experiments were therefore
carried out to examine if Permixon®, a known 5aRl-inhibiting agent, would also
affect the regulatory interaction between 5aRl and aromatase, first in a co-
transfection model and then in prostatic cells in primary culture.
5.1.1 Effects of Permixon® on COS-1 cells co-transfected with plasmids encoding
5aRl and aromatase
To investigate any effect of Permixon® on the interaction between 5aRl and
aromatase, the co-transfection model described in sections 3.2 & 3.3 was used.
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Briefly, COS-1 cells co-transfected with plasmids encoding human 5aRl
(pCMV2.5aRl) and aromatase (pCMV2.arom) were incubated with 10 nM
androstenedione and various concentrations of Permixon® for 3 h. Steroids were
then extracted from the medium and analysed by HPLC; cells were lysed and
luciferase activity measured as described in sections 2.6.1 & 2.5.4 respectively.
Initially, concentrations of Permixon® up to 10 mg/1 were used as described in
previous studies, which reported significant inhibition of 5aRl activity by 10 mg/1
Permixon® in prostatic cells in primary culture (Bayne et al. 1999). In the present
study, however, 10 mg/1 Permixon® did not affect 5aRl activity expressed in COS-1
cells transfected with either pCMV2.5aRl only or both pCMV2.5aRl and
pCMV2.arom (data not shown). The concentration of Permixon® was therefore
increased to 200 mg/1 in subsequent experiments.
Permixon® (up to 200 mg/1) did not affect aromatase activity in cells
transfected with pCMV2.arom only (fig. 5.1a), whereas 5aRl activity in cells
transfected with pCMV2.5aRl only was inhibited by 100-200 mg/1 Permixon® (fig.
5.1b). In COS-1 cells co-transfected with both pCMV2.5aRl and pCMV2.arom,
Permixon® not only inhibited 5aRl activity but also led to a concomitant increase in
aromatase activity (fig. 5.1c). This effect of Permixon® on the regulatory interaction
between the two enzymes is similar to that of the 5aRl-specific inhibitor LY306089
described in section 3.3.2 (fig. 3.6, pp.98-99).
5.1.2 Effects of Permixon® on the interaction between 5aRl and aromatase in
prostatic cells in primary culture
Previous experiments (Bayne et al. 1999) and preliminary work at the
beginning of this project (data not shown) demonstrated that Permixon at a
concentration of 20 mg/1 or above (but not 10 mg/1) inhibited the proliferation of
both epithelial cells and fibroblasts in primary culture. To investigate the effects of
Permixon® on the interaction between 5aRl and aromatase in prostatic cells in
primary culture, the concentrations of Permixon® used in medium were thus limited
to 10 mg/1 or below.
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Figure 5.1 Effects of Permixon® on enzyme activities in COS-1 cells transfected
with (a) pCMV2.arom (aromatase-encoding plasmid) only, (b) pCMV2.5aRl
(5aRl-encoding plasmid) only, and (c) both pCMV2.arom and pCMV2.5aRl.
Enzyme activities are expressed as mean of triplicates ± s.e.m. Arbitrary unit of
steroid-metabolising enzyme activity is calculated by the following formula: steroid
formation (pmol) x 106 / luciferase activity (relative light unit). Results are
representative of 3 separate experiments. +P<0.05 and *P<0.01 compared with
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In section 3.5, epithelial cells in primary culture converted androstenedione to
both 5aA (5aRl activity) and testosterone (17PHSD activity), but not Ei (aromatase
activity). Here Permixon® (10 mg/1) was shown to inhibit 5aRl activity in epithelial
cells in primary culture as predicted (fig. 5.2a), whereas metabolism of
androstenedione to testosterone was not affected by up to 10 mg/1 Permixon® (fig.
5.2b). No Ei or E2 was detectable even in the presence of 10 mg/1 Permixon®.
In contrast, androstenedione was converted to 5aA, Ei and testosterone in
prostatic fibroblasts in primary culture. Permixon® (10 mg/1) decreased 5aA
formation in fibroblasts as expected (fig. 5.3a), whereas the metabolism of
androstenedione to testosterone was unaffected by Permixon® up to 10 mg/1 (fig.
5.3b). In fibroblasts in primary culture, Permixon® increased the conversion of
androstenedione to Ej in a dose-dependent manner (fig. 5.3c). Again, the effects of
Permixon® on 5aA and Ei formation in prostatic fibroblasts are similar to those of
the 5aRl specific inhibitor LY306089.
5.2 Effects of Permixon® on Oestradiol Catabolism in Prostatic Cells in
Primary Culture
The above data demonstrate that by inhibiting 5aRl, Permixon® can
indirectly increase aromatase activity and hence local oestrogen formation from
androgen precursors (oestrogen anabolism) in prostatic cells. In Chapter 4, prostatic
fibroblasts and epithelial cells in primary culture were also shown to actively
metabolise E2 to the weaker oestrogen Ei; no conversion from Ej to E2 was
detectable in either cell type. The next set of experiments aimed to examine if
Permixon® can also affect E2 catabolism (17PHSD activity) in prostatic cells.
Epithelial cells and fibroblasts in primary culture were incubated with
radiolabeled E2 and various concentrations of the phytotherapeutic agent. To avoid
any effect ofPermixon® on cell proliferation, concentrations of Permixon® used were
again limited to 10 mg/1 or less. Preliminary experiments of E2 catabolism (17PHSD
activity) in both cell types have been described in section 4.4.
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Fig. 5.2 Effects of Permixon® on the metabolism of androstenedione to (a) 5a-
androstanedione, and (b) testosterone in epithelial cells in primary culture.
Values are mean of triplicates ± s.e.m. **P<0.001, compared with controls. A,
androstenedione; 5aA, 5a-androstanedione; T, testosterone. Results are
representative of 2 experiments using prostatic epithelial cells cultured from 2
different BPH patients. For experimental details, please refer to fig. 3.13 (pp. 112-
113). No aromatase activity (formation ofEj or E2) was detectable in epithelial cells.
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Fig. 5.3 Effects of Permixon® on the metabolism of androstenedione to (a) 5a-
androstanedione, (b) testosterone, and (c) oestrone in prostatic fibroblasts in
primary culture. Values are mean of triplicates ± s.e.m. **P<0.001, +P<0.05
compared with controls. A, androstenedione; 5aA, 5a-androstanedione; Ei, oestrone;
T, testosterone. For experimental details, please refer to fig. 3.12 (pp. 110-111).
Results are representative of 3 separate experiments using prostatic fibroblasts
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In epithelial cells in primary culture, Permixon® inhibited the conversion of
E2 to E) in a dose-dependent manner (IC50 = 7.8 mg/1, fig. 5.4). In comparison, 10
mg/1 Permixon® decreased E2 metabolism to Ei by approximately 18% in fibroblasts
(fig. 5.5).
5.3 Discussion
Intraprostatic oestrogen concentrations depend, among other factors, on the
availability of androgen precursors and local expression of oestrogen-producing and
• • (r) •
oestrogen-inactivating enzymes. In this chapter, Permixon is demonstrated to have
two effects on oestrogen metabolism in prostatic cells in primary culture. Firstly,
• (R)
Permixon indirectly increased aromatase activity and thus local oestrogen
biosynthesis by inhibiting 5aRl in fibroblasts. Secondly, by inhibiting the
conversion of E2 to Ej, it increased the concentrations of the more active oestrogen in
both epithelial cells and fibroblasts. This is the first report on the effects of
Permixon® on oestrogen metabolism in prostatic cells.
These pro-oestrogenic properties of Permixon® are in contrast to the only
previous study reporting on the phytotherapeutic agent's interference with oestrogen
action, in which Permixon®-treated patients were shown to have decreased
concentrations of nuclear, but not cytosolic, oestrogen receptors in their prostate
tissue compared with the placebo-treated group (Di Silverio et al. 1992). In the same
study, nuclear concentrations of both androgen and progesterone receptors were also
lower in the Permixon®-treated group than the control group; total concentrations of
oestrogen, androgen and progesterone receptors in the prostate were however not
mentioned in the study. The decreased concentrations of nuclear oestrogen,
androgen and progesterone receptors were most likely due to damage of nuclear
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Fig. 5.4 Effects of Permixon® on the conversion of oestradiol (E2) to oestrone
(Ei) in epithelial cells in primary culture. 5 x 104 cells/well in triplicate were
plated in 6-well plates in serum-free EGM. 48 h later, the medium was replaced by 2
ml serum-free EGM containing 10 nM radiolabeled E2 and various concentrations of
Permixon® or ethanol in control wells (1%, v/v). The medium was collected after 4
h incubation. Steroids were extracted with ethyl acetate and analysed by HPLC.
Cells were lysed and protein concentrations were determined as described in sections
2.6.2 & 2.3.4 respectively. Results are expressed as mean ± s.e.m. (n=9) from 3
separate experiments using epithelial cells (passage number 1) from 3 BPH patients.
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Fig. 5.5 Effects of Permixon® on the conversion of oestradiol (E2) to oestrone
(Ei) in prostatic fibroblasts in primary culture. 5 x 104 cells/well in triplicate
were plated in 6-well plates in phenol red-free RPMI supplemented with 10% DCC-
FCS. 48 h later, the medium was replaced by 2 ml of the same medium containing
10 nM radiolabelled E2 and various concentrations of Permixon® or 1% ethanol (v/v)
in control wells. The medium was collected after 4 h incubation. Steroids were
extracted with ethyl acetate and analysed by HPLC. Cells were lysed and protein
concentrations were determined as described in sections 2.6.2 & 2.3.4 respectively.
Results are expressed as mean ± s.e.m. (n=9) from 3 separate experiments using
fibroblasts (passage number 2 or 3) from 3 BPH patients. +P<0.05, compared with
controls.
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Using electron microscopy, Bayne et al. (2000) demonstrated widespread
damage to the nuclear membrane in prostatic epithelial cells and fibroblasts in
primary culture treated with 10 mg/1 Permixon® for 2 d. It is therefore conceivable
that the steroid receptors in Permixon®-treated prostates in the previous study by Di
Silverio et al. (1992) either diffused through damaged nuclear membrane from the
nucleus to the cytosol or failed to be transported from the cytosolic to the nuclear
compartment. While classical oestrogen action depends on the presence of oestrogen
receptor-ligand complex within the nucleus, it is not clear if the phytotherapeutic
agent's effects on local oestrogen concentrations would be counteracted by its effects
on nuclear receptor concentrations.
In this study, higher concentrations ofPermixon® were required to inhibit 5a-
reductase activity in COS-1 cells than in prostatic cells in primary culture. This is in
keeping with a previous report in which widespread morphological changes were
observed in prostatic cells in primary culture treated with Permixon® (10 mg/1) but
not in other cell cultures including epididymal, testicular, kidney, skin and breast
cells (Bayne et al. 2000). Moreover, after oral administration, ingredients of
Permixon® including lauric acid, oleic acid and (3-sitosterol were selectively
concentrated in the rat prostate to the exclusion of other organs (Chevalier et al.
1997). Given that fatty acids, essential components of cell and nuclear membranes,
constitute approximately 90% of all ingredients of Permixon®, the cell-type
selectivity of the phytotherapeutic agent might possibly be explained by differences
in phospholipid and fatty acid composition between different cell types.
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Chapter 6
Final Discussion and Future Studies
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The present study was designed to examine, on the one hand, the role of 5a-
reductase type 1 isozyme in the human prostate, and on the other hand, the effects of
oestrogens on prostatic cells. Two hypotheses are tested in this thesis. Firstly, the
hypothesis that 5aRl can regulate aromatase activity was investigated initially in a
co-transfection model and then in primary cultures of prostatic cells. Secondly, it
was hypothesised that prostatic cells are not only oestrogen target cells expressing
oestrogen receptors but also capable of further metabolism of oestrogens, thereby
modulating their effects on the prostate. Furthermore, the mechanism of action of
(§)Permixon , a phytotherapeutic agent for the treatment of BPH, is not entirely clear;
the effects of Permixon® on oestrogen metabolism in primary cultures of prostatic
cells were also explored.
Steroid metabolism in primary cultures ofprostatic cells
Steroid metabolic pathways examined in this thesis are summarised in fig.
6.1. In epithelial cells in primary culture, androstenedione was converted to both
5aA (by 5aRl) and testosterone (by 17PHSD). Testosterone and androstenedione
were interconverted to each other in epithelial cells. E2 was metabolised to Ei but
not vice versa (fig. 6.1a). Aromatase activity was not detectable in epithelial cells.
With the exception of the aromatase activity expression, steroid metabolic
pathways found in fibroblasts are similar to those in epithelial cells (fig. 6.1b).
Androstenedione was metabolised to Ei (by aromatase), 5aA (by 5aRl) and
testosterone (by 17PHSD). 17PF1SD also oxidised both testosterone to
androstenedione and E2 to Ei; however, Ei was not converted to E2 in fibroblasts.
Despite the presence of aromatase activity in fibroblasts, E2 was not detectable as a
metabolite when androstenedione was added to fibroblasts as a substrate. This was
possibly due to the relatively high oxidative 17pFISD activity in fibroblasts removing
any E2 formed by testosterone aromatisation in the same cells. Therefore, in
interpreting results of steroid metabolism in cell cultures, the highly dynamic and













Figure 6.1 Overview of steroid metabolic pathways in prostatic cells in primary
culture reported in the present study. 5a-reductase type 1 isozyme (5aRl)
activity is present in both (a) epithelial cells and (b) fibroblasts in primary culture,
reducing androstenedione (A) to 5a-androstanedione (5aA). 17P-hydroxysteroid
dehydrogenase (17PHSD) activity occurs predominantly in the oxidative direction,
converting oestradiol (E2) to oestrone (E,) and testosterone (T) to A. 17PE1SD
reduction of A to T is also present in both cells types. Aromatase activity occurs in
fibroblasts in primary culture, converting A to E,, but not in epithelial cells.
Aromatisation of T to E2 (broken arrow) has not been demonstrated in the present
thesis but possibly occurs in fibroblasts in primary culture.
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Interaction between 5aRl and aromatase
In both the co-transfection model and fibroblasts in primary culture,
inhibition of 5aRl activity by either LY306086 or Permixon® led to an increase in
aromatase activity. By converting androstenedione to a non-aromatisable steroid,
5aRl can limit substrate availability to the enzyme aromatase. An alternative
explanation for the observed regulatory interaction between the two enzymes is that
5aA, the product of 5aRl metabolism of androstenedione, acts as an inhibitor of
aromatase. 5aA was indeed reported to be an inhibitor of aromatase activity in
human breast carcinoma cells (Perel et al. 1984) and in rat granulosa cells (Hillier et
al. 1980). The aromatisation of androstenedione (4 nM) in human breast carcinoma
cells in primary culture was inhibited approximately 70% and 95% by 10 nM and
100 nM 5aA respectively (Perel et al. 1984). The same study also reported that
breast carcinoma cells with the most active formation of 5a-reduced androgen
metabolites including 5aA had the lowest rate of androstenedione aromatisation,
whereas those cells with the lowest formation of 5a-reduced metabolites had the
highest aromatase activities. Likewise, in another study, Hillier et al. (1980) reported
that in rat granulosa cells, testosterone aromatisation was competitively inhibited by
5aA; lp.M 5aA decreased the aromatisation of 100 nM by 73%. In both of these
studies, other 5a-reduced steroids were found to be less potent aromatase inhibitors
than 5aA; these steroids were dihydrotestosterone (DHT), androsterone, 5a-
androstane-3P,17(3-diol (3pAdiol) and 5a-androstane-3a,17p-diol (3aAdiol) (Perel
et al. 1984, Hillier et al. 1980). It is thus possible that by converting androstenedione
to 5aA, 5aRl not only limits aromatase access to its substrate, but also produces a
steroid metabolite which can directly inhibit the enzyme aromatase. Further kinetic
studies are required to examine the effects of 5aA and other 5a-reduced androgen
metabolites on aromatase activity in prostatic cells.
Although inhibition of 5aRl by either LY306089 or Permixon® led to an
increase of aromatase activity in fibroblasts, the conversion of androstenedione to
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testosterone (17PHSD activity) was unaffected by 5aRl inhibition in either epithelial
cells or fibroblasts in primary culture. One possible explanation is that 5aA is not an
inhibitor of 17PHSD conversion of androstenedione to testosterone in either cell
type. Alternatively, though 5aRl inhibition led to increased androstenedione
availability for 17PHSD reduction to testosterone, very high oxidative 17pHSD
activity present in the same cells might have prevented the increased formation of
testosterone from androstenedione.
Aromatase mRNA and activity were found in fibroblasts but not in epithelial
cells in primary culture in the present study. Yet 5aRl mRNA levels (Habib et al.
1998) and activity in epithelial cells (present study, section 3.5) were shown to be
higher than in stromal cells. The function of 5aRl in epithelial cells awaits further
elucidation. A speculative role for 5aRl in epithelial cells is that it may, in
conjunction with various 17PHSD isozymes and 5aR2, regulate androgen activation
and inactivation, and thus play a part in the control of androgen response in the
prostate.
Balance between 5aRl and 5aR2
In considering a potential role for 5aRl in androstenedione catabolism, it
should be noted that 5aR2 is in general regarded as the more important of the two
isozymes within the human prostate. As well as being the predominant isozyme, it
also exhibits higher substrate affinity than 5aRl (Thigpen et al. 1993a, Levy et al.
1995). Although the role of 5aRl may be minor compared with that of 5aR2, it is
feasible that a balance in the expression of the two isozymes is important to the
normal control of intra-prostatic androgen/oestrogen balance. Evidence suggests that
increased 5aRl or decreased 5aR2 expression may be associated with malignancy of
the human prostate. Firstly, recent data show that 5aRl mRNA expression was
higher in prostate cancer than in normal or hyperplastic tissues, but no difference in
5aR2 mRNA levels was found between normal and malignant tissues (Iehle et al.
1999). Secondly, the catalytic efficiency (Vmax/Km) of 5aRl in stromal tissues of
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malignant tissue was 3 times higher than in BPH (Hudson & Wherrett 1990).
Thirdly, in contrast to normal prostate and BPH, where 5aR2 is the major isozyme,
in prostate cancer cell lines including DU145, LNCaP and PC3, 5aRl is the
predominant 5a-reductase isozyme (Smith et al. 1996, Negri-Cesi et al. 1998, Negri-
Cesi et al. 1999). Whether malignant prostate tissues have increased 5aRl
expression compared with normal tissues, and thus decreased local oestrogen
biosynthesis, is unknown. However, oestrogens have been shown to directly inhibit
the growth of prostatic adenocarcinoma in rat (Daehlin et al. 1987) and the
proliferation of PC3 cells, a human prostate cancer cell line (Lau et al. 2000). If
increased 5aRl expression or imbalance between the two 5a-reductase isozymes is a
contributing factor to malignancy, 5aRl may open new doors to the treatment and
prevention of prostatic carcinoma.
Aromatase
In this study, both aromatase mRNA and activity were detectable in primary
cultures of fibroblasts but not in epithelial cells. Similarly, in both BPH and normal
prostate tissue sections, aromatase immunostaining in the epithelium was either
absent or much lower than in the stroma (Matzkin & Soloway 1992, Hiramatsu et al.
1997). It is therefore very likely that in vivo aromatase activity is higher in the
stroma than in the epithelium of prostatic tissue. In a study comparing benign and
malignant conditions of the prostate, Schweikert (1979) reported higher aromatase
activity in fibroblasts cultured from BPH than those cultured from cancer specimens.
As a result, oestrogens locally produced by the high aromatase activities in BPH
fibroblasts could thus be a contributing factor to the pathogenesis of BPH. This is
consistent with the finding that E2 stimulated the proliferation of fibroblasts in
primary culture (section 4.2). Hence aromatase may play a potential role in the













Fig. 6.2 Schematic diagram outlining a hypothesised role for aromatase in BPH
pathogenesis. Here it is proposed that a yet unknown mechanism can trigger
abnormal stromal proliferation and thus an overall increase in aromatase activity,
which in turn produces more oestrogens locally, stimulating the proliferation ofmore
stromal cells. The increasing plasma oestrogen/androgen ratio with advancing age is
a possible factor in triggering abnormal proliferation ofprostatic stromal cells.
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Aromatase expression in epithelial cells in primary culture was undetectable
(present study) and aromatase immunostaining in the epithelium in both BPH and
normal prostate tissue sections was either absent or much lower than in the stroma
(Matzkin & Soloway 1992, Hiramatsu et al. 1997). Yet mRNA of both oestrogen
receptor subtypes have been identified in epithelial cells in primary culture (present
study) and immunostaining of ERa and ERp was reported in the epithelial
compartment of human prostate tissues (Royuela et al. 2001, Pasquali et al. 2001a).
A speculative explanation is that oestrogens locally produced by aromatase activity
in the stroma/fibroblasts act in a paracrine manner on neighbouring epithelial cells.
Whether a stromal-epithelial interaction via oestrogens is important to normal or
pathological prostate development needs further investigation. Also, the effects of
oestrogens on prostatic epithelial cells are not entirely clear but this area of research
will be highly relevant to the understanding and treatment of prostate cancer, which
is an epithelial disease. Further studies to examine the effects of oestrogens on
epithelial cells in primary culture could compare (both qualitatively and
quantitatively) the protein expression patterns in cells treated with various
oestrogenic compounds with those in control cells.
Oestrogens
In considering a role for oestrogens in BPH pathogenesis, it is important to
note that oestrogens can exert both direct and indirect effects on the prostate.
Firstly, systemic administration of oestrogens can inhibit gonadotrophin secretion,
leading to decreased testicular output of androgens and lowered plasma androgen
levels, which in turn cause regressive changes in the prostate. Secondly, oestrogens,
either derived from plasma or produced locally within the prostate, can exert their
effects directly on prostatic cells. It is likely that oestrogen response in the prostate
depends on a number of factors including plasma levels of oestrogens, local
concentrations of oestrogens, expression of oestrogen receptor subtypes, interaction
between oestrogen receptors and co-activators/co-repressors and so on.
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It is paradoxical that BPH, an androgen-dependent disease, manifests in men
at a time when their testicular activities and plasma androgen levels are declining.
However, with advancing age, plasma oestrogen/androgen ratios are increased
(reviewed in section 1.7.3a). Results from in vitro fibroblast proliferation
experiments in the present study and from previous in vivo experiments in dog
(Walsh & Wilson 1976, DeKlerk et al. 1979) strongly suggest a role for oestrogens
in BPH pathogenesis. However, whether increased plasma oestrogen/androgen ratios
or increased local oestrogen concentrations due to oestrogen biosynthesis are
responsible for BPH is currently unknown. Sharpe (2001) suggested that a balance
in action between androgens and oestrogens may be a critical factor in the normal
development of the male reproductive system; exposure of the fetal testis to an
abnormal endocrine environment (decreased ratios of androgens to oestrogens) may
lead to testicular cancer, cryptorchidism, hypospadias and decreased sperm counts.
Whether BPH is related to this group of testicular dysgenesis disorders requires
further investigations.
Besides E2, 3pAdiol was also shown to stimulate the proliferation of
fibroblasts in primary culture. 3pAdiol binds to both ERa and ERp (Kuiper et al.
1997) but not androgen receptor (Turcotte et al. 1988). Although compared with E2,
the relative binding affinities of 3pAdiol for ERa and ERp were only 3% and 7%
respectively (Kuiper et al. 1997), 3pAdiol concentrations are 10 times higher than
those of E2 in plasma and >30 times higher in BPH prostate tissues (reviewed in
section 1.7.3a). Recently, Weihua et al. (2001) suggested that 3pAdiol may be an
important endogenous ERp ligand in the prostate; it decreased prostatic androgen
receptor levels in wild-type but not ERp knockout mice. Data from the present study
show that both 3pAdiol and E2 stimulated proliferation of prostatic fibroblasts to a
similar extent. Moreover, maximum stimulation occurred at 100 nM for both
compounds in medium supplemented with 2% DCC-FCS, indicating that 3pAdiol
may also have significant oestrogenic effects in vivo. Having higher affinity for ERP
than ERa (Kuiper et al. 1997), 3pAdiol can potentially elicit different effects to E2,
which has similar affinity for both ER subtypes.
169
Another putative oestrogen which may be of importance in prostatic
pathophysiology is androst-5-ene-3p,17(3-diol (A5diol). It can be synthesised from
dehydroepiandrosterone, the most abundant steroid in plasma, by the action of
17[3HSD, and further metabolised by 3(3HSD to testosterone. Compared with E2, its
relative binding affinities to ERa (6%) and ERP (17%) are even higher than those of
3pAdiol (Kuiper et al. 1997). Also, concentrations of A5diol in both plasma and
BPH tissues are higher than those of 3pAdiol and E2 (table 1.7, p.36). If 3pAdiol
and A5diol are proven to be more important oestrogens than E2 in the human
prostate, our understanding of the balance and interconversion between androgens
and oestrogens within the gland will need to be re-examined.
To date, the only comprehensive study reporting the binding affinities of
various oestrogenic compounds to the two ER subtypes compared the human ERa
with the rat ERP (Kuiper et al. 1997). Given that findings in one species cannot
always be extrapolated to another, it would be useful to know the binding affinities
of various oestrogens, including E2, 3pAdiol and A5diol, to the human ERp. Yet
binding affinity of a compound to ER is not equivalent to its potential in eliciting
oestrogen action. To better understand the role of the putative oestrogens 3pAdiol
and A5diol in oestrogen action in the prostate, their abilities to transactivate
oestrogen-responsive genes can also be examined. To this end, cells can be
transfected with plasmids encoding either ER subtype and a known oestrogen
responsive gene linked to a reporter system. Addition of an oestrogenic compound
to the transfected cells will then result in binding of the ligand to the ER subtype, ER
dimerisation, binding of the ER-ligand complex to oestrogen response elements
(ERE), initiation of gene transcription and expression of the reporter gene.
Compared with binding affinity studies, this type of transfection experiments gives a
better indication as to the potential of an oestrogenic compound in eliciting
functional oestrogen action. The work presented in this thesis has established that
prostatic cells in primary culture express mRNA of both ER subtypes and that
proliferation of fibroblasts is responsive to oestrogen stimulation. BPH-derived
primary cell cultures would thus serve as a model for future investigations of the
mechanism and regulation of action of oestrogens in the prostate.
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Permixon
Two pro-oestrogenic properties of Permixon® on prostatic cells in primary
culture were demonstrated in Chapter 5. E2 conversion to Ei by 17PHSD in
epithelial cells was more sensitive to Permixon® inhibition than in fibroblasts; 10
mg/1 Permixon® inhibited 17PHSD oxidation of E2 in epithelial cells and fibroblasts
by 75% and 18% respectively. In comparison, Delos et al. (1995) reported that
testosterone oxidation to androstenedione by 17PHSD was also inhibited by
Permixon® more so in primary cultures of epithelial cells (IC50 = 40 mg/1) than in
fibroblasts (TC50 = 200 mg/1). One possible reason to this difference in the degree of
17PHSD inhibition is that different isozymes of 17PHSD were expressed in the two
different cell types, which are differentially inhibited by Permixon®. Furthermore,
the observation that 10 mg/1 Permixon® did not affect androstenedione reduction to
testosterone by 17PFISD also lends support to Permixon®'s selectivity on 17PE1SD
isozyme inhibition. Considering that 17PHSD isozymes are important regulators of
steroid activation and inactivation within prostatic cells, further studies can identify
the various 17PHSD isozymes expressed in primary cultures, with a view to specific
17PHSD isozyme regulation and possible therapeutic intervention.
Another pro-oestrogenic property of Permixon® reported in this thesis is the
indirect increase in aromatase activity secondary to inhibition of 5aRl. However, if
3pAdiol is really a more important oestrogen within the prostate gland, Permixon
may have anti-oestrogenic effects by inhibiting both 5aRl and 5aR2 activities,
thereby depleting the intraprostatic supply of androgen precursors for 3pAdiol
formation. Similarly, the effects of Permixon® on 17PHSD conversion of
dehydroepiandrosterone to A5diol should also be examined.
®
The implications of the above pro-oestrogenic properties of Permixon are
currently unclear. Despite these pro-oestrogenic properties and the fact that
®
oestrogens increased proliferation of fibroblasts in primary culture, Permixon was
171
shown by studies to effectively decrease the size of prostate in BPH patients.
Clinical follow-up studies are required to determine Permixon®'s long-term effects
on BPH patients and their prostates, which have not been reported. Permixon® also
contains small amount of phytosterols including P-sitosterol, which is a
phytoestrogen. Phytoestrogens (natural oestrogenic compounds derived from soya,
fruits and vegetables) are generally believed to be protective against the development
of prostate cancer and contribute to the geographical differences in the prevalence of
prostate cancer among different parts of the world. The soya-derived phytoestrogen
genistein, for example, has high binding affinity to ERp (36% compared with E2,
Kuiper et al. 1997). It would be interesting to examine not only the interaction
between phytoestrogens and the two ER subtypes but also their effects on prostatic
cells in primary culture.
Primary cultures ofprostatic cells
Compared with immortalised cell lines with repeated passaging, BPH-derived
epithelial cells and fibroblasts in primary culture are closer to prostatic cells in vivo
in terms of cellular characteristics. However, primary cell culturing is known to alter
some of the endocrinological attributes of prostatic cells. For example, the
expression of both 5aR2 and androgen receptor in epithelial cells and fibroblasts
quickly disappears after a short period of primary culture. In the present study, it is
not clear if the process or conditions of cell culture had altered the mRNA expression
patterns of aromatase and ER subtypes in prostatic cells. Differences in conditions
of primary cultures, primer design or RT-PCR conditions between the present and
previous studies may the reason for different mRNA levels reported. Also, it is
important to note that the presence of mRNA does not necessarily mean the
expression of the encoded functional protein. However, the stimulatory effects of
oestrogens on the proliferation of prostatic fibroblasts demonstrated in Chapter 4,
which were antagonised by the anti-oestrogen ICI 182780, strongly suggest that
either or both ER subtypes were indeed expressed in this cell type.
172
Proliferation of fibroblasts grown in medium supplemented with 10% DCC-
FCS was stimulated by micromolar concentrations of E2 and 3pAdiol, whereas
nanomolar concentrations of both compounds were enough to increase the
proliferation of fibroblasts in medium supplemented with 2% DCC-FCS. A
speculative explanation is that 10% DCC-FCS stimulated the proliferation of
fibroblasts to such an extent that high concentrations of oestrogens were required to
further stimulate their growth. Alternatively, high DCC-FCS concentrations might
have anti-oestrogenic effects on fibroblasts, e.g. down-regulation of ER gene
expression. This difference in the oestrogen concentrations required to stimulate
proliferation of fibroblasts grown in medium supplemented with different
concentrations of DCC-FCS again highlights the fact that cell growth and
characteristics are determined to a large extent by the culture conditions.
Lastly, despite the aforementioned shortcomings, prostatic cells in primary
culture still offer advantages as a model in the study of steroid metabolism and
actions in prostate. For instance, the results of ER mRNA expression in the two cell
types and also the exclusive aromatase activity in fibroblasts are similar to
immunohistochemical findings in prostatic tissues. The highly dynamic metabolic
pathways reported in the present study may not be identical to those found in human
prostatic cells in vivo; prostatic cells in primary culture remain possibly the model
most representative of the in vivo situation to date.
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